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Abstract 
ABSTRACT 
The Caliciviridae family are a group of small, non-enveloped viruses that contain a 
single stranded positive sense RNA genome approximately 7.5 kb in size. Several 
members of this virus family are significant pathogens of both animals and man. 
Perhaps the most well known member is Norovirus, which is reported to be the 
leading cause of viral gastroenteritis worldwide (approx. 95% of cases). Despite this, 
the molecular effects of the virus on host cells and pathogenicity of the disease has 
not been well reported due to the inability to grow most of these viruses in cell 
culture. Two members of the Caliciviridae, however, have been shown to replicate 
efficiently in certain cell lines. These are feline calicivirus (FCV) a member of the 
Vesivirus genus and murine norovirus-1 (MNV-1) a member of the Norovirus genus. 
For this reason, these viruses are being used as models to study virus/host 
interactions. Previous work with FCV showed that cells infected with FCV undergo 
apoptosis, more specifically that the FCV capsid protein was cleaved during infection, 
caspase-2, -3, -7 and -9 were activated, bax translocated to the mitochondria and 
subsequent cytochrome c release into the cytosol occurred. 
The aim of this project was to (i) further characterise the molecular mechanisms of 
FCV-induced apoptosis by examining the events that occur upstream of bax 
translocation to the mitochondria; (ii) examine the molecular mechanisms of 
apoptosis occurring during infection of CRFK cells with virulent systemic disease 
causing isolates of FCV and (iii) perform preliminary investigations into the 
mechanism of cell death occurring during MNV-1 infection. In this study we have 
demonstrated that calpains are activated during FCV infection. We have also shown 
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that phosphatidylserine externalisation on the plasma membrane and caspase-3 
activation during FCV infection were prevented with calpain inhibitors. We further 
demonstrated that expression of human calapastatin (a specific calpain inhibitor) 
within CRFK cells reduced the number of cells undergoing apoptosis following 
infection. 
This work also contains the first evidence for a delay in apoptosis during infection of 
cells with virulent strain disease-causing FCV isolates, and we suggest that this delay 
is mediated at the mitochondrial step of the apoptotic pathway. 
Finally, we have provided the first demonstration of apoptosis occurring in cells 
infected with MNV-1, evidenced by cleavage of caspase-3, a loss of A4),, and release 
of cytochrome c from the mitochondria to the cytosol. However, phosphatidylserine 
externalisation on the plasma membrane did not occur, suggesting that this 
calicivirus may induce apoptosis but this is followed by secondary necrosis in the 
RAW 264.7 cell line. age of caspase-3 occurs during infection and that 
phosphatidylserine externalisation on the plasma membrane is not occurring. We 
also demonstrate a loss of Aq)m and release of cytochrome c from the mitochondria 
to the cytosol and suggest that this calicivirus also induces apoptosis followed by 
secondary necrosis in the RAW 264.7 cell line. 
This data suggests that infection of cells with different members of the calicvirus 
family results in apoptosis, and that this may be a general mechanism in the 
pathogenesis of disease by these viruses. 
ii 
Acknowledgements 
ACKNOWLEDGEMENTS 
I would like to thank my supervisors Dr Lisa 0. Roberts and Dr George E. N. Kass for 
their continual help and support throughout the last three years, and for giving me 
the opportunity to undertake this PhD project. They are wonderful supervisors and 
their expertise in each of their fields, both theoretically and practically, has been 
invaluable. I would also like to thank Dr Elizabeth Royall and Dr Margaret Carter for 
their great practical advice when I have experienced difficulties in the lab. 
I would also like to thank my lab-mates Elisabetta, Andreas and Nicole for making 
the sometimes-long hours in the lab thoroughly enjoyable. 
Special thanks go to my close friends Alex, Andy, Debra, Fiona, George, Harry, Matty 
and Phill who have got me through the ups and downs of the last three years, to get 
me to this point. Thank you so much, I will never forget it. 
Finally, I would like to thank the Medical Research Council, UK for funding this 
project. 
III 
Contents 
CONTENTS 
ABSTRACT 
................................................................................................................... 
ACKNOWLEDGEMENTS 
.................................................................................................. III 
CONTENTS 
................................................................................................................. IV 
LIST OF FIGURES 
......................................................................................................... XII 
LIST OF TABLES ........................................................................................................... XV 
LIST OF ABBREVIATIONS .............................................................................................. XVI 
1 INTRODUCTION .................................................................................................... 1 
1.1 The Caliciviridae ................................................................................................. 1 
1.2 Vesiviruses ......................................................................................................... 3 
1.2.1 Vesicular Exanthema of Swine virus (VESV) .............................................. 3 
1.2.2 San Miguel Sea Lion virus (SMSV) .............................................................. 3 
1.2.3 Feline Calicivirus - (FCV) ............................................................................ 4 
1.3 Lagovirus ............................................................................................................ 5 
1.3.1 Rabbit Haemorrhagic Disease virus (RHDV) .............................................. 5 
1.4 Noroviruses ........................................................................................................ 6 
1.4.1 Human caliciviruses (HuCv) ........................................................................ 6 
1.4.2 Murine Norovirus (MNV-1) 
........................................................................ 8 
1.5 Sapoviruses ........................................................................................................ 8 
1.6 Calicivirus Morphology ...................................................................................... 9 
1.7 Genomic Organisation of the Caliciviruses ...................................................... 13 
1.7.1 Feline Calicivirus Genome ........................................................................ 13 
iv 
Contents 
1.7.2 Murine Norovirus-1 (MNV-1) Genome .................................................... 
14 
1.8 Calicivirus Subgenomic RNA ............................................................................ 
17 
1.9 Calicivirus Non-Structural Proteins (ORF 1) ..................................................... 
18 
1.9.1 2C-like NTPase .......................................................................................... 
21 
1.9.2 VPg ........................................................................................................... 
21 
1.9.3 3C-like Protease ....................................................................................... 
23 
1.9.4 RNA-dependent RNA polymerase ............................................................ 
24 
1.10 Calicivirus Structural Proteins (ORF 2& 3) ...................................................... 
25 
1.10.1 FCV Capsid Protein ................................................................................... 
25 
1.10.2 Norovirus Capsid Protein ......................................................................... 
27 
1.10.3 Minor Structural Protein (VP-2) ............................................................... 
27 
1.11 Calicivirus Replication ...................................................................................... 
28 
1.12 Apoptosis ......................................................................................................... 
31 
1.12.1 Discovery of the genetic basis of apoptosis ............................................. 
33 
1.13 The Caspases .................................................................................................... 
37 
1.13.1 Classification / organisation of the caspase family .................................. 
37 
1.13.2 Caspase structure ..................................................................................... 
38 
1.13.3 The initiator and effector caspases .......................................................... 
41 
1.13.4 Caspase activation mechanisms .............................................................. 
43 
1.14 The Death Receptor pathway .......................................................................... 
44 
1.15 The Mitochondrial Pathway ............................................................................. 
49 
1.16 Caspase Substrates .......................................................................................... 
53 
1.17 Regulation of Apoptosis ................................................................................... 
53 
1.17.1 The Bcl-2 family of apoptotic regulators ................................................. 
53 
V 
Contents 
1.18 The Calpains ..................................................................................................... 57 
1.18.1 Members and family structural organization .......................................... 57 
1.18.2 Calpain-1 and -2 ....................................................................................... 59 
1.18.3 Physiological roles of the calpains ........................................................... 61 
1.18.4 Pathological roles of the calpains ............................................................ 62 
1.19 Viruses and Apoptosis ...................................................................................... 66 
1.20 Mechanisms by which viruses inhibit apoptosis ............................................. 67 
1.20.1 Inhibition of the interferon response ...................................................... 67 
1.20.2 Inhibition of the death receptor pathways .............................................. 68 
1.20.3 Inhibitors of Caspase activity ................................................................... 70 
1.20.4 Viral BcI-2 homologues ............................................................................ 72 
1.20.5 Virus-mediated transcriptional regulation of apoptosis ......................... 73 
1.21 Mechanisms by which viruses induce / activate apoptosis ............................. 73 
1.21.1 Caspase Activators ................................................................................... 73 
1.21.2 Inhibition of BcI-2 family members ......................................................... 74 
1.21.3 Receptor signalling mimics ...................................................................... 74 
1.22 Calicivirus-induced Apoptosis .............................................................. 
1.23 Project Aims ..................................................................................................... 77 
2 MATERIALS AND METHODS .................................................................................. 
78 
2.1 Growth and maintenance of cell lines ............................................................. 78 
2.1.1 Growth of Crandell-Rees Feline Kidney cells (CRFK) or Feline Embryonic 
Cell Line A (FEA) ....................................................................................... 78 
2.1.2 Growth of RAW 246.7 murine macrophages ........................................... 79 
VI 
Contents 
2.2 Growth of FCV-F9, UKOS-A, AB087, AB088 or MNV-1 for viral stock ............. 79 
2.3 Tissue Culture Infectious Dose50 Assay (TCID50) .............................................. 80 
2.4 Time course of infection .................................................................................. 80 
2.4.1 Calculation of Multiplicity of Infection .................................................... 83 
2.5 Transfection of plasmid DNA into CRFK cell line ............................................. 83 
2.6 Flow Cytometric Analysis ................................................................................. 84 
2.6.1 Cell Culture ............................................................................................... 84 
2.6.2 Annexin V Binding Assay .......................................................................... 84 
2.6.3 Active Caspase-3 detection ...................................................................... 85 
2.6.4 Mitochondrial Membrane Potential Analysis .......................................... 85 
2.7 Calpastatin / GFP Plasmid Construction .......................................................... 86 
2.7.1 Plasmid Vector Preparation - digestion and dephosphorylation............ 86 
2.7.2 Gel electrophoresis and visualisation of plasmid DNA ............................ 87 
2.7.3 Purification of DNA sample using gel extraction (QlAquick Gel Extraction 
Kit) ............................................................................................................ 87 
2.7.4 Human calpastatin cDNA preparation - Primer design ........................... 87 
2.7.5 Human calpastatin cDNA preparation - PCR ........................................... 88 
2.7.6 Ligation of calpastatin PCR fragment into pGEM T-Easy Vector ............. 89 
2.7.7 Transformation of competent E. coli DH5a cells with ligation mix......... 89 
2.7.8 Overnight Broth Cultures ......................................................................... 90 
2.7.9 Minipreparations of plasmid DNA by'Phenol method' .......................... 90 
2.7.10 Restriction enzyme-digest screening for calpastatin fragment insertion9l 
2.7.11 Ligation of calpastatin PCR fragment into pEGFP-N1 vector ................... 91 
2.7.12 Restriction enzyme digest screening for calpastatin fragment insertion92 
vii 
Contents 
2.7.13 Extraction of EMCV IRES .......................................................................... 92 
2.7.14 Restriction digestion of pEGFP-N1/Calpastatin construct ....................... 93 
2.7.15 Ligation of EMCV IRES into pEGFP-N1/Calpastatin linearised vector...... 93 
2.7.16 Restriction enzyme screening for EMCV IRES insertion .......................... 94 
2.7.17 PCR to check the orientation of EMCV IRES in pEGFP-N1/Calpastatin 
vector ............................................................................................................... 
94 
2.7.18 Transformation of competent E. coli DHSa cells for midi preparations.. 95 
2.7.19 Midi preparations of plasmid DNA ........................................................... 95 
2.7.20 DNA Concentration and Purification ....................................................... 95 
2.7.21 Sequencing of vector to confirm EMCV IRES Inserted ............................. 96 
2.8 Preparation of cell extracts for Western Blot Analysis .................................... 98 
2.8.1 Preparation of total cell extracts ............................................................. 98 
2.8.2 Preparation of cell extracts for cytochrome c analysis ............................ 98 
2.8.3 Quantification of protein concentration in cell extracts ......................... 99 
2.8.4 SDS-PAGE and Western Blot Analysis .................................................... 
100 
2.9 Caspase -3/-7 Activity Assay .......................................................................... 
103 
2.9.1 Cell Preparation ..................................................................................... 103 
2.9.2 Caspase -3/-7 Activity Assay .................................................................. 103 
2.10 Determination of Intracellular and Extracellular Viral Titres ........................ 104 
2.11 Lactate Dehydrogenase Assay (LDH) Cytotoxicity Assay ............................... 105 
2.12 Isolation of Viral RNA from Tissue Culture .................................................... 
105 
2.12.1 RNA Isolation Procedure ........................................................................ 
105 
2.12.2 Reverse Transcription Polymerase Chain Reaction ............................... 106 
2.13 Primer design for UKOS A Sequencing ........................................................... 107 
viii 
Contents 
2.14 Amplification of fragments of UKOS A genome by PCR ................................ 107 
2.14.1 Processing of UKOS A PCR Fragments ................................................... 
108 
3 ASSESSING THE ROLE OF CALPAINS IN FCV-INDUCED APOPTOSIS ..................................... 
110 
3.1 Introduction ................................................................................................... 
110 
3.2 Calpains are activated in FCV-infected cells .................................................. 
112 
3.3 Inhibition of calpain activity prevents apoptosis in FCV-infected cells ......... 
116 
3.3.1 Calpain inhibitors prevent caspase-3 activation during FCV-induced 
apoptosis ............................................................................................................ 
119 
3.4 The Calpain inhibitor calpeptin prevents PS translocation in FCV-infected cells 
........................................................................................................................ 
121 
3.5 The specific calpain inhibitor calpastatin inhibits apoptosis in FCV-infected 
cells ................................................................................................................ 
123 
3.6 Effect of the calpain inhibitors Calpeptin and ALLN on FCV replication and 
virus release ................................................................................................... 
125 
3.7 Discussion ....................................................................................................... 
129 
4 FELINE CAUCIVIRUS ISOLATED FROM CATS WITH VIRULENT SYSTEMIC DISEASE APPEARS TO DELAY 
APOPTOSIS IN VITRO .................................................................................................. 
135 
4.1 Introduction ................................................................................................... 135 
4.2 Apoptosis is the mechanism of cell death occurring during UKOS A infection... 
........................................................................................................................ 
138 
4.3 UKOS A-infected cells show a delay in cell death when compared to FCV-F9 
infected cells .................................................................................................. 
140 
IX 
Contents 
4.4 UKOS A-infected cells show a delay in PS translocation ................................ 142 
4.5 Caspase -3/-7 activation is delayed in UKOS A-infected cells ........................ 144 
4.6 Caspase-9 activation is delayed in UKOS A-infected cells ............................. 147 
4.7 Cytochrome c release from mitochondria is delayed in UKOS A-infected cells.. 
........................................................................................................................ 149 
4.8 The delay in apoptosis in UKOS A-infected cells is not due to a delay in viral 
replication ...................................................................................................... 151 
4.9 Other putative VSD-isolates also delay apoptosis ......................................... 153 
4.10 UKOS A genome sequencing .......................................................................... 155 
4.11 Discussion ....................................................................................................... 157 
5 INDUCTION OF APOPTOSIS IN MNV-1 INFECTED CELLS IN CULTURE ................................ 160 
5.1 Introduction ................................................................................................... 160 
5.2 PS translocation during MNV-1 infection ...................................................... 162 
5.3 Detection of caspase-3 activation during MNV-1 infection .......................... 164 
5.4 Cytochrome c translocation occurs during MNV-1 infection ........................ 167 
5.5 MNV-1 infection induces a loss of A(n)n, in RAW cells .................................. 169 
5.6 Discussion ....................................................................................................... 174 
6 GENERAL DISCUSSION 
........................................................................................ 
177 
7 REFERENCES 
..................................................................................................... 
202 
8 APPENDICES 
..................................................................................................... 
228 
8.1 EMCV IRES Orientation Sequencing ............................................................... 228 
8.2 UKOS A Genome Sequencing ......................................................................... 230 
X 
Contents 
8.3 Vector Map: Human Calpastatin Plasmid - pTicCs ....................................... 232 
8.4 Vector Map: pEGFP-N1 .................................................................................. 233 
8.5 Chemicals ....................................................................................................... 233 
8.6 General Solutions ........................................................................................... 234 
8.7 Cell Culture Media ......................................................................................... 236 
8.8 Gel Electrophoresis Solutions ........................................................................ 236 
8.9 Western Blot Solutions .................................................................................. 238 
8.10 Commercial Kits Used .................................................................................... 238 
XI 
List of Figures 
LIST OF FIGURES 
INTRODUCTION 
Figure 1.1 ................................................................................................................. 11 
Figure 1.2 ................................................................................................................. 12 
Figure 1.3 ................................................................................................................. 16 
Figure 1.4 ................................................................................................................. 20 
Figure 1.5 ................................................................................................................. 36 
Figure 1.6 
................................................................................................................. 
40 
Figure 1.7 
................................................................................................................. 
42 
Figure 1.8 ................................................................................................................. 45 
Figure 1.9 ................................................................................................................. 48 
Figure 1.10 ............................................................................................................... 51 
Figure 1.11 ............................................................................................................... 56 
Figure 1.11a 
............................................................................................................. 
58 
Figure 1.12 ............................................................................................................... 
65 
MATERIALS AND METHODS 
Figure 2.1 ................................................................................................................. 96 
ASSESSING THE ROLE OF CALPAINS IN FCV-INDUCED APOPTOSIS 
Figure 3.1 ............................................................................................................... 113 
Figure 3.2 ............................................................................................................... 114 
Figure 3.3 ............................................................................................................... 
117 
xii 
List of Figures 
Figure 3.4 ............................................................................................................... 119 
Figure 3.5 ............................................................................................................... 121 
Figure 3.6 ............................................................................................................... 123 
Figure 3.7 ............................................................................................................... 126 
Figure 3.8 ............................................................................................................... 127 
FELINE CALICIVIRUS ISOLATED FROM CATS WITH VIRULENT SYSTEMIC DISEASE APPEARS TO DELAY 
APOPTOSIS IN VITRO 
Figure 4.1 ............................................................................................................... 138 
Figure 4.2 ............................................................................................................... 140 
Figure 4.3 ............................................................................................................... 142 
Figure 4.4 ............................................................................................................... 144 
Figure 4.5 ............................................................................................................... 145 
Figure 4.6 ............................................................................................................... 147 
Figure 4.7 ............................................................................................................... 149 
Figure 4.8 ............................................................................................................... 151 
Figure 4.9 ............................................................................................................... 153 
Figure 4.10 ............................................................................................................. 155 
INDUCTION OF APOPTOSIS IN MNV-1 INFECTED CELLS IN CULTURE 
Figure 5.1 ............................................................................................................... 163 
Figure 5.2 ............................................................................................................... 165 
Figure 5.3 ............................................................................................................... 166 
Figure 5.4 ............................................................................................................... 168 
xiii 
List of Figures 
Figure 5.5 ............................................................................................................... 171 
Figure 5.6 ............................................................................................................... 173 
XIV 
List of Tables 
LIST OF TABLES 
INTRODUCTION 
Table 1.1 ..................................................................................................................... 2 
Table 1.2 ................................................................................................................... 68 
MATERIALS AND METHODS 
Table 2.1 ................................................................................................................... 80 
Table 2.2 ................................................................................................................... 81 
Table 2.3 ................................................................................................................... 87 
Table 2.4 ................................................................................................................. 102 
Table 2.5 ................................................................................................................. 108 
ASSESSING THE ROLE OF CALPAINS IN FCV-INDUCED APOPTOSIS 
Table 3.1 ................................................................................................................. 116 
xv 
List of Abbreviations 
LIST OF ABBREVIATIONS 
Aým 
Iab 
VI 
VM 
A 
Ac-DEVD-AFC 
ADP 
AEV 
AFC 
AIDS 
AIF 
ALLN 
Amp 
ANT 
Apaf-1 
ATP 
AV 
AV-FITC 
Bad 
Bak 
Bax 
BcI-2 
BcI-W 
BcI-X1 
BEC-Jena 
BH 
Bid 
Bik 
Bim 
BIR 
Bok 
bp 
BSA 
C 
C. elegans 
CaCI2 
CAD 
Calpeptin 
CARD 
Casp 
Caspase 
CCCP 
CD 
Mitochondrial transmembrane potential 
Microgram 
Microlitre 
Micromolar 
Adenine / Alanine / Ampre 
N-acetyl-Asp-Glu-Val-Asp-amino-4-trifluoromethyl coumarin 
Adenosine diphosphate 
Avian Encephalomyelitis Virus 
amino-4-trifluoromethyl coumarin 
Acquired Immunodeficiency Syndrome 
Apoptosis Inducing Factor 
N-acetyl-leucinyl-leucinyl-norleucinal 
Ampicillin 
Adenine nucleotide translocator 
Apoptotic protease-activating factor-1 
Adenosine triphosphate 
Annexin V 
Fluorescein isothiocyanate conjugate of Annexin V 
Bcl-antagonist of cell death 
Bcl-antagonist killer 1 
Bcl-associated X protein 
B-cell lymphoma 
Bcl-2-like-2 
Bcl-2-like 1 long 
Bovine Enteric Calicivirus-Jena 
BcI-2 homology 
BH3 interacting domain death agonist 
Bcl-2 interacting killer 
Bcl-2 interacting mediator of cell death 
Baculovirus IAP Repeat 
Bcl-2-related ovarian killer 
Base Pair 
Bovine serum albumin 
Cytosine / Cysteine 
Caenorhabditis elegans 
Calcium Chloride 
Caspase activated DNase 
Benzyloxycarbonyldipeptidyl aldehyde 
Caspase recruitment domain 
Caspase 
Cysteinyl aspartate-specific proteases 
Carbonyl cyanide 3-chiorophenylhydrazone 
Cluster of Differentiation 
xvi 
List of Abbreviations 
CD-95 
cDNA 
Ced 
Ces 
c-FLIPL 
c-FLIPS 
CFRK 
CHAPS 
c-IAPs 
Cm 
Conc. 
COX 
CPE 
CRD 
CrmA 
C-terminus 
Cyto c 
D 
dATP 
DCFDA 
DcR 
DD 
DED 
dH2O 
Diablo 
DISC 
DMSO 
DNA 
DR 
Ds 
DTT 
E 
E. coli 
E1A 
E1B 
EBHSV 
EDTA 
EGTA 
OF 
Endo G 
ER 
F 
FADD 
Fas-L 
Fas-R 
FBS 
FCV 
Cluster of Differentiation-95 
Complementary DNA 
Cell death abnormal 
Cell death specification 
Cellular-FLICE-like inhibitory protein long 
Cellular-FLICE-like inhibitory protein short 
Crandell-Rees Feline Kidney 
3-[(3-chloamidopropyl)-dimethylammonio]-1-propanesulphate 
Cellular-IAPs 
Centimetre 
Concentration 
Cytochrome c oxidase 
Cytopathic Effect 
Cysteine rich domain 
Cytokine response modifier A 
Carboxyl-terminus 
Cytochrome c 
Aspartic Acid 
Deoxyadenosine triphosphate 
2', 7'-dichlorofluorescin diacetate 
Decoy receptor 
Death domain 
Death effector domain 
Distilled water 
Direct IAP binding protein with low p1 
Death inducing signalling complex 
Dimethyl suiphoxide 
Deoxyribonucleic acid 
Death receptor 
Double stranded 
Dithiothreitol 
Glutamate 
Escherichia coli 
Early region 1A protein of Adenovirus 
Early region 1B protein of Adenovirus 
European Brown Hare Syndrome Virus 
Ethylene diamine tetraacetic acid 
Ethylene glycol-bis (ß-aminoethylether)-N, N, N', N'-tetraacetic acid 
Eukaryotic initiation factor 
Endonuclease G 
Endoplasmic Reticulum 
Phenylalanine 
Fas associated death domain 
Fas-ligand 
Fas-receptor 
Foetal Bovine Serum 
Feline Calicivirus 
xvii 
List of Abbreviations 
FITC Fluoroscein isothiocyante 
FLICE Fas-associated death-domain-like IL-10-converting enzyme 
FMDV Foot and Mouth Disease Virus 
g Gram 
G Guanine / Gylcine 
GG Genogroup 
Gp Glycoprotein 
GTP Guanosine triphosphate 
H Histidine 
h Hours 
HCV Hepatitis C Virus 
HIV Human Immunodeficiency Virus 
HIV-1 Human Immunodeficiency Virus-1 
Hsc 70 Heat Shock Cognate protein 70 
HuCV Human Caliciviruses 
IAP Inhibitor of apoptosis protein 
ICAD Inhibitior of CAD 
ICE Interleukin-10 converting enzyme 
ICH-1 Ice and ced-3 homologue 
ICTV International Committee on Taxonomy of Viruses 
Ig Immunoglobulin 
IL-10 Interleukin 10 
INF Interferon 
IPTG Isopropyl-ß-D-thiogalactopyranoside 
IRES Internal Ribosome Entry Site 
JAM-1 Junctional Adhesion Molecule-1 
K Lysine 
Kb Kilobase 
kDa KiloDalton 
L Leucine / Litre 
LB Lauria Bertani 
LD Leader of the capsid 
LDV Lordsdale Virus 
LPS Lipopolysaccharide 
M Molar 
M7G Methyl-7-guanosine 
MEM Minimal Essential Media 
mg Milligram 
MG-132 Carbobenzoxy-leucyl-leucyl-Ieucinal 
MIM Mitochondrial Inner Membrane 
Min Minute 
ml Millilitre 
mm Millimetre 
mm Millimolar 
MNV-1 Murine Norovirus-1 
MOl Multiplicity of infection 
MOM Mitochondrial outer membrane 
xviii 
List of Abbreviations 
MOMP 
mRNA 
MW 
N 
NaN3 
Net 
NF-KB 
ng 
N-IAP 
nm 
nM 
NS 
nt 
N-terminus 
NTP 
NTPase 
nuc-1 
NV 
0 
0/N 
°C 
ORF 
P 
p. i. 
p35 
p53 
PAGE 
Pan-1 
PAPB 
PARP 
PBS 
PE 
PEC 
pi 
PI 
pmol 
Po-Cowden 
Pro-pol 
PS 
PTP 
PUMA 
Q 
R 
RdRp 
RH DV 
RIP-1 
RNA 
Mitochondrial outer membrane permeablisation 
Messenger RNA 
Molecular Weight 
Asparagine 
Sodium Azide 
Negative factor in HIV-1 
Nuclear factor KB 
Nanogram 
Neuronal IAP 
Nanometre 
Nanomolar 
Non-structural Protein 
Nucleotide 
Amino-terminus 
Nucleoside Triphosphate 
Nucleoside Triphosphatase 
Nuclease-1 
Norovirus 
Oxygen 
Overnight 
centigrade 
Open Reading Frame 
Protruding domain 
Post infection 
Baculovirus protein 
Transcriptional regulator 
Polyacrylamide gel electrophoresis 
Primate Calicivirus-1 
Poly(A)-binding protein 
Poly(ADP-ribose) polymerase 
Phosphate Buffered Saline 
Phycoerythrin 
Porcine Enteric Calicivirus 
Isoelectric point 
Propidium Iodide 
Picomole 
Porcine Enteric Calicivirus - Cowden 
Protease-Polymerase 
Phosphatidylserine 
Permeability transition pore 
p53 upregulated modulator of apoptosis 
Glutamine 
Arganine 
RNA-dependent-RNA-polymerase 
Rabbit Haemorrhagic Disease Virus 
Receptor-interacting protein-1 
Ribonucleic acid 
Ax 
List of Abbreviations 
rpm 
RT 
S 
SDS 
SDS-PAGE 
Sec 
SHV 
Smac 
SMSV 
SNARE 
SV 
SV40 
T 
TAE Buffer 
Tat 
TBE Buffer 
t-Bid 
TE Buffer 
TEMED 
TMRE 
TNFR-1 
TNFa 
TRADD 
TRAF-2 
TRAIL 
U 
UTR 
UV 
V 
v/v 
VADC 
VESV 
v-FLIP 
v-IAPs 
VLP 
VP1 
VP2 
VPg 
Vpr 
VSV 
w 
w/v 
X 
X-Gal 
X-IAP 
Y 
z-DEVD-AFC 
Revolutions per minute 
Room Temperature 
Serine / Shell domain 
Sodium dodecyl sulphate 
Sodium dodecyl sulphate-Polyacrylamide gel electrophoresis 
Second 
Southampton virus 
Second mitochondria activator of caspases 
San Miguel Sealion Virus 
Sensitive factor attachment protein receptor 
Sapporo Virus 
Simian virus 40 
Threonine / Thyamine 
Tris-acetate disodium EDTA 
Trans-acting transcription factor 
Tris-borate disodium EDTA 
Truncated-Bid 
Tris-HCI disodium EDTA 
N, N, N', N'-tetramethylethylenediamine 
Tetramethylrhodamine ethyl ester 
Tumour necrosis factor receptor-1 
Tumour necrosis factor a 
Tumour necrosis factor receptor-associated death domain 
Tumour necrosis factor receptor-associated factor-2 
Tumour necrosis factor-related apoptosis-inducing ligand 
Unit (of enzyme activity) 
Untranslated region 
Ultraviolet 
Volt / Valine 
Volume/volume 
Voltage dependent anion channel 
Vesicular exanthema swine virus 
Viral-FLIP 
Viral-IAPs 
Virus like particle 
Virus Protein 1 
Virus Protein 2 
Virion Protein genome-linked 
Viral protein r 
Vesicular Stomatitis Virus 
Tryptophan 
Weight/volume 
Any amino acid 
5-bromo-4-chloro-3-indoyl-p-galactopyranoside 
x-chromosome-linked IAP 
Tyrosine 
Benzyloxycarbonil-Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcumarin 
xx 
List of Abbreviations 
z-VAD-fmk Benzoxycarbonil-Val-AIa-DL-fluoromethylketone 
xxi 
Introduction 
1 INTRODUCTION 
1.1 The Caliciviridae 
The calicivirus family is a group of small, positive sense, single stranded RNA viruses 
of an approximate size of 27 - 40 nm. This family of viruses is responsible for 
causing a wide range of diseases of both humans and animals (Clarke and Lambden, 
1997a; Thiel and Konig, 1999; Clarke and Lambden, 2000). Until 1978, the viruses in 
this family were considered to be members of the Picornaviridae, due to similarities 
in their appearance under the electron microscope. Upon further examination it was 
noted, however, that these viruses differed in structure and replication strategies to 
that of the Picornaviridae and were eventually reclassified into a new family group, 
the Caliciviridae (Green et al., 2000). 
The Caliciviridae family is divided into four phylogenetically distinct genera, each 
containing viruses that share distinct characteristics, such as viral genomic 
organisation into two or three open reading frames, with sequences encoding the 
non-structural proteins located at the 5' end and a single capsid protein encoded by 
a subgenomic mRNA (Green et al., 2000). The four major genera are as follows: 
Lagovirus, Norovirus, Sapovirus and Vesivirus. Table 1.1 summarises the current 
classification of the Caliciviridae family along with selected examples of the species 
contained within each genus. 
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Family Genus 
Lagovirus 
Norovirus 
Sapovirus 
Vesivirus 
Species 
Rabbit Haemorrhagic 
Disease Virus.: (RHDV) 
European Brown Hare 
Syndrome Virus (EBHSV) 
Norovirus (NV) 
" Genogroup I: 
Luton, 
Southampton & 
Norwalk strains. 
" Genogroup II: 
Leeds, Lordsdale 
Hawaii & 
Camberwell strains 
" Genogroup III: 
Bovine Enteric 
Calicivirus - Jena 
(BoCV) 
Others: Murine norovirus- 
1 (MNV-1), Tulane Virus 
(member of proposed new 
genus 'Recovirus)' 
Sapporo virus (SV) 
Manchester virus 
London/92 
Porcine Enteric Calicivirus 
- Cowden (PoCV-Cowden) 
Vesicular Exanthema of 
Swine virus (VESV) 
San Miguel Sea Lion Virus 
(SMSV) 
Canine Calicivirus 
Walrus Calicivirus 
Feline Calicivirus 
((Ossiboff, 2007 244 /id): 
F9, Urbana & UKOS A 
Table 1.1: Taxonomy of the Callciviridae family. Table characterising the members of the Caliciviridae 
by family, genus and species (Clarke and Lambden, 1997b; Green et al., 2000; Wobus et at., 2004; 
Farkas et al., 2008). 
2 
Introduction 
1.2 Vesiviruses 
1.2.1 Vesicular Exanthema of Swine virus (VESV) 
This virus was the first documented calicivirus associated with a disease in 1932 in 
the United States and is thought to be the prototypical species of the entire 
Caliciviridae (Smith and Akers, 1976; Clarke and Lambden, 1997b) 
Infection results in vesicular lesions of the snout, tongue, oral cavity and feet, With 
the severity of the disease dependant on strain with some carrying a high risk of 
piglet mortality. The last outbreak occurred in the US in 1956, with clinical 
symptoms that were indistinguishable from foot and mouth disease (FMDV)(Thiel 
and Konig, 1999). As the virus did not infect all of the usual FMDV hosts and 
immunological studies failed to show a link between the two viruses, the virus was 
designated VESV (Cubitt WD., 1996) 
1.2.2 San Miguel Sea Lion virus (SMSV) 
This virus is closely related to VESV and was discovered in 1973 by Smith et al, where 
it was isolated from vesicular lesions on the flippers of the resident sea lion 
population of San Miguel Island, California (Smith et al., 1973). It was demonstrated 
that SMSV could be found in other marine mammals that the sea lions fed on, 
indicating that the virus could be passed on through ingestion of contaminated food 
(Carter et al., 1991). Although serologically distinct from VESV, the two viruses are 
clearly related, shown by high sequence similarity and parallels in both host range 
and clinical symptoms. SMSV can even cause vesicular exanthema symptoms when 
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inoculated into pigs (Neill et al., 1995) indicating a possibility that VESV is of marine 
origin and spread to pigs through contaminated food stuffs (Clarke and Lambden, 
1997a). 
1.2.3 Feline Calicivirus - (FCV) 
Feline calicivirus is a member of the Vesivirus genus of the Caliciviridae family. The 
virus was first recovered from cats suffering with and dying from panleukopenia in 
New Zealand in 1957 (Carter et al., 1991). Infection with FCV causes a variety of 
symptoms within the cats and the morbidity and mortality associated with infection 
is strain specific. Symptoms of infection include conjunctivitis, rhinitis, tracheitis, 
ulceration of the mouth, fever, anorexia and lethargy (Radford et al., 2007). With 
more virulent strains, mortality associated with infection can reach 33%, particularly 
in juvenile cats and young kittens; in these cases severe respiratory disease and/or 
pneumonia is usually seen (Carter and Cubitt, 1998). Transmission of the virus 
occurs through inhalation or ingestion of infected sputum and once in the body the 
virus disseminates and viral particles can be isolated from the respiratory tract, 
spleen, lymph nodes, blood and kidneys (Studdert et al., 1970; Studdert and Martin, 
1970). 
Within the last few years highly virulent strains of FCV have been associated with 
outbreaks of disease with a high mortality, particularly within the USA and UK. The 
outbreaks have been termed as FCV-associated virulent systemic disease (Ohe et al., 
2008), displaying haemorrhagic fever-like symptoms (Pedersen et al., 2000; 
Pesavento et al., 2004; Hurley et al., 2004). Up to 50% of infected cats die or are 
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euthanized in extreme cases. The adult cats are frequently affected more severely 
than kittens and vaccination does not seem to be proving effective, as even 
vaccinated cats were succumbing to infection. Symptoms of infection have been 
reproduced experimentally with one VSD isolate of FCV, demonstrating the role of 
this virus in this disease (Pedersen et al., 2000; Coyne et al., 2006; Ossiboff et al., 
2007). 
Until very recently FCV and RHDV were the only members of the calicivirus family 
that were able to be grown in vitro in tissue culture systems and are therefore the 
most studied of all of the Caliciviridae. FCV is the archetypal model for other 
calicivirus family members such as the noroviruses (Doultree et al., 1999; Green et 
al., 2000). More recent work has focused on the development of infectious clones of 
FCV to allow for mutagenic studies to be performed and further understand the 
differing functions of each region of the genome (Sosnovtsev et al., 2002). 
1.3 Lagovirus 
1.3.1 Rabbit Haemorrhagic Disease virus (RHDV) 
Rabbit Haemorrhagic Disease virus (RHDV) is the causative agent of rabbit 
haemorrhagic disease, a highly contagious and often fatal illness of domestic and 
wild rabbits (Laurent et al., 1994; Meyers et al., 2000; Meyers, 2007). The virus was 
first described in China in 1984 in imported domestic rabbits. Outbreaks of the 
disease showing similar clinical symptoms have also been documented in Korea, 
Europe, Mexico and New Zealand (Ohlinger et al., 1990; Meyers et al., 2000). Virus 
could be isolated from the livers of infected rabbits and was initially described as a 
picornavirus or parvovirus until the causative agent RHDV was identified as a 
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calicivirus in 1990 (Ohlinger and Thiel, 1991). The course of the viral infection, 
lasting 48 - 72 h, results in death from acute necrotic hepatitis and haemorrhage in 
the respiratory system (Ohlinger et al., 1990; Laurent et al., 1994). The genome of 
RHDV was the first ever full length sequence obtained for any of the caliciviruses 
(Meyers et al., 1991a) and was demonstrated to be closely related to European 
Brown Hare Syndrome virus (EBHSV), a virus found in several countries all over 
Europe with a similar pathology to that of RHDV (Wirblich et al., 1994). Due to 
difficulties in the development of in vitro systems to study this virus, expression of 
viral sequences has been carried out in prokaryotic, insect and mammalian cells to 
enable the study of viral polyprotein processing and replication (Laurent et al., 1994; 
Meyers, 2007). Like FCV, efforts have been made to generate infectious clones of 
RHDV so further studies of the virus can take place, while improving the ease with 
which this virus is propagated in cell culture systems (Liu et al., 2007). 
1.4 Noroviruses 
1.4.1 Human caliciviruses (HuCv) 
Human caliciviruses are the major cause of non-bacterial acute gastroenteritis in 
humans worldwide. Because of this a great deal of work has been done in trying to 
characterise and determine norovirus pathogenicity, (reviewed by Clarke and 
Lambden, 2000). Norwalk virus (NV), the prototypic human calicivirus, was first 
associated with disease during an outbreak of gastroenteritis at a school in Norwalk, 
Ohio in 1968 (Graham et al., 1994). The disease is characterised by nausea, 
vomiting, non-bloody diarrhoea, abdominal cramps, myalgias, malaise and headache 
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(Lopman et al., 2002; Chris, 2003; Lopman et al., 2008). Transmission of NV tends to 
occur via the faecal-oral route or through the ingestion of contaminated food or 
water. Outbreaks are seen particularly in large institutional-like settings where 
people are confined together in small places such as hospitals, schools, prisons, army 
camps and cruise ships. It is reported that noroviral related treatment of patients 
costs the UK NHS approx £100 million a year (McCarthy et al., 2000; Lopman et at., 
2004). Despite being identified over thirty years ago, until recently it could not be 
propagated in cell culture or in animal models which has greatly impeded the 
understanding of norovirus biology (see subsection 1.4.2). In the main, experimental 
work has focused on defining the structural components of the virus, identifying the 
composition of the viral genome and in vitro transcription/translation experiments 
(Liu et al., 1996; Belliot et al., 2003; Blakeney et al., 2003; Kuyumcu-Martinez et al., 
2004; Belliot et al., 2005; Chang et al., 2008). 
Upon characterisation of the polymerase and capsid region of the noroviral genome, 
the norovirus genus was divided phylogentically into three distinct genogroups I, II & 
Ill. Genogroups I and II contain several strains capable of infecting humans such as 
Ando (GI) or Ni/Hawaii (Gil). Gill contains animal-infecting viruses such as Bovine 
Enteric Calicivirus-Jena (BEV-Jena) (reviewed by Green et al., 2000). In recent 
months, new culture systems for human norovirus have been reported. Here, the 
leader sequence of the capsid protein of FCV was placed under the control of the 
cytomegalovirus promoter. The LC protein could therefore be provided in trans to 
replicating calicivirus genomes bearing a reporter gene, allowing for replication of 
NV in tissue culture (Chang et al., 2008). 
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1.4.2 Murine Norovirus (MNV-1) 
In 2003, a tissue culture and small animal system was established for a newly 
discovered member of the Norovirus genus, Murine Norovirus-1 (MNV-1). MNV-1 
was first isolated from RAG-2/STAT-1 knockout mice that sporadically succumbed to 
a systemic disease that could be serially passaged by intracerebral inoculation. 
Since its discovery, the virus has been found in approx 22% of all research mice 
within the USA and Canada through serum testing. The virus is able to infect the 
cells comprising the intestinal tract of mice following oral inoculation (Karst et al., 
2003). It is also able to grow proficiently in murine macrophages and dendritic cells, 
providing the first efficient tissue culture model for a norovirus (Wobus et al., 2004; 
Wobus et al., 2006). MNV-1 shares many of the important characteristics and 
molecular properties with other noroviruses and caliciviruses in general such as size, 
icosahedral shape, buoyant density as well as the three open reading frames 
characteristic of two genera within the Caliciviridae (Karst et al., 2003). More recent 
work on murine norovirus biology has focused on the development of reverse- 
genetic systems to further understand norovirus replication strategies (Ward et al., 
2006; Chaudhry et al., 2007). 
1.5 Sapoviruses 
Sapporo virus (SV) is the prototypical member of this genus and was first isolated 
during an outbreak of gastroenteritis in an orphanage in Japan in 1976, as well as in 
an infant school in Glasgow in 1979, but was indistinguishable from NV at the time 
(Madeley and Cosgrove, 1976; Chiba et al., 1979). Saporoviruses differ in 
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morphology from noroviruses in that they possess a cup-shaped morphology 
whereas noroviruses do not, the saporoviruses also have a different genome 
organisation (Chiba et al., 2000; Lopman et al., 2002). 
Like the noroviruses, the saporovirus genus is divided into three genogroups, the 
first two containing human viruses, whilst the third contains animal viruses: 
genogroup I (Manchester virus), genogroup II (London/92 virus) or genogroup III 
(Porcine Enteric Calicivirus-Cowden) (Lopman et al., 2002). In 1994, SV was shown to 
be antigenically different from NV; this was further strengthened through the 
analysis of full-length genomic sequencing of two sapoviruses, Plymouth and 
Manchester virus, which revealed that the open reading frame usage was 
substantially different between the classical HuCVs and Sapporo-like viruses (Liu et 
at., 1995; Clarke and Lambden, 2000). 
1.6 Calicivirus Morphology 
Caliciviruses have small, non enveloped virions, approximately 27-40 nm in diameter. 
Their name is derived from the characteristic cup (calyx = Latin meaning cup/chalice) 
shaped depressions that can be seen on the capsid surface of the majority of the 
family members (Figure 1.1). When viewed by negative stain electron microscopy, 
cryoelectron microscopy or three-dimensional image reconstruction, virions are 40.5 
nm in diameter with 32 large cup-like surface structures, comprised of 90 arch-like 
capsomeres arranged in a T= 3 icosahedral symmetry. Each one of the capsomeres is 
comprised of dimerised viral capsid protein (180 units in all) (Prasad et al., 1994a; 
Clarke and Lambden, 1997b; Green et al., 2000). Depending on the axis of 
symmetry, the cup-shaped surface depressions or hollows display characteristic 
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patterns. Virions show four dark hollows seen arranged as a cross along their two- 
fold axis of symmetry, a central dark hollow surrounded by six others forming a 'Star 
of David' configuration along the three-fold axis and finally a central hollow with ten 
spike-like projections around the edge of the particle forming the 'ten-pointed 
sphere' (Prasad et al., 1994a; Cubitt WD. et al, 1995) (Figure 1.2). 
The individual capsomeres described earlier, which are dimerised viral capsid 
proteins, have two domains: the shell (S) and protruding (P) domains. The S domain 
forms the inner part of the capsid that surrounds the RNA genome; this is the N- 
terminal region of the capsid protein and is well conserved among the Caliciviridae. 
The P domain forms the arch-like capsomeres that stem from the shell (Prasad et al., 
1994a; Prasad et al., 1994b). The P domain can be split into two subdomains, P1 and 
P2, P1 being the central stem and P2 a distal globular bi-lobed head domain, the 
latter being highly variable in nature (Prasad et al., 1994b). The P domain shows 2 
types of structural variation and it is suggested that this hypervariable P2 domain is 
involved in host specificity, the antigenic structure of the virus and binding of the 
virus to host cells (Chen et al., 2004) 
10 
Introduction 
Figure 1.1: Structure and morphology of the Caliciviridae. Negatively stained electron 
micrographs of (A) norovirus and (B) 'Classic' human calicivirus, bar represents 50 nm. (C) The x-ray 
structure of SMSV viewed along the icosahedral twofold axis. The S domain, P1 and P2 are coloured 
blue, yellow, and orange respectively. (D) Image reconstruction from cryo-electron microscopy of 
norovirus (Clarke and Lambden, 1997b; Green et at., 2000; Chen et al., 2006). 
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Figure 1.2: Three dimensional structures of calicivirus virions. (Fiore et al., 1998b) Diagram 
demonstrating the 2 (cross), 3 (star of David), & 5-(ten pointed sphere) fold axis of symmetry. (Right) 
Negative contrast electron micrographs of calicivirus virions, showing the representative cup-shaped 
hollows on the surface of the virion. Taken from (Green et al., 2000) 
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1.7 Genomic Organisation of the Caliciviruses 
The calicivirus genome is comprised of a 7.8 kb single-stranded, positive sense RNA 
molecule that is polyadenylated at the 3' end and has a 15 kDa viral protein 
covalently linked to the 5' end (named virus protein, genome-linked; VPg) (Carter et 
al., 1991; Carter et al., 1992a; Clarke and Lambden, 2000). The non structural 
protein coding regions are located at the 5' end of the genome with the structural 
protein coding sequences located in the 3' end of the genome (Figure 1.3)(Green et 
al., 2000). 
Within the Caliciviridae there are two distinct types of genomic organisation based 
upon the arrangement of the open reading frames (ORFs). The first type, as seen in 
the vesiviruses and noroviruses, is characterised by the presence of three ORFs with 
the non-structural and structural protein coding sequences in different reading 
frames. The second type, representative of the lagoviruses and sapoviruses, is 
characterised by the presence of two open reading frames in which the non- 
structural proteins and the viral capsid protein are joined together to code for one 
large polyprotein from ORF 1 (Figure 1.3) (Clarke and Lambden, 1997b; Clarke and 
Lambden, 2000; Green et al., 2000) 
1.7.1 Feline Calicivirus Genome 
The genome of FCV is divided into 3 ORFs (Carter et al., 1992a). The initiating codon 
for ORF 1 starts at nucleotide 19 and proceeds to nucleotide 5314. The polyprotein 
produced from this reading frame contains all of the viral non-structural proteins 
(Carter et al., 1992b). This long polypeptide is proteolytically cleaved by the virus- 
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encoded cysteine protease to produce mature proteins including: NTPase, Vpg, 
cysteine protease and an RNA-dependent RNA polymerase (Sosnovtsev et al., 1998; 
Sosnovtsev et al., 2002). ORF 2 (encoding the viral capsid protein) begins at 
nucleotide 5314 and due to the overlap with the end of ORF 1, ORF 2 is therefore 
frameshifted backwards (-1) with respect to open reading frame 1. The encoded 76 
kDa capsid protein precursor is also cleaved by the cysteine protease to yield a 62 
kDa mature capsid protein (Sosnovtsev et al., 1998). ORF 3 (coding for a small 
component of a highly basic structural protein, VP2) is also frameshifted (-1) with 
respect to ORF 2 and the latter's termination sequence overlaps by 4 bases into ORF 
3. Experimentation has demonstrated that the latter cistron is translated through a 
termination-reinitiation process, not requiring the eIF4G or eIF4F complexes (Poyry, 
2007 1 /id; Luttermann, 2007 574 /id). Both ORF 2 and ORF 3 encoded proteins are 
produced by translation of a subgenomic RNA (Herbert et al., 1996). 
1.7.2 Murine Norovirus-1 (MNV-1) Genome 
The genome of the noroviruses shows similar genomic organisation to that of FCV 
with the non-structural protein encoded sequences found in ORF 1 (Figure 1.3). The 
structural proteins, the major capsid protein (Girod et al., 2002) and minor capsid 
protein (VP 2) are coded for in ORF 2 and ORF 3, respectively (Clarke and Lambden, 
2000; Asanaka et al., 2005). As with FCV, ORF 2 is frameshifted relative to ORF 1 and 
the 3' end of the RNA-dependent RNA polymerase overlaps with the 5' end of the 
capsid protein ORF. The extent of this overlap varies depending on the genogroup of 
norovirus; in genogroup-1 by 17 nt and in genogroup-2 by 20nt. However, in 
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noroviruses ORF 3 is in a different reading frame to that of ORF 2, but in the same 
frame as ORF 1. The first base of the initiation codon of ORF 3 overlaps the last 
residue of the stop codon of ORF 2 (Clarke and Lambden, 2000). 
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Figure 1.3: Genomic Organisation of the Caliciviridae. The calicivirus genome is a positive 
sense single stranded RNA molecule with a covalently linked viral protein (VPg) at the 5' terminus and 
polyadenylated tail at the 3' terminus. The genomes of the Vesivirus and Norovirus genera are 
organised into three open reading frames (ORFs); ORF 1 encodes the non-structural proteins, ORF 2 
encodes the precursor to the viral capsid protein and ORF 3 the minor component of VP2. The 
Lagovirus and Sapovirus genera contain two ORFs, with the non-structural polyprotein and capsid 
protein coding regions forming one large ORF (ORF 1). The caliciviruses produce an abundant 
subgenomic RNA which is 3' coterminal to the genomic RNA and is also VPg-linked and 
polyadenylated. This sRNA contains the capsid protein and VP2 (Clarke and Lambden, 2000; Green et 
al., 2000; Asanaka et al., 2005). 
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1.8 Calicivirus Subgenomic RNA 
During the process of calicivirus infection and replication it was found that in 
addition to the 7.5-8.3 kb genomic RNA, the caliciviruses produce an abundant 
amount of a 2.4 kb subgenomic RNA (Harada et al., 2008) (Neill and Mengeling, 
1988; Neill, 2002). It was demonstrated in 1996 by Herbert et al that this 
subgenomic RNA was VPg-linked at the 5' terminus, 3' polyadenylated and was 3' co- 
terminal to the larger genomic RNA (Herbert et al., 1996). The subgenomic RNA 
produced encoded for both the major and minor capsid proteins (Girod et al., 2002) 
and hence ORF 2 and 3 of the FCV genome (Neill et al., 1991; Herbert et al., 1997). 
The detection of minus strand copies of the sRNA suggested that the it was capable 
of being replicated like the larger genomic RNA (Carter, 1990). 
Subgenomic RNA has also been detected in other genera of the Caliciviridae through 
RNA analysis including: SMSV (Schaffer et al., 1980); VESV (Black and Brown, 1975); a 
2.2 kb sRNA in RHDV infected cells (Meyers et al., 1991b) and more recently in the 
newly discovered MNV-1 infected cells (Wobus et al., 2004). It has also been 
demonstrated that human norovirus may also produce sRNA, when a 2.3 kb RNA 
molecule was isolated from a stool sample of an infected human volunteer (Jiang et 
al., 1993). Primer extension mapping of the 5' end of the NV subgenomic RNA 
revealed that the sequence was identical to that of the capsid protein and the entire 
open reading frame of the genomic RNA. This along with the sequencing of the 
RHDV genome allowed for the mapping of the sRNA to nucleotide 5292 of the viral 
genome (Neill et al., 1991; Meyers et al., 1991b). 
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It was noted that during FCV infection some strains, particularly vaccine or low 
virulence strains, produced defective interfering particles of a lower density than 
that of the normal virion (Neill, 2002). The 2.4 kb RNA fragment isolated from these 
particles mapped to the same point as the 2.4 kb sRNA purified from infected cells. 
It is not known why the sRNA is encapsidated, however it is hypothesised that 
changes in the nucleotide sequence of the 5' leader region of the sRNA to make it 
more homologous to genomic RNA may increase the chance of encapsidation of the 
sRNA (Meyers et al., 1991b; Neill, 2002; Morales et al., 2004; Casais et al., 2008). 
1.9 Calicivirus Non-Structural Proteins (ORF 1) 
Open Reading Frame 1 of the calicivirus genome encodes for a large non-structural 
polyprotein (200-250 kDa protein, dependent on viral genome organisation). 
Proteins created during FCV infection were analysed and it was found that several 
non-structural proteins were present with approximate sizes ranging from 27 to 96 
kDa (Carter, 1989). From this it was hypothesised that these proteins had arisen as a 
result of proteolytic cleavage of a larger polyprotein, as several polypeptides within 
ORF 1 have high amino acid sequence homology to that of the picornavirus 
polyprotein (Neill, 1990). These regions were identified as the genome-linked VPg, 
2C-like NTPase, 3C-like cysteine protease and the 3D RNA-dependent RNA 
polymerase (Neill, 1990; Jiang et al., 1993). Sosnovtseva et al demonstrated that the 
3C-like protease encoded in ORF 1 mediated the autocatalytic processing of the non- 
structural polyprotein at cleavage sites with either E or Q residues at the P1 position, 
in a time dependent manner. Mutagenesis experiments on cysteine 1193 within 
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ORF 1, thought to be the region coding for the 3C-protease, showed that the 3C 
protease was dependent on this amino acid residue being conserved for its activity 
(Sosnovtseva et al., 1999). Elucidation of the exact order of genes encoded in ORF 1 
was achieved through in vitro examination of the FCV-ORF 1. This demonstrated five 
cleavage sites present that are cleaved by the viral 3C-protease, giving rise to 6 
mature proteins; mutagenesis studies using reverse genetics with FCV showed that 
cleavage of the different gene products is critical for the ability of the virus to 
replicate (Sosnovtsev et al., 2002). The order of the genes for the ORF 1 polyprotien 
is as follows (from N terminus): p5.6/ p32/ - (NTPase) p39/ p30/ VPg/3C like 
protease - Pol (RNA-dependent RNA Polymerase). 
It has also been demonstrated that a similar cleavage pattern occurs during MNV-1 
infection. The 3C- like protease of MNV-1 maps to amino acids 995 - 1177 of the 
polyprotein gene and processes the viral genome into 6 proteins by cleaving at 5 
different sites, again with either E or Q residues at the P1 position. The gene order 
of the MNV-1 ORF 1 is as follows (from N terminus): p38.3 (Nterm)/ p39.6 (NTPase)/ 
p18.6/ p14.3 (VPg)/ p19.2 (Pro)/ p57.5 (Pol) (Sosnovtsev et al., 2006) (Figure 1.4). 
19 
Introduction 
Feline Calicivirus 
E06/A E331/D 
i 
E"s/N 
NHz 
p5.6 p32 NTPase 
Murine Norovirus-1 
E/G3e2 
p30 
Q/N706 E/G371 E/A995 
V Pg 
aG117s 
Pro-Pol 
NH2 -____ JCOOH 
NTerm NTPase p18 
E960/A E1°71/S 
i 
COOH 
VPg Pro Pol 
Figure 1.4: Schematic representation of different Calicivirus ORF 1 polyprotein processing. 
The calicivirus ORF 1 is proteolytically cleaved by co-translational autocatalytic cleavages by the viral 
3C-like protease. This cleavage results in the maturation of approximately six non-structural proteins. 
The diagram shows these six proteins in the order they appear in the polyprotein and the major 
cleavage sites of the protease are shown (dashed arrows). Amino acid one-letter code denotes the 
specific cleavage site for each of the non-structural proteins (A: alanine; D: aspartic acid; E glutamic 
acid; G: Glycine; N: asparagine; Q: glutamine and S: serine) Adapted from (Sosnovtsev et al., 2002; 
Sosnovtsev et al., 2006) 
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1.9.1 2C-like NTPase 
This region of ORF 1 is thought to contain a NTP-binding domain and the 2C protein 
produced shares significant homology with the picornavirus 2C polypeptides (Neill, 
1990; Clarke and Lambden, 1997b). The FCV 2C protein also shows similarities in 
amino acid sequence with other NTPases from other caliciviruses, in particular that 
of RHDV and SHV (Meyers et al., 2000; Sosnovtsev et al., 2002). This protein is 
thought to play a role in viral membranous replication complexes, although its exact 
role is still yet unclear (Green et al., 2002; Kaiser et al., 2006). 
1.9.2 VPg 
The presence of a genome-linked protein covalently attached to the 5' end of the 
genomic and subgenomic RNA is now a well documented feature of many of the 
positive stranded RNA viruses. In caliciviruses, the protein is approximately 10-15 
kDa in size (Clarke and Lambden, 2000; Sosnovtsev et al., 2002). In the FCV genome, 
the VPg-coding sequence is localised immediately before the 3C-protease gene in 
contrast to the picornaviruses (Pathak et al., 2008). Comparison of this sequence to 
that of other caliciviruses such as RHDV, the primate calicivirus (PAN-1) or 
Southampton virus (Shapiro et al., 2006) shows similarities of 58,69 and 36% 
respectively (Sosnovtseva et al., 1999). There is a common structural feature 
conserved in all three of these caliciviral viral VPgs and the presence of two 
hydrophilic amino acid clusters at the amino terminus of the protein, one consisting 
of basic residues, the other acidic (Sosnovtseva et al., 1999). In RHDV, the latter of 
the two motifs contains a tyrosine residue at position 21 that is involved in in vitro 
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uridylylation by the RHDV polymerase and is thought to be the site at which the 
protein is linked to the viral RNA (Machin et al., 2001; Mitra et al., 2004). Further to 
this, in FCV, substitution of tyrosine-24 of VPg to a serine, threonine or 
phenylalanine proved to be lethal to virus growth, indicating that this tyrosine 
residue is important in the formation of a covalent bond between the VPg and the 
viral RNA (Mitra et al., 2004; Goodfellow et al., 2005). 
It has been shown that some viruses translate their mRNA using a methyl guanine 
cap-independent mechanism such as poliovirus. This was also shown by Herbert et 
al, 1997 where they demonstrated that removal of the VPg from FCV mRNA 
dramatically decreased the ability of the virus to translate its RNA into protein. Yet 
more evidence has recently been found to show that VPg plays a role in the initiation 
of protein synthesis. The VPg of NV has been shown to bind to purified eukaryotic 
initiation factor-3 (Daughenbaugh et al., 2003) both in mammalian cell lysates and in 
vitro cell free translation reactions (Daughenbaugh et al., 2003). More recently, it 
was demonstrated that FCV VPg interacts with eIF4E and that this interaction was 
essential for translation of the viral mRNA (Goodfellow et al., 2005; Chaudhry et al., 
2006). The VPg of the newly discovered MNV-1 also plays a role in translation 
initiation by binding elF3, eIF4GI, eIF4E, and ribosomal proteins. MNV-1 VPg also co- 
precipitated eIF4GI and elF4E from infected cells, providing evidence that VPg 
interacts with components of the translation machinery in norovirus infected cells 
(Daughenbaugh et al., 2006). All of these observations across the different genera of 
the Caliciviridae suggest that VPg functions as a potential 'cap substitute' to enable 
the recruitment of eukaryotic initiation factors and initiate viral protein synthesis in a 
cap-independent manner. 
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1.9.3 3C-like Protease 
The 3C-like cysteine protease (3C) is located immediately upstream of the RNA- 
dependent RNA polymerase (RdRp) within the calicivirus ORF 1.3C is able to cleave 
the calicivirus polyproteins into mature non-structural proteins (Boniotti et al., 1994; 
Sosnovtseva et al., 1999; Sosnovtsev et al., 2002). It was first predicted that this 
region may have potential 3C activity through the sequencing of the FCV genome by 
Neill et al (1990) and then later confirmed when amino acid alignment analysis of 
this region of RHDV ORF 1 showed significant homology to the picornavirus 3C 
protease (Boniotti et al., 1994). In FCV the 3C protease exists in a stable 76 kDa 
complex with the RdRp and was shown to cleave the amino terminus of ORF 1 at five 
cleavage sites (Figure 1.4) (Sosnovtseva et al., 1999). 
Mutagenic analysis of the RHDV 3C has shownthree amino acids histidine-1135, 
aspartic acid-1152 and cysteine-1212 to be the components of its catalytic core, the 
cysteine-1212 being the nucleophilic residue as substitution to glycine reduced the 
proteolytic activity dramatically (Boniotti et al., 1994; Oka et al., 2007). 
As well as cleaving the polyprotein of ORF 1,3C has also been reported to play a role 
in the inhibition of cellular translation during calicivirus infection. Poly(A)-binding 
protein (PABP) can be cleaved and inactivated by the calicivirus 3C. The FCV protein 
3C Pro was able to cleave both feline and human PABP; the cleavage site on human 
PABP was mapped to a region not usually utilised by other proteases such as the 3C 
Protease of PV. This cleavage removes the C-terminal domain of PABP, and 
therefore may allow the virus to down-regulate cellular mRNA translation late in 
infection (Kuyumcu-Martinez et al., 2004). Structural analysis has revealed that four 
amino acids are crucial for protease activity: H39, E60, C122, and H137for FCV, the 
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residues being found positioned closely along the inner surface of the potential 
binding cleft for the 3CPro substrate (Oka et al., 2007). 
1.9.4 RNA-dependent RNA polymerase 
This viral enzyme is responsible for the replication of calicivirus genomic material. It 
is able to efficiently synthesise RNA from an RNA template (Vazquez et al., 1998). In 
FCV the active form of the polymerase is found as a 76 kDa bi-functional protease- 
polymerase precursor. Proteolytic cleavage between the two domains is not 
necessary for polymerase activity and it is this precursor molecule that accumulates 
to significant levels in FCV-infected cells in vitro (Wei et al., 2001). This is also 
thought to be the case in RHDV-infected cells, where the pro-pol polyprotein 
accumulates in infected hepatocytes (Konig et al., 1998). 
In norovirus infection two active forms of the polymerase have been described, the 
fully active and cleaved polymerase and the pro-pol polyprotein precursor, both of 
which have a similar level of activity within the cell. As with FCV, the NV Pro-pol 
polyprotein is thought to be bi-functional and act as both a protease and polymerase 
(Belliot et al., 2005). 
More recent work has focused on the structure and function of sapovirus 3D-pol. It 
provided evidence that the properties of the SV 3D polymerase are similar to that of 
human norovirus but not to lagovirus. This clustering between pathogenic human 
calicivirus RdRps raises the question of the role and relevance of RdRps in virulence 
and pathogenicity (Fullerton et al., 2007; Zamyatkin et al., 2008). 
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1.10 Calicivirus Structural Proteins (ORF 2& 3) 
In caliciviruses the structural proteins are encoded in ORF 2 and ORF 3 of the RNA 
genome as well as the bicistronic subgenomic RNA; however, protein is only 
produced from the latter. In the case of the Lagovirus or Sapovirus genera the major 
structural protein, the capsid protein, is part of the fused polyprotein encoded by 
ORF 1 and is in frame with the non-structural protein-coding region, as described in 
Section 1.9. Therefore, the capsid protein is matured and released by proteolytic 
cleavage of ORF 1 by the viral protease (Wirblich et at., 1995). The Norovirus and 
Vesivirus genera genomic organisation differs slightly, in that ORF 2 is not in the 
same reading frame with respect to ORF 1. This problem is overcome through the 
use of the bicistronic subgenomic RNA which encodes both ORF 2 and ORF 3 of the 
genome allowing sufficient production of the capsid protein (Carter et al, 1992b 
; Meyers et al, 2007 ; Poyry et al, 2007) 
ORF 3 is a small open reading frame found at the 3' end of the genomic and 
subgenomic RNA and is once again frame shifted with respect to that of ORF 2 
(Clarke and Lambden, 2000). It encodes the minor structural protein virion protein 2 
(Sosnovtsev et al., 2005). Due to the frameshift in this ORF, the level of VP-2 
expressed in the cells is about 10 % of the level of VP 1 (Herbert et al., 1996; Belliot 
et al., 2008). 
1.10.1 FCV Capsid Protein 
ORF 2 of the FCV genome encodes a single capsid protein called virion protein 1 (VP- 
1). The precursor molecule of the capsid protein was first detected by Carter et al 
(Carter, 1989). It was detected in FCV-infected cells following post-translational 
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cleavage by the virus encoded 3C protease from a 76 kDa precursor to a 62 kDa 
mature capsid protein (Carter et al., 1992b; Clarke and Lambden, 1997a; Sosnovtsev 
et al., 1998). This maturation occurs through the removal of a 14 kDa fragment from 
the amino terminus of the capsid protein (known as the leader region). This small 
fragment released by capsid maturation can be readily detected in FCV-infected 
cells; however it is not detectable in mature FCV virions (Tohya et al., 1999; Chang et 
al., 2008). Mutational analysis of the capsid protein that prevented this cleavage 
maturation or propagation of the virus at elevated temperatures dramatically 
decreased the production of infectious virus particles to near undetectable levels 
(Carter, 1989; Sosnovtsev et al., 1998; Karakasiliotis et al., 2006). As previously 
stated, the capsid protein is encoded for by the abundant subgenomic RNA; this was 
further evidenced by the detection of the capsid protein using FCV antisera at 3h 
post infection by Western blotting, approximately 1 hour after the subgenomic RNA 
was first detectable (Neill and Mengeling, 1988; Karakasiliotis et al., 2006). The FCV 
capsid protein can also be cleaved later in infection to yield a fragment of 
approximately 40 kDa and this cleavage is mediated by caspases. It has been 
demonstrated that this cleavage can be inhibited using the pan caspase inhibitor z- 
VAD-fmk, and that caspases -2 and -6 are able to cleave recombinant FCV capsid 
protein in vitro to yield the 40 kDa cleavage product (Carter, 1989; Al-Molawi et al., 
2003). This finding is significant as it implies a role for virus-induced apoptosis in the 
viral replication cycle. 
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1.10.2 Norovirus Capsid Protein 
The noroviral capsid protein was first discovered in 1981 by Greenberg et al, when 
the group isolated and identified a 58 kDa and a 32 kDa capsid protein from the stool 
of volunteers infected with norovirus (Greenberg et al., 1981). 
Baculovirus expression system technologies have allowed for the production of large 
amounts of 58 kDa VP1 protein that is capable of self assembly into virus-like 
particles that are morphologically and antigenically identical to that of the native NV 
capsid protein; these particles elicited a strong virus-specific serum antibody 
response and could therefore be beneficial in the development of a norovirus 
vaccine (Jiang et al., 1992; Clarke and Lambden, 1997b). 
As well as the 58 kDa protein, a smaller 32 kDa minor protein was detected in NV- 
infected stool samples; this was found to be a trypsin-mediated cleavage product of 
the 58 kDa protein at lysine-227. Amino terminal sequence analysis of the 32 kDa 
fragment showed that it mapped to residues 217 -226 of the larger capsid protein. It 
is thought that this cleaved soluble protein plays a role in mediating the immune 
response to NV and the pathophysiology and the clinical outcome of infection (Hardy 
et al., 1995). 
1.10.3 Minor Structural Protein (VP-2) 
Every member of the Caliciviridae discovered thus far has been found to have a small 
3'-terminal ORF encoding a small basic protein called virion protein 2. One to two 
copies are found per mature virion (Sosnovtsev and Green, 2000). This protein is 
produced from ORF 2 in the case of the Lagoviruses and ORF 3 in the Vesivirus and 
27 
Introduction 
Norovirus genera (Clarke and Lambden, 2000). The protein produced is 8.5 - 23 kDa, 
depending on the genera and its amino acid sequence shows approximately 95 % 
identity between FCV strains. Similar observations can be found with other viruses 
such as NV, RHDV, VESV and SMSV (Carter et al., 1991; Herbert et al., 1996). 
Although the exact role of VP-2 is unclear, Glass et al (2003) showed that the 
sequence between amino acids 108 and 152 of the NV VP-2 was responsible for the 
interaction of VP-1 and VP-2 at the protein level (Glass et al., 2003). There have also 
been reports of protein-protein interactions between the FCV ProPol and ORF3; 
however this is a weak interaction, and it's significance is not yet known (Kaiser et 
al., 2006). Deletion of the entire ORF 3 sequence was lethal for the virus. 3' 
deletions and point mutations to ORF 3 were tolerated by the machinery responsible 
for replicating the virus, but the viruses produced were not infectious. However, an 
infectious phenotype could be rescued from a ORF 3 mutant clone if trans 
complementation was performed with functional VP2 expressed from a mammalian 
expression vector (Sosnovtsev et al., 2005). This led to the hypothesis that ORF 3 is 
not required for the formation of virus like particles, but is needed for virus viability 
and this suggests a role for it in virus replication (Sosnovtsev et al., 2005). 
1.11 Calicivirus Replication 
Due to a lack of suitable tissue culture systems to propagate growth of the 
caliciviruses in vitro, studies on the replication strategies of these viruses have fallen 
behind that of many other positive stranded RNA viruses. Perhaps the best 
characterised calicivirus replication cycle is that of FCV, owing to its ability to be 
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propagated in tissue culture (Crandell et at, 1973). However, more recently, due to 
technological advancements and discoveries it is now possible to propagate a 
norovirus in tissue culture. Wobus et al (2004) demonstrated for the first time a 
murine norovirus capable of propagation in tissue culture, isolated from 
recombination-activating gene 2 (RAG2) and signal transducer and activator of 
transcription 1 (STAT-1) (RAG2/STAT1-/- mice) knock out mice. It was discovered 
that MNV-1 infects macrophage-like cells in vivo and replicates in cultured primary 
dendritic cells and macrophages. Ward et al (2006) and Chaudry et al (2007) have 
taken this one step further and developed infectious clone reverse genetic systems 
for MNV-1 under the control of DNA polymerase II or fowipox T7 promoters 
respectively. These systems now allow the recovery of genetically defined 
noroviruses and will aid the analysis of the effects of genetic variation on norovirus 
pathogenesis (Karst et al., 2003; Wobus et al., 2004; Ward et al., 2006; Chaudhry et 
al., 2007). Other more recent work has shown that the FCV leader of the capsid 
protein can promote the growth of human NV when it is transfected in trans with 
noroviral genomes (Chang et at., 2008). Here it was demonstrated that the FCV 
leader of the capsid protein region could be provided in trans to complement NV 
replication. From this work Chang et al concluded that the leader of the capsid 
protein region of FCV may be a viral factor which promotes the replication of NV in 
cells (Chang et at., 2008). 
The viruses gain entry to the cell via receptor mediated mechanisms; however for 
many of the members of the caliciviruses it is still unclear as to the exact identity of 
each receptor. Studies with human noroviruses have revealed that different 
genogroups of NV bind to different human blood group antigens (HBGA). It is 
29 
Introduction 
thought that the structure of the P2 domain of the NV capsid protein is responsible 
for its binding affinity to a particular HBGA (Tan and Jiang, 2005a; Tan and Jiang, 
2005b). In the case of FCV, it has been demonstrated that the feline junctional 
adhesion molecule-1 (feline JAM-1) is a potential functional receptor (Makino et al., 
2006). Makino et al demonstrated that cells previously non-permissive to FCV 
infection could be made permissive to infection by expression of feline JAM-1 on the 
cell surface. 
Early work suggested that entry of FCV into cells is sensitive to lysosomotrophic 
agents such as chloroquine, which prevent the acidification of intracellular vesicles, 
suggesting that this acidification is necessary (Kreutz and Seal, 1995). More recent 
work using knock out FCV mutants to rab5 and eps15 and drug treatments of 
chlorpromazine, chloroquine, and bafilomycin Al have shown that FCV enters cells 
via clathrin-mediated endocytosis and require endosome acidification (Stuart and 
Brown, 2006). 
Following uncoating and entry of FCV into the cytoplasm, production of the genomic 
and subgenomic RNAs can be detected approx 2h post infection (Neill and 
Mengeling, 1988) with active replication complexes containing all the mature viral 
proteins (e. g. pro-pol) being detected at 5hp. i. (Green et al., 2002). Infected cells 
start to demonstrate cytopathic effects (cpe) at approximately 5-6 h p. i. and in the 
latter stages of infection the replication of FCV causes the host cell to undergo an 
apoptotic death (Sosnovtsev et al., 2003; Roberts et al., 2003; Al-Molawi et al., 2003) 
It has been demonstrated that FCV induces the mitochondrial pathway of 
apoptosis, through the translocation of bax from the cytosol to the mitochondria, 
with loss of mitochondrial membrane potential, the release of cytochrome c from 
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the mitochondria, and the activation of caspase 9 and caspase -3 (Natoni et al., 
2006). The induction of apoptosis appears to be a virally mediated event as UV- 
inactivated virus particles that could bind and enter cells were added to cells in vitro 
and it was found that they failed to induce an apoptotic response (Sosnovtsev et al., 
2003). This is discussed further in Section 1.22. 
1.12 Apoptosis 
Apoptosis is characterised by a series of morphological and biochemical events 
ultimately leading to death of the cell. It is a highly mediated intrinsic cell suicide 
programme used by multicellular organisms as an essential component of 
development in morphogenesis, deleting unwanted bodily structures (such as inter- 
digital webbing of the hands and feet), sexual differentiation and recognition of self 
within the immune system (Jacobson et al., 1997; Saraste and Pulkki, 2000; Yuan and 
Yankner, 2000; Kerr, 2002; Zuzarte-Luis and Hurle, 2005). 
Although apoptosis has been described in older scientific reports dating back to the 
mid 19th Century, it was not formally described until 1972 by Kerr et al (Kerr et al., 
1972). He and his group noted that the morphology of the dying hepatocytes he was 
studying resembled that described by Gluckmann in 1951 for developmental cell 
death. Kerr noticed that the cell death occurred in individual hepatocytes and he 
demonstrated that this form of cell death was different to that of necrotic cells (Kerr 
et al., 1972; Kerr, 2002). Kerr et al, adopted the term 'Apoptosis' from two Greek 
words meaning 'dropping off or 'falling off as in leaves from a tree, to describe this 
method of cell death (Kerr et al., 1972; Wyllie et al., 1980). 
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Further characterisation of apoptosis by this group showed that the cells undergoing 
apoptosis shrunk, their chromatin condensed, the nucleus became fragmented and 
irregular and the cells were packed into small membrane-bound vesicles termed 
'apoptotic bodies'. These dying cells were quickly removed by immune cells such as 
macrophages and therefore prevented the release of cytokines and pro- 
inflammatory responses from the cells in the surrounding tissues, thereby localising 
the potential tissue damage (Kerr et al., 1972; Wyllie et al., 1980). This specific 
recognition of the apoptotic cells was found to be mediated by the exposure of a 
membrane lipid phosphatidyl serine (PS) on the cell surface. PS is normally localised 
to the inner leaflet of the cell membrane, but as the cells undergo apoptosis it is 
translocated to the outer leaflet of the cell membrane allowing direct recognition of 
the cell by the immune system leading to its engulfment and degradation without 
massive tissue damage (Fadok et al., 1992). 
As well as an importance in the developmental stages of life, apoptosis also has 
many roles within the tissues of the adult. It is responsible for controlling cellular 
proliferation and removal of non-functional cells, either due to defective 
differentiation or cells that have acquired mutations, removal of infected cells or the 
removal of potentially harmful cells such as auto-reactive lymphocytes (Raff, 1992; 
Jacobson et al., 1997; Birge and Ucker, 2008). 
The process of apoptosis is extremely regulated and when working correctly is an 
excellent homeostatic mechanism for controlling cellular proliferation / death. This 
does, however, mean that any perturbance in its regulation could lead to disease. 
Deregulation of apoptosis is therefore thought to be responsible for many human 
diseases. It has been implicated in human B cell lymphomas; these cancerous cells 
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over-express the anti-apoptotic protein Bcl-2 and was one of the first indications 
that failure of the cell death process could lead to cancer (Vaux et al., 1988). Some 
tumour cells will also try to evade the immune system by down-regulation of the Fas 
receptor on tumour cells to prevent T cell- / natural killer cell-mediated death 
(Cheng et al., 1994). Excessive apoptosis may also be a feature of the underlying 
pathology of many other conditions such as auto-immune diseases (HIV, Systemic 
lupus erythrematosus); neurodegenerative diseases (Alzheimer's disease and 
Parkinson's disease) or in ischemia-associated injury (myocardial ischemia due to 
lack of blood supply and hence oxygen to the cardiomyocytes) (reviewed in (Elmore, 
2007)). 
It is clear, therefore, that understanding of the apoptotic process is necessary to 
provide a clue to the pathology of these diseases and aid in the development of 
therapies. 
1.12.1 Discovery of the genetic basis of apoptosis 
The first evidence of the genetic basis of apoptosis came through the examination of 
the nematode Caenorhabditis elegans (Ellis and Horvitz, 1986). During the 
development of C. elegans into a mature adult hermaphrodite, 131 of the 1090 cells 
undergo a cell death that closely resemble apoptosis (Horvitz, 1999; Salvesen, 1999). 
Studies have determined that within this organism there are three groups of genes 
that are involved in the apoptotic process (Horvitz, 1999). The first group of genes 
contain ces-1 and ces-2 (cell death specification) that prevents the death of sister 
cells of the two neurosecretory motor neurons. The second group of genes affect 
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nearly all of the 131 cells that undergo apoptosis including egl-1 (egg-laying 
defective), ced-3 (cell-death abnormal), ced-4 and ced-9 (Ellis and Horvitz, 1986). 
The third and final group of genes include nuc-1 (nuclease-1), involved in the 
degradation of C. elegans DNA and ced-1, ced-2, ced-5 ced-6, ced-7, ced-10 and ced- 
12 the primary function of which is in the phagocytic processing of the apoptotic 
cells (Liu and Hengartner, 1999). 
The second group of genes is by far the best characterised and studied and is 
responsible for the apoptotic process in C. elegans. Ellis et al (Ellis and Horvitz, 1986) 
demonstrated that the loss of functional ced-3 or ced-4 through genetic 
manipulation caused all the 131 normally apoptotic cells to survive, implicating the 
role of these genes in programmed cell death (Ellis and Horvitz, 1986). On the other 
hand, it was shown that ced-9 had anti-apoptotic properties (Liu and Hengartner, 
1999). Ced-3 was found to encode a protein that shared sequence homology with 
the mammalian protease called ICE (interleukin-13-converting enzyme; aka caspase- 
1) responsible for the processing and activation of the cytokine interleukin-10 (Yuan 
et al., 1993). 
Following on from this it was found that the protein encoded by the nematode ced-4 
gene was homologous to the mammalian Apaf-1 (apoptotic protease activating 
factor-1). Apaf-1 is similar to CED-4 as it acts as an adaptor molecule in the 
apoptosome, which is responsible for the activation of caspase-9 (Yuan and Horvitz, 
1992). It has also been discovered that the function of CED-4 is to interact with and 
activate the CED-3 protein (Chinnaiyan et al., 1997). 
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As stated earlier in this section the CED-9 protein appears to have anti-apoptotic 
properties. It has been discovered that this protein also has a mammalian 
homologue and this is the BcI-2 protein (Liu and Hengartner, 1999). 
It has also been demonstrated that the egl-1 product EGL-1 contains homology to a 
mammalian counterpart in the form of a 1313-like domain. The EGL-1 protein has 
been found to bind directly to CED-9 and inhibit its function, thereby causing the 
cells to enter into cell death (Horvitz et at., 1994). 
Once all of the characteristics and actions of all of the nematode gene products were 
in place, it was possible to obtain a clear picture of the mechanism of apoptosis 
occurring within the nematode cells. The proposed linear model is as follows in 
normal healthy cells: CED-9 binds to CED-4 in the mitochondria, preventing the 
activation of CED-3, while in cells programmed to die, EGL-1 binds to CED-9 which 
allows for the release of CED-4 from the mitochondria, which in turn binds to and 
activates CED-3 (Figure 1.5). 
Now that homologues between the nematode and mammalian proteins had been 
found, the search uncovered a group of cysteinyl aspartate specific proteases in 
mammals that were thought to be involved in apoptosis. 
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1.13 The Caspases 
The caspases are a group of cysteine proteases that cleave their substrates on the 
carboxyl side of an aspartic acid residue (Alnemri et al., 1996). The first caspase to 
be discovered was named interleukin-10-converting enzyme (ICE) or more 
commonly, caspase-1. Surprisingly, this enzyme was not involved in the execution of 
apoptosis but rather identified as an important regulator of the inflammatory 
response, cleaving pro-interleukin 10 to its active components (Budihardjo et al., 
1999; Earnshaw, 1999). The first indication that this newly discovered protease 
could be implicated in the apoptotic process came when it was found to be 
homologous to CED-3, a pro-apoptotic protein from the nematode C. elegans (Yuan 
et al., 1993). 
Subsequently, up to 14 other mammalian caspases have been identified, 8 of which 
have been implicated in apoptosis. All of the identified proteases have homologues 
in nematodes, hydra or insects (Earnshaw, 1999; Fuentes-Prior and Salvesen, 2004). 
Much work has now been done to show the importance of the caspases in the 
apoptotic process; over-expression of caspases within cells enhances cell death, 
inhibitors of caspases (either natural or synthetic) prevent the occurrence of 
apoptosis in vitro. In vivo knock out mice, deficient in various caspases, displayed 
dramatic defects in apoptosis (Zhivotovsky, 2003). 
1.13.1 Classification l organisation of the caspase family 
This family of proteases contains up to 14 mammalian caspase members. All but 3 of 
them can be found in humans, the exceptions being caspase -11 and -12 found in 
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mice and caspase -13 in bovines (Shi, 2002). Based on the results of phylogenetic 
analyses, the caspases are divided up into 3 major subfamilies: the ICE, CED-3 and 
ICH-1 (Ice and ced-3 homologue) (Cohen, 1997; Donepudi and Grutter, 2002). The 
ICE subfamily consists of caspases-1, -4, -5, -11, -12 and -13 most of which are 
inflammatory caspases, whereas the CED-3 family consists of caspases-3, -6, -7, -8 
and -10 and are primarily involved in apoptosis and finally the ICH-1 subfamily 
contains caspase-2 and -9 (Zhivotovsky, 2003). (Cohen, 1997). 
1.13.2 Caspase structure 
The caspases are present in the cell as inactive single chain pro-enzymes called 
zymogens. The zymogen is comprised of an amino-terminal pro domain, a large 
subunit and a carboxyl-terminal small subunit (Donepudi and Grutter, 2002). The 
caspases contain a conserved QACXG pentapeptide contained within the large 
subunit that has the active site cysteine (Wolf and Green, 1999). An aspartic acid 
cleavage site separates the large and small domains. Some of the proteins also 
contain a short inter-domain linker region containing one or two aspartate cleavage 
sites located between the large and small subunits (Cohen, 1997; Earnshaw, 1999; 
Wolf and Green, 1999). There are two real major differences between the individual 
caspases, their substrate specificity and the length ' and sequence of the amino 
terminal prodomain (Shi, 2002; Donepudi and Grutter, 2002). 
The caspases need to recognise a sequence of four amino acids for cleavage to 
occur, designated P4-P1, dependent on the caspase, with cleavage occurring on the 
carboxyl side of the P1 residue. Caspases have an absolute requirement for P1 to be 
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an aspartic acid residue for cleavage to occur(Kohler et al., 2002; Fuentes-Prior and 
Salvesen, 2004). 
The length and sequence of the amino-terminal pro-domain is another determining 
feature in distinguishing the caspases. Caspase-8 and all members of the ICE and 
ICH-1 subfamilies have long pro-domains of greater than 90 amino acids. Caspase-3, 
-6 and -7 display much shorter amino-terminal pro-domains of approx 20-30 amino 
acids (Wolf and Green, 1999; Kohler et al., 2002) (Figure 1.6). The caspases can also 
be classified according to their mechanism of activation; in this case the apoptotic 
caspases can be divided up into the initiator (casp-2, -4, -8, -9, -10 & -12) and 
executioner (casp-3, -6 & -7) caspases (Earnshaw, 1999; Denault and Salvesen, 2002) 
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Figure 1.6: Schematic representation of the mammalian caspases. The caspases have been 
grouped according to their in vivo role: cytokine activators, initiator caspases and executioner 
caspases (with casp-14 found in the epidermis, involved in keratinocyte differentiation). All possess a 
regulatory domain, a large and a small subunit. The initiator caspases are characterised by a long 
regulatory region in which two different types of element can be found, the caspase recruitment 
domain 'CARD' (green) and the death effecting domain 'DED' (yellow) domains. The executioner 
caspases by comparison have a short regulatory domain containing the N-peptide (red) that is 
removed during apoptosis. Diagrams are drawn to scale. Adapted and re-drawn: (Cohen, 1997; 
Denault and Salvesen, 2002). 
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1.13.3 The initiator and effector caspases 
Within either of the apoptotic pathways, the initiator caspases are the first to be 
activated. This activation is facilitated by domains present within their long amino- 
terminal regulatory domains. There are two main kinds of element found within 
these regulatory domains; these are the death effector domains 'DED' or caspase 
recruitment domains 'CARD' (Wolf and Green, 1999). It has been demonstrated that 
both elements have similar structures of six anti-parallel a-helices (Fuentes-Prior and 
Salvesen, 2004) It is through these elements that the interaction between the pro- 
domains of the initiator caspases and other adaptor molecules is mediated 
(Stennicke and Salvesen, 2000). The caspase-8 DED is hydrophobic in nature and 
thought to bind to the complementary DED domains of its adaptor molecule FADD 
(Fas associated death domain). The hydrophilic/charged CARD of caspase-9 binds to 
complementary surfaces of its adaptor protein Apaf-1 (Stennicke and Salvesen, 
2000). Studies have shown that there are differing numbers of these elements 
contained within the various caspases depending on their biological roles. Caspase-8 
and -10, involved primarily in the death receptor-mediated pathway of apoptosis 
(see section 1.14), contain two DED elements within their amino terminal domains, 
while caspase-9 involved in the mitochondrial pathway of apoptosis only contains 
one CARD element (see section 1.15) (Fesik, 2000). 
The effector caspases tend to be activated later in the apoptotic process and usually 
by one of the initiator caspases. This activation usually occurs through limited 
proteolysis within their interdomain linker region, as the short amino terminal 
domain does not allow for the presence of any of the recruitment elements seen in 
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Figure 1.7: Diagram showing the proteolytic activation of the pro-caspases. Caspases are 
expressed as inactive zymogens. Activation occurs by cleavage of the zymogen at aspartic acid 
residues leading to the release of a large and small subunit; some proteins also have a small linker 
region between the two subunits. The active site is formed by a heterodimer of a large and small 
subunit, and the active caspase is a tetramer of two of these heterodimers. Adapted from (Donepudi 
and Grutter, 2002). 
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the initiator caspases. However, this short amino-terminal domain does appear to 
be important for efficient activation of the executioner caspases in vivo, possibly 
playing a role in the cellular localisation or spatial arrangement of the caspase 
molecule (Meergans et al., 2000; Denault and Salvesen, 2002). Once activated, the 
executioner caspases cleave nearly all known apoptotic substrates, giving rise to all 
of the morphological and biochemical changes that comprise the apoptotic process 
(Saraste and Pulkki, 2000). 
1.13.4 Caspase activation mechanisms 
Caspases can become activated through a variety of mechanisms such as 
autoproteolytic processing, oligomerisation or proteolytic cleavage. The active form 
of a caspase is a heterodimer of two monomers composed of the large and small 
subunits of a single caspase molecule (Fuentes-Prior and Salvesen, 2004; Salvesen 
and Riedl, 2008) (Figure 1.7). Activation can be divided into two mechanisms, homo- 
activation and hetero-activation. The first mechanism defines the activation of the 
initiator caspases and corresponds to their ability to activate on their own. The 
second corresponds to activation of the executioner caspases by other molecules 
such as the initiator caspases or other cellular proteases. In vivo adaptor molecules 
mediate the oligomerisation of the initiator procaspases thereby increasing their 
local concentration and promoting their activation (Muzio et al., 1998; Salvesen and 
Dixit, 1999; Fuentes-Prior and Salvesen, 2004). 
There are two mechanisms that can induce the homo-activation of the caspases; the 
first is through the interaction of a membrane-associated death receptor binding 
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with its ligand and the second involves the participation of the mitochondria 
(Budihardjo et al., 1999; Adams, 2003b; Yuan and Horvitz, 2004). 
1.14 The Death Receptor pathway 
The death receptor pathway is triggered by the binding of cell surface death 
receptors with their associated ligands and the pathway initiated is thought to be a 
key component in developmental and immune-tolerance related apoptosis (Peter 
and Krammer, 2003). The death receptors are a family of transmembrane proteins 
that belong to the tumour necrosis factor 'TNF' receptor super family. The 
mammalian death receptors include the following 8 members thus far: TNF-R1, 
CD95/DR2/APO-1/Fas, DR3/APO-3/LARD/TRAMP/WSL-1, TRAIL-1/DR4/APO-2, TRAIL- 
2/DR5/KILLER/TRICK2, DR6, EDAR and nerve growth factor receptor 'NGFR' 
(Budihardjo et al., 1999; Wajant, 2003; Lavrik et al., 2005). All have corresponding 
homotrimeric ligands that are structurally related to the receptor and facilitate signal 
transduction, such as fas ligand (Fas-L) binding to Fas receptor, TNF-a binding to 
either TNF-R1 or -R2 or Apo-3L binding to Apo-3R (French and Tschopp, 2003). All 
the receptors described share a conserved cysteine residue in their extracellular 
domain which is ultimately responsible for determining which ligand is capable of 
binding. The receptors also possess an intracellular amino acid sequence of 
approximately 80 residues termed a Death Domain (DD) (Fesik, 2000; Adams, 
2003a). 
The best characterised death receptor pathway is that of FasL binding to its receptor 
Fas. This results in a clustering of the cytosolic DD and the recruitment of an adaptor 
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protein, Fas-associated death domain, 'FADD'. FADD contains a DD in its carboxyl 
terminus and is able to bind to the FasR at the cytoplasmic tail through the 
interactions between the two DDs. It was found that FADD had another DED present 
in the amino terminal portion of the protein which facilitated the recruitment of 
procaspase-8 through interaction with its death domains. The complex of Fas, FADD 
and procaspase-8 is called the Death-Inducing Signalling Complex (DISC) (Chang et 
al., 2003; Peter and Krammer, 2003). Within the DISC complex, procaspase-8 is 
dimerised to become catalytically active and is then cleaved into caspase-8 through 
cleavage of the interchain domain, followed by the removal of the amino terminal 
prodomain (Chang et al., 2003). Activated caspase-8 can then activate the effector 
caspases e. g. the cleavage of procaspase-3 into its active form. Caspase-10 has also 
been shown to interact with FADD through the homotypic association with its DED 
and recently procaspase-10 was shown to be associated with the DISC complex and 
be proteolytically activated (Figure 1.8) (Kischkel et al., 2001; Wang et al., 2001). 
The signalling processes involved in the TNF-R1 response differ from that of the Fas- 
mediated response in that binding of the ligand to its receptor can either induce 
apoptosis or invoke an anti-apoptotic response through the activation of nuclear 
factor KB (NF-KBr AP-1); therefore two complexes need to be formed to regulate 
procaspase activation (Chang et al., 2003; Micheau and Tschopp, 2003). The first 
complex is formed at the membrane and comprises TNF-a, TNF-R1, Receptor- 
interacting Protein 'RIP', TNFR-associated death domain protein 'TRADD' and TNFR- 
associated factor-1/-2 'TRAF-1/-2'. This complex then triggers the NF-KB signalling 
pathway and invokes anti-apoptotic gene expression. The primary complex lacks 
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Figure 1.8: Model of Fas-induced death receptor pathway. When Fas-L binds to the FasR, 
conformational changes in the receptor allow the binding of FADD and either procaspase -8 (Yellow) 
or -10 (Green) to 
form the DISC through interactions with DDs (Red) and DEDs (Blue). The 
procaspases are then proteolytically cleaved into their active forms, which can then go on to activate 
the executioner caspases and therefore the apoptotic phenotype. Re-drawn from (Peter and 
Krammer, 2003). 
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FADD and the procaspases but it is thought to translocate to the cytoplasm where 
the adaptor molecules disassociate from the receptor, freeing the DD to facilitate 
the binding of FADD and procaspases and the formation of the complex II 
'traddosome'. The formation of complex II is dependent on the ability and strength 
of induction of complex I. NF-KB signalling induces the production of anti-apoptotic 
gene products such as c-FLIPUs that block procaspase-8 activation in the traddosome 
(Micheau and Tschopp, 2003; Lavrik et al., 2005)(Figure 1.9). 
There are several mechanisms built in to the death receptor signalling pathway that 
take into account accidental or unwanted activation of the initiator caspases. There 
are several different levels of modulation, such as expression of decoy receptors 
(DcRs) that do not possess death domains so cannot form a signalling complex, such 
as; TRAIL-R3/DcR1, TRAIL-R4/DcR2, DcR3 or osteoprotegerin (OPG) (Lavrik et al., 
2005). There are also inhibitors of the procaspase-8: DISC interaction; this is 
mediated by a protein called Fas-associated death domain-like IL-10converting 
enzyme [FLICE]-like inhibitory protein 'FLIP'. Originally discovered as a viral protein 
expressed in y-herpesvirus infections, two human homologues have since been 
recognised, c-FLIP-short or c-FLIP-Long (c-FLIPs/1) (Peter and Krammer, 2003) The 
FLIP molecule prevents binding of the procaspases due to direct competition for 
recruitment into the DISC, mediated by two DEDs present on FLIP, thereby blocking 
the death receptor pathway (Stennicke and Salvesen, 2000). C-FLIP resembles 
caspase-8 but lacks its activity due to several absent amino acid residues in the 
protease like domain (Budihardjo et al., 1999; Peter, 2004). 
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Figure 1.9: Model of TNF-induced death receptor pathway. After binding of TNFa to its 
receptor, the first complex is formed at the membrane and comprises TNF-a, TNF-R1, Receptor- 
interacting Protein 'RIP', TNFR-associated death domain protein 'TRADD' and TNFR-associated factor- 
1/-2 'TRAF-1/-2'. This complex then triggers the NF-KB signalling pathway and invokes anti-apoptotic 
gene expression. The primary complex lacks FADD and the procaspases but it is thought to 
translocate to the cytoplasm where the adaptor molecules disassociate from the receptor, freeing the 
DD to facilitate the binding of FADD and procaspases and the formation of the complex II 
'traddosome'. The formation of complex II is dependent on the ability and strength of induction of 
complex I. NF-KB signalling causes the production of anti-apoptotic gene products such as c-FLIP,, S 
that block procaspase-8 activation in the traddosome. Adapted from (Chen and Goeddel, 2002; 
Micheau and Tschopp, 2003). 
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1.15 The Mitochondrial Pathway 
The mitochondrial pathway of apoptosis is activated by many stimuli such as DNA 
damage, exposure to cytotoxic drugs or UV irradiation, ER Stress, reactive oxygen 
species and calcium overload (Kroemer and Reed, 2000; Jiang and Wang, 2004). All 
of these events ultimately lead to mitochondrial membrane permeablisation. This 
then results in the loss of mitochondrial membrane potential, and the release of 
caspase-activating proteins such as cytochrome c and Smac/DIABLO from the 
mitochondrial inner-membrane space into the cytosol. Other caspase-independent 
factors are also released, such as apoptosis-inducing factor (AlF), causing DNA 
fragmentation and chromatin condensation, (another AlF function is to regulate the 
permeability of the mitochondrial membrane upon apoptosis); and endonuclease G 
(endoG) that cleaves DNA at GC rich areas (Kroemer et al., 2007). Cytochrome c is 
normally involved in the electron transport chain, however when released into the 
cytosol it binds to a 130 kDa protein called Apaf-1. Apaf-1 is a cytosolic protein that 
contains a CARD element, a nucleotide binding domain homologous to CED-4 and 
multiple WD-40 repeats (Kroemer and Reed, 2000; Wang, 2001). Following binding 
of cytochrome c to Apaf-1, a conformational change occurs in cytochrome c and 
there is an increase in its affinity for dATP/ATP. This nucleotide binding to the 
cytochrome c/ Apaf-1 complex causes it to oligomerise, forming a heptameric 
complex called the 'apoptosome'. The heptamerisation allows the CARD domain of 
Apaf-1 to be exposed, which allows for the binding of multiple procaspase-9 
molecules and their subsequent activation. The bound active caspase-9 molecules 
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can then activate executioner caspases such as caspase-3 (Vaughn et al., 1999; Zou 
et al., 1999; Jiang and Wang, 2004). (Figure 1.10). 
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Figure 1.10: The role of the mitochondria during apoptosis. Various factors lead to the 
permeablisation of the mitochondrial outer membrane. This then triggers the BH3-only proteins to 
associate with Bcl-2 on the mitochondria; the permeablisation is aided by the recruitment of Bax and 
Bak oligomers on the mitochondrial outer membrane. The release of cytochrome c along with ATP 
induces the oligormerisation of apaf-1, which in turn binds procaspase-9 to form the apoptosome. 
This in turn proceeds to activate caspase-3. Other proteins released concurrently from the 
mitochondria with cytochrome c such as Smac and Omi incapacitate the IAPs present in the cytosol 
which bind to the apoptosome and prevent caspase activation. AIF and EndoG enter the nucleus and 
aid in DNA degradation. Re-drawn from (Adams, 2003b). 
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Other proteins are also released into the cytoplasm following mitochondrial 
membrane permeablisation concurrently with cytochrome c; one such protein is 
Smac. Upon release from the mitochondria, Smac has its mitochondrial targeting 
sequence removed and the new N-terminus facilitates the binding of Smac to BIR 
(baculovirus IAP repeat) domains on the Inhibitor of Apoptosis Proteins 'IAPs'. (Du et 
al., 2000; Chai et al., 2000). The four amino acids that facilitate the binding of smac 
to the BIR-3 domain of XIAP (X-chromosome-encoded IAP) (Ala-Val-Pro-Ile) are 
similar to those of the XIAP binding domain of active caspase-9 (Ala-Thr-Pro-Phe). 
The binding of IAP to caspase-9 results in the inactivation of caspase-9, therefore 
smac relieves this inhibition by competing with caspase-9 to bind the IAP (Srinivasula 
et al., 2001). Smac is also able to complex with the BIR-2 domains of XIAP, and the 
region just prior to this is directly involved in XIAP-mediated inhibition of caspase-3 
and -7 (Chai et al., 2000; Chai et al., 2001). This inactivation provides a sufficient 
safety barrier for accidental leakage of cytochrome c from the mitochondria; 
however, if the damage to the mitochondria is sustained, more smac will be released 
along with the cytochrome c, allowing IAP-mediated inhibition of apoptosis to be 
overcome (Srinivasula et al., 2001). Smac may also play a role in death receptor- 
mediated apoptosis as both the death receptor and mitochondrial pathways 
converge at the level of caspase-3 activation. High levels of IAPs will prevent 
caspase-3 activation; therefore the death receptor pathway utilises the activation of 
BH3-only proteins such as Bid through caspase-8 (not susceptible to XIAP inhibition) 
to cause the release of the pro-apoptotic mitochondrial proteins i. e. smac. If the 
death receptor signal is of a sufficient strength and duration, this will be enough to 
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overcome the inhibition of apoptosis (Gross et al., 1999b; Riedl et al., 2001). The 
roles of BH3 and Bcl-2 will be discussed further in section 1.17. 
1.16 Caspase Substrates 
Both the mitochondrial and death receptor pathways of apoptosis eventually lead to 
the activation of the executioner caspases which are responsible for the 
morphological and biochemical changes seen during apoptosis, with a vast number 
of proteins shown to be cleaved in vivo and in vitro by the executioner caspases. The 
functions of the cell affected by executioner caspase activation range from cellular 
signalling, cell repair, DNA metabolism, as well as cleavage of structural proteins 
such as actin, fodrin and gelsolin (Cohen, 1997; Saraste and Pulkki, 2000; Fischer et 
al., 2003). Once activated, caspase-3 has been shown to act in a positive feed-back 
manner, cleaving caspase-6 which in turn activates the initiator caspase-8. Caspase- 
3 is also thought to act back on the apoptosome and promote the cleavage of 
procaspase-9 (Chang et al., 2003; Pop et al., 2006; Pop et al., 2007). 
1.17 Regulation of Apoptosis 
1.17.1 The Bcl-2 family of apoptotic regulators 
The Bcl-2 family of apoptotic regulatory proteins focus much of their efforts at the 
level of the mitochondria during apoptosis regulation. The genes controlling these 
proteins were first discovered in follicular B-cell lymphomas (Bcl) and are 
homologues of the nematode gene ced-9, which functions as a regulator of the 
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apoptotic pathway by inhibiting its activation (Levine et al., 2008; Galluzzi et al., 
2008b). 
The Bcl-2 family of proteins possess up to four conserved Bcl-2 homology (BH) 
domains designated BH1 - BH4, which correspond to a-helical segments of the 
protein (Cory et al., 2003). Based on function and conservation of BH domains, the 
Bcl-2 family can be divided into three groups (Figure 1.11). The anti-apoptotic 
members such as Bcl-2, Bcl-XL, Bcl-W and Mcl-1 display sequence conservation in all 
four domains. The pro-apoptotic members such as Bax, Bak and Bok display less 
sequence conservation of the first helical segment BH4, but high homology in BH1- 
BH3. A final subgroup of this family was discovered through deletion and 
mutagenesis studies and found to only be homologous within the BH3 region, the 
'BH3-only' subgroup. Such molecules as Bid, Bad, Bik, Bim, PUMA, NOXA are all 
thought to be pro-apoptotic. Many of the family members also contain a 
hydrophobic carboxyl-terminal domain, for example Bcl-2, that is important in the 
targeting of these proteins to the mitochondrial outer membrane (Cory et at., 2003). 
Before the apoptotic signal is given, most of the pro-apoptotic Bcl-2 family members 
localise to different subcellular compartments to those of the anti-apoptotic 
members. The pro-apoptotic members localise to the cytosol or cytoskeleton 
whereas the anti-apoptotic members are found as integral membrane proteins of 
the mitochondria, endoplasmic reticulum or nuclear membranes (Cory et al., 2003). 
Upon death signalling, BH3-only proteins are activated through a variety of 
mechanisms such as translocation (Bim), dephosphorylation (Nie et at., 2002), 
cleavage (Bid) and an upregulation of transcription (Gross et al., 1999a). Upon 
activation, these proteins are able to exert their apoptotic-inducing actions by two 
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mechanisms. Bad or NOXA interact with anti-apoptotic Bcl-2 proteins (Bad with Bcl- 
2) causing them to disassociate from BH3 or Bax/Bak-like proteins that mediate 
mitochondrial membrane permeability. The other more direct mechanism involves 
truncation of proteins such as bid (t-Bid) which can have effects on the multi-domain 
pro-apoptotic proteins such as Bax or Bak. T-Bid can stimulate the translocation of 
Bax to the mitochondrial membrane. Truncated Bid mediates N-terminal 
conformational changes in Bax that oligomerises and forms a channel that allows for 
the release of cytochrome c. (Danial and Korsmeyer, 2004; Galonek and Hardwick, 
2006; Adams and Cory, 2007). Other proteins such as Bad translocate to the 
mitochondria where they bind via their BH3 domains to inactivate the anti-apoptotic 
family members such as Bcl-2 and Bcl-XL on the mitochondrial outer membrane. This 
binding prevents them from inactivating the pro-apoptotic members such as Bax 
(Parone et al., 2003). 
The anti-apoptotic regulators such as Bcl-2 and Bcl-XL act to block the 
oligomerisation of Bax or Bak and prevent the apoptotic cascade; however 
experiments have demonstrated that they do not prevent translocation from the 
cytosol (Gross et al., 1999b). 
One of the BH3-only members, Bid, is also responsible for mediating the interaction 
or so called 'crosstalk' between the two different apoptotic pathways. Following a 
TNF-a induced cell death signal, activated caspase-8 cleaves Bid to generate a p15 
fragment. The cleaved Bid is then targeted towards the mitochondrial outer 
membrane where it interacts with Bax/Bak as previously described (Gross et al., 
1999b). 
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Figure 1.11: The members of the Bcl-2 family of proteins and their structure. The three 
different subfamilies are represented, the anti-apoptotic BcI-2 subfamily and the pro-apoptotic Bax 
and B1-I3-only subfamilies. BH1 - BH4 are conserved Bcl-2 homology domains. A hydrophobic 
carboxyl terminal region is also present in some family members 'TM'. Adapted from (Gross et at., 
1999a). 
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As the direct cleavage of the executioner caspase-3 by caspase-8 may not be enough 
to overcome the inhibitory effects exerted by X-IAP (discussed in section 1.15), the 
translocation of Bid will promote the release of other mitochondrial proteins such as 
Smac which will remove X-IAP inhibition through direct binding. This allows an 
efficient feedback loop to be established mediated through the activation of 
caspase-6 by caspase-3. Caspase-6 can then go on to cleave more caspase-8 (Slee et 
al., 1999a; Slee et al., 1999b; Bratton and Cohen, 2003). 
1.18 The Calpains 
1.18.1 Members and family structural organization 
The calpains are a group of cysteine proteases that are found within the cytoplasm 
and require the presence of calcium ions for their activation. The 'typical' calpains 
(calpains-1, -2, -3, -8, -9, -11,12, and -13) are composed of four domains, with 
calpain -1, -2 and -9 associating with a 28 kDa regulatory subunit. Domain 1 is in the 
amino terminus of the protein; domain II contains the catalytic triad sequence (Cys- 
His-Arg) with the cysteine being present in domain Ila and the others present in Ilb. 
The location of these amino acids configures an active catalytic pocket in the 
presence of Ca 2+ ions. Domain III is a linker region between the catalytic core of the 
protein and the Ca 2+ domain. Finally, Domain IV is the calmodulin-like domain 
consisting of five sets of EF-hand sequences (EF). Each EF hand consists of a twelve- 
residue loop flanked by a twelve residue a-helical domain. EF 1-4 are involved in 
calcium binding and the fifth is involved in the dimerisation with the 28 kDa subunit 
producing an active protein (Figure 1.11a). The 'Atypical' calpains (Calpains -5, -6, -7, 
-10 and -15) do not possess this calmodulin-like domain. 
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Figure 1.11a: Schematic representation of µ- or m- calpain. Domain structure of human µ- and 
m-calpain as predicted by their amino acid sequence. The six EF-hand sequences in the 80-kDa 
subunit and the five EF-and sequences in the 28-kDa subunit are shown by the vertical white bars. EF- 
hand at the COOH-terminal ends of domains IV and VI of the 28- and the 80-kDa subunits, 
respectively, is involved in association of the two subunits and not in Ca" binding. (Adapted from Goll 
et al, 2003). 
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Currently, 14 genes have been identified that encode the large 80 kDa catalytic 
subunit which contains the cysteine protease domain of domain II. Another two 
genes have been found that encode a 30 kDa regulatory subunit that contains EF- 
hand Ca 2+ binding motifs (a helix-turn-helix structural domain found in a large family 
of calcium-binding proteins); however the very carboxyl termini of the fifth motif in 
domains IV and VI are thought to interact with each other forming a heterodimer 
complex (Suzuki et al., 2004). 
The small subunit contains a further two domains. Domain V is an amino terminal 
glycine-rich unstructured region and domain VI contains five EF-hand calcium 
binding domains similar to that of domain IV (Goll et al., 2003; Suzuki et al., 2004; 
Saez et al., 2006; Croall and Ersfeld, 2007). 
The distribution of the calpains is wide ranging, with some isoforms being 
ubiquitously expressed whilst others are defined by tissue type specific expression. 
1.18.2 Calpain-i and -2 
Both calpain-1 (µ-calpain) and calpain-2 (m-calpain) are ubiquitously expressed 
heterodimers of non-identical 80 kDa catalytic subunits and an identical 30 kDa 
regulatory subunit which is necessary for the correct folding of the larger subunit 
and regulates the calcium sensitivity of the two calpains (Suzuki et al., 1995; 
Sorimachi et al., 1997). The names are derived from the different ranges of calcium 
concentrations needed for their activation in vitro; milli or micromolar levels of 
calcium are required for m- or µ-calpain, respectively. The calpains exist in the 
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cytoplasm as inactive enzymes and translocate to membranes in response to 
increasing cellular calcium levels. Here, the calpains are activated in the presence of 
calcium and phospholipids. During this process, hydrolysis of domain I occurs and 
the 30 kDa subunit disassociates as a result of this, allowing the now active calpain to 
cleave substrate proteins (Suzuki et al., 1995). In vitro experimentation has shown 
that Cat+-induced structural changes are a prerequisite for activation of the calpains. 
The proposed mechanism for activity regulation in m-calpain consists of two stages, 
The first requires the release of structural constraints as the catalytic triad of amino 
acids are too far apart to function. The binding of CaZ+ to domains IV, VI and III 
releases domain I from VI and domain II from III which also causes the release of the 
smaller 30 kDa subunit. The second stage consists of the rearrangement of the 
catalytic domain by the binding of CaZ+ ions to sub-domains lla and lib. Binding of 
calcium to domain III is responsible for the translocation of calpains to membranes, 
which is a similar process to that seen in protein kinase C and phopholipase C 
(Tompa et al., 2001; Moldoveanu et al., 2002). 
While trying to purify m-calpain, a calpain inhibitory protein was discovered. This 
protein, termed 'calpastatin', is a ubiquitously expressed specific endogenous 
inhibitor for the regulation of proteolytic activity of calpains in mammalian cells 
(Reviewed in Ray et al, 2003 ). The 100 kDa calpastatin protein contains an N- 
terminal L domain and four repeated domains of 140 amino acid residues (I-IV), all 
capable of independently inhibiting calpains. The conserved inhibitory amino acid 
residues are found clustered in 3 regions, A, B, and C, within the four domains. It has 
been demonstrated that conserved region B binds to calpain domain II, while regions 
A and C bind to calpain domains IV and VI, respectively. This interaction with the 
60 
Introduction 
calpains prevents the production of the autolytic form of calpain and thereby inhibits 
its catalytic activity. The binding of a calpastatin fragment containing subdomains A 
&C to calpains prevents the binding of calpains to membranes. It has been 
hypothesized that calpains bind to membranes in close proximity to calcium 
channels so that the local calcium concentrations would be great enough to activate 
them (Goll et al., 2003; Ray et al., 2003; Suzuki et al., 2004). 
1.18.3 Physiological roles of the calpains 
The physiological roles of the calpains are still not absolutely clear; however, through 
disruption of the calpain genes and the use of calpain inhibitors, a number of 
potential substrates and cellular roles have been determined. Calpains have been 
implicated in the remodeling of the cytoskeleton and cell membrane during cell 
fusion and motility and degradation of enzymes involved in controlling progression 
through the cell cycle (Goll et al., 2003; Franco and Huttenlocher, 2005; Raynaud and 
Marcilhac, 2006). These studies have been hampered by the lack of use of the 
specific inhibitor calpastatin, due to the technical difficulties of administering the 
protein to cells. Other inhibitors that have been used have co-incidental effects 
which could give false accounts of the calpains' physiological roles . For example 
calpain I inhibitor efficiently reduces calpain activity but also is a good inhibitor of 
cathepsins B and L and the cellular proteasome (Goll et al., 2003). The use of 
genetically altered knockout mice has helped to overcome this problem, for example 
homologous knockout of the CAPN4 gene in mice. This eliminated the 30 kDa 
subunit and hence µ and m-calpain activity. This did not present a problem in the 
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adult mice of the F1 generation that had a wildtype or heterozygous gene function, 
and these animals displayed phenotypically normal calpain activity. However, this 
knockout was embryonically lethal with apparent defects in the cardiovascular 
system and erythropoiesis in the animals that were homozygous for deletion of the 
gene in both alleles. This showed an indispensable role for the calpains in embryonic 
development that could not be compensated for by other proteolytic systems 
(Zimmerman et al., 2000; Arthur et al., 2000). 
1.18.4 Pathological roles of the calpains 
Many pathological conditions have been linked to the calpains or to inappropriate 
calpain activities. These range from genetic disorders such as limb girdle muscular 
dystrophy type 2A and Type 2 diabetes mellitus. Calpains are also implicated in 
other calcium homeostasis-linked pathologies such as Alzheimer's disease, cataract 
formation, myocardial infarctions, multiple sclerosis, neuronal ischemia (Fiore et al., 
1998a), obsessive compulsive disorders and spinal cord injuries (reviewed in (Goll et 
al., 2003)). 
There are also many reports that the calpains play a key role in the process of cell 
death (Figure 1.12). It has been shown that in the context of neuronal apoptosis, the 
calpains cleave Bax, thereby promoting the release of cytochrome c. Cleavage of Bid 
and its role in mitochondrial permeablisation has been attributed to calpain activity 
in cell death following cardiac ischemia (Gao and Dou, 2000; Chen et al., 2001). 
Calpains have also been reported to interact with the caspase pathways by either 
enhancing activity or by blocking the caspase functions. Calpains are also able to 
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activate the caspases by direct cleavage; this was demonstrated by Nakagawa & 
Yuan (2000) who showed that activation of caspase-12 occurred through cleavage by 
m-calpain during endoplasmic reticulum stress-mediated apoptosis of neuronal cells 
(Nakagawa and Yuan, 2000). During neutrophil apoptosis induced through the 
removal of initiators of an inflammatory response or death receptor mediated 
events, µ-calpain is activated and plays an upstream role by controlling the release of 
cytochrome c and Smac from the mitochondria through the cleavage of Bax 
(Altznauer et al., 2004). 
Finally, the calpains have more recently been implicated in playing a role in several 
viral infections. Following reovirus infection of Murine L929 fibroblasts (L cells) an 
increase in calpain activity was demonstrated. This activity, along with reovirus- 
induced apoptosis, could be ablated by the addition of calpain inhibitors. However, 
it was not clear where in the cascade of apoptotic events the calpains play a role 
(Debiasi et al., 1999). 
Calpains have also been shown to be required for the efficient replication of human 
echovirus-1 RNA in Green Monkey Kidney cell lines. It was shown that calpain 
inhibitors blocked viral infection of the SAOS-a2ß1 cells. The virus-infected cells also 
showed elevated calpain levels 3h post infection and confocal microscopy 
demonstrated a co-localisation of calpain-1 and -2 to caveolin/echovirus-containing 
vesicles. It was also demonstrated that intracellular calcium levels in the cytosol 
increased following echovirus infection, possibly contributing to the calpain activity. 
When echovirus RNA was microinjected into the cytoplasm, infection was blocked in 
the presence of calpeptin, indicating a critical role of calpains in the replication of the 
viral RNA genome (Upla et al., 2008). 
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More recent work has implicated a role of calpains in the replication of 
Coxsackievirus-B4 'CVB4' in rat primary neurons. Here they demonstrated that 
infection with CVB4 induced the autophagy pathway (a process in which aberrant 
cellular organelles are sequestered into double-membrane vesicles for lysosomal 
breakdown) to aid in viral replication. It was also demonstrated that calpain 
inhibitors reduced autophagosome formation; while conversely, inhibitors of the 
autophagy pathway reduced calpain activity although the exact roles each of these 
play is still unclear (Yoon et al., 2008). 
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Calpains in apoptosis 
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Figure 1.12: Diagram illustrating the regulation of apoptosis by the calpains. 1) Cleavage of Bax 
by calpains leads to the formation of truncated Bax (tBax) which promotes the release of cytochrome 
c; 2) Bid cleavage by calpains to truncated Bid 
(tBid) leads to (a) direct release of cytochrome c and/or 
(b) permeabilisation of the mitochondrial outer membrane, translocation of calpain to the 
intermembrane space resulting in AIF cleavage (tAIF) and its subsequent release; 3) Calpain-mediated 
BCI-XL inactivation and cytochrome c release. Adapted from (Raynaud and Marcilhac, 2006) 
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1.19 Viruses and Apoptosis 
Apart from the roles of apoptosis discussed in previous sections, such as in 
development or in maintenece of cellular proliferation, it also functions as an 
important mechanism in the complex defence response to intracellular parasites 
mediated by the immune system, such as viruses (Roulston et al., 1999; Boya et al., 
2004). Multicellular organisms have developed exquisite multi-step immune 
responses, with the first line of defence being the generation of cytokines such as 
TNF-a, which activate and recruit macrophages, NK cells and neutrophils that 
phagocytose infected cells. However, in many cases, viral infection can cause serious 
damage before an adequate immune response can be mounted. Therefore, other 
mechanisms, such as the induction of interferon by the presence of viral nucleic 
acids prevent the spread of the virus by inducing an anti-viral state in neighbouring 
cells (Everett and McFadden, 1999; Gantier and Williams, 2007). Viruses can activate 
pro-apoptotic mechanisms either directly or indirectly upon entering a cell, either 
through unscheduled activation of the cell cycle being detected or through viral 
peptides being processed and presented on the surface of an infected cell to 
promote immune recognition. Viruses have therefore evolved mechanisms to 
regulate the apoptotic response and use it to their benefit (Roulston et al., 1999; 
Thomson, 2001). Viruses have evolved mechanisms of either delaying or blocking 
apoptosis to allow for efficient replication of virus particles or conversely the virus 
can trigger the apoptotic pathways to allow for efficient spread of progeny to 
neighbouring cells, while limiting the induction of the host inflammatory response 
(Roulston et al., 1999). The mechanisms by which the viruses achieve this vary 
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greatly; however many viruses have now been found to express viral proteins that 
have either pro- or anti-apoptotic functions (Boya et al., 2004; Galluzzi et al., 2008a; 
Galluzzi et al., 2008b). Examples of these viral proteins can be found in Table 1.2 and 
some of their mechanisms of action will be described in more detail. 
1.20 Mechanisms by which viruses inhibit apoptosis 
1.20.1 Inhibition of the interferon response 
Several viruses are known to produce proteins that target the interferon response 
and its effects in establishing an anti-viral state. Vaccinia virus produces two 
proteins E3L and K3L, both of which interfere with the Protein Kinase R 'PKR' 
response. 
PKR is a protein that contains an amino-terminal dsRNA binding domain (dsRBD) and 
a C-terminal kinase domain that give it a pro-apoptotic functions and is generally 
activated during viral infections, due to the creation of a dsRNA intermediate during 
the viral replication cycle. This dsRNA intermediate binds to the PKR N-terminus and 
activates the protein, inducing apoptosis to prevent further viral spread. 
E3L is a double stranded RNA-binding protein that competes for binding to PKR with 
the viral RNA. K3L on the other hand mimics the eukaryotic initiation factor eIF2a, 
interfering with PKR-eIF2a interactions (Jentarra et al., 2008). Another example can 
be found in Herpes Simplex Virus-1 infections. In this case the virus produces a 
protein called y134.5 that causes the translocation of an enzyme phosphatase 1 
which causes the dephosphorylation of eIF2a, thereby eliminating its role in the 
cessation of protein synthesis and the induction of apoptosis (Pasieka et at., 2008). 
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1.20.2 Inhibition of the death receptor pathways 
During adenovirus infections various proteins of the adenovirus E3 transcription unit 
are able to inhibit apoptosis. Of these proteins the E3-10.4K and E3-14.5K form the 
a and ß subunits of a complex responsible for receptor internalisation and 
degradation (RID). This allows RID to inhibit the death receptor pathways by 
internalisation of the Fas, TNFR, TRAIL-R1 and -R2 receptors, leading to their 
lysosomal degradation. The RID proteins are transmembranous with their carboxyl- 
terminus orientated in the cytoplasm. The ß subunit contains a C-terminal tyrosine 
residue that is required for the internalisation of the receptors involved in Fas and 
TRAIL-induced apoptosis (Zhang and Xu, 2007) 
Certain viruses are also capable of producing proteins that mimic the death 
receptors or the ligands that bind to them. Of note are the poxviruses; cowpox virus 
produces two secreted proteins, CrmB and CrmC, that mimic the extracellular 
domains of the TNF receptors and therefore compete with them for Iigand binding, 
abrogating the induction of apoptosis (Smith et al., 1996; Gileva et al., 2006). 
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(A): Viruses / Viral Proteins that inhibit apoptosis 
Virus 
Cytomegalovirus 
Epstein-Barr Virus 
Vaccinia virus 
Poxviruses 
Human 
papillomavirus 
Adenovirus 
Effector / Target/ 
Gene product 
Effects 
Bax inhibition; modulates ER Ca 2+ release and ATP levels; 
mitochondrial fragmentation 
pUL37xl 
(Pauleau et al., 
2007) 
BALF1 Interacts with Bax/Bak; protects from serum deprivation 
Blocks apoptosis mediated by death receptors, c-myc, 
BHRF1 granzyme B, DNA damage, infection, radio- or 
chemotherapy 
F1L Inhibits Bax/Bak activation 
NiL Structural vBcl-2; inhibits multiple BcI-2 like proteins 
CrmB, CrmC, Inhibition of the Fas/TNF pathway though the production 
CrmD or CrmE of TNF-L mimics 
E6 protein Inaction of p53 
E1B Multiple inhibitory mechanisms (See subsection 1.20.4) 
(B): Viruses / Viral Proteins that activate apoptosis 
Virus 
Avian 
Encephalomyelitis 
virus 
Effector / 
Target/ Gene 
product 
Effects 
Induction of the caspase cascade leading to apoptosis 
2C 
VP3 
Hepatitis C Virus 
Foot and Mouth 
Disease virus 
Human 
Immunodeficiency 
Virus-1 
Tat 
Human T-cell 
leukaemia virus 
Accumulation in the mitochondria, mitochondrial 
membrane potential loss, Cyt C release, casp-3 activation 
Reduction in endogenous levels of Bcl-2, activation of the 
caspases & Cyt C release 
Bax up-regulation; Cyt C release, caspase activation; 
Involvement of p53 and NF-KB 
Lysosomal membrane permeabilisation, cathepsin D 
release, Bax activation 
BcI-2 depletion, NF-KB activation, Casp-3, -8 & -9 
activation; Bid cleavage, PARP cleavage 
Accumulation in the mitochondria, mitochondrial 
membrane potential loss, ROS overproduction, caspase 
activation, Bim inactivation; regulation of p53, Bax and 
Bci-2 
N54A 
Unknown 
Env 
Nef 
Protease 
Tax Induction of Fas/TNF induced apoptosis 
Table 1.2: Table listing a selection of viruses that can either: (A) inhibit / delay apoptosis during 
Infection, or produce viral proteins that can; (B) activate / initiate apoptosis, or produce viral 
proteins that can. Adapted from (Roulston et al., 1999; Galluzzi et al., 2008a). 
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Poxviruses and Herpesviruses have also evolved another mechanism to overcome 
apoptosis; this is through the production of proteins that perform the same 
functions as the death receptor signalling factors. These proteins are designated as 
viral FLIPS (vFLIPs). Proteins such as HHV-8 protein K13 or MC159 / MC160 of 
molluscum contagiosum poxvirus are good examples of this group. These viral 
products bind to FADD through regions of the viral protein that are homologous to 
DED domains, thereby preventing the binding and subsequent activation of 
procaspase-8. Other proteins bind directly to procaspase-8, preventing its 
activation, such as the herpesvirus proteins E1.1 and E8 (Bertin et al., 1997; Sturzl et 
al., 1999; Micheau et al., 1999; Shisler and Moss, 2001). 
1.20.3 Inhibitors of Caspase activity 
The p35 protein of baculoviruses has been implicated in the inhibition of apoptosis in 
baculovirus infection. This protein contains sequences that act as a substrate for 
many caspases. It was noticed that p35 blocked both TNF- and Fas-induced killing 
and that the protein Poly (ADP)ribo polymerase (PARP), usually cleaved by the 
caspases, remained untouched. It is thought that p35 is cleaved into two fragments 
at Asp-87 (10 & 25 kDa) by the caspases, then irreversibly binds to many of them, 
such as caspase-1, -3, -6, -7, -8 and -10 (la Cruz et al., 2001; Clem, 2007) 
Poxviruses also encode several proteins that are homologues of mammalian 
chymotrypsinlike serine proteases, the serpins. Cowpox viral serpin CrmA is the 
most well characterised and is able to inhibit apoptosis induced by the death 
receptors by binding to and inhibiting caspase-8 and -1 (Cassens et al., 2003; 
Nathaniel et al., 2004). Other viral serpins have been discovered, such as the 
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vaccinia virus B13R or rabbitpox virus SPI-2, which have a similar function and 
structure, whereas others such as rabbitpox SPI-1 only have a 45 % sequence 
identity to CrmA, and possess different reactive centres to the enzyme (Brooks et al., 
1995; Takahashi et al., 1996; Jackson et al., 2005). It was shown that infection of 
cells with a myxomavirus with a knock out of the Serp2 protein led to a greater 
induction of apoptosis in the host cell compared to the wild type virus, indicating this 
gene product may aid viral pathogenesis by impairing host mediated inflammatory 
processes and apoptosis through inhibition of caspase-1 mediated pathways 
(Messud-Petit et al., 1998; MacNeill et al., 2006). 
Baculoviruses are also able to mediate caspase inhibition through another 
mechanism, the production of viral inhibitor of apoptosis proteins (vIAPs), each 
containing a carboxyl ring finger and multiple Cys/His residues known as baculovirus 
IAP repeats. These vIAPs inhibit the procaspases such as caspase -3, -7 and -9 
downstream of the mitochondria, thereby regulating both mitochondrial and death 
receptor-mediated apoptosis (Roy et al., 1997). 
Coxsackievirus B4 (CVB4) has also been shown to inhibit apoptosis, through the 
regulation of caspase-3 activity. Immunoprecipitation of active caspase-3 from 
infected HeLa cells revealed it co-precipitated with a 48 kDa protein. This was later 
discovered to be the viral protein 2BC, and further experimentation with purified 
2BC revealed that upon transfection both caspase-3 activity and staurosporine- 
induced apoptosis were significantly reduced (Salako et al., 2006). 
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1.20.4 Viral Bcl-2 homologues 
The archetypal member of this group is the adenoviral E1B gene product E1B-19K. 
This protein allows adenovirus to block apoptosis, thereby allowing for the 
maintenance of viral replication. The E113-19K protein is able to inhibit cell death 
induced through many different mechanisms such as E1A activation of p53, growth 
factor deprivation, binding of ligands to TNFR, Fas or TRAIL-R1 at the cell surface and 
bax expression. This is mediated through its homology to Bcl-2; E113-19K has a large 
portion of its body located within the mitochondria, where it is able to interact with 
and inhibit many of the proapoptotic members of the BcI-2 family like Bax and Bak 
(Farrow et al., 1995; Huang et al., 1997). 
Human Cytomegalovirus (CMV) is also capable of producing similar apoptotic 
inhibitory effects through the CMV gene UL37 (pUL37x1) which is a viral 
mitochondria-localised inhibitor of apoptosis (Pauleau et al., 2007) and exacts its 
effects at the level of mitochondrial membrane permeablisation. The N-terminal 
portion of the protein contains the mitochondrial targeting signal whereas the C- 
terminus contains the inhibitory portion of the protein. The CMV vMIA can 
specifically interact with Bax, recruit it to the mitochondria and neutralise its effects. 
vMIA has been reported to closely resemble Bcl-XL; however it does not interact with 
Bax through the BH domain, in contrast to Bcl-X1. It interacts through an 
electrostatic interaction with a region of Bax between its BH2 and BH3 domains 
which is not conserved in Bak and an a-helical domain located within the previously 
defined Bax-binding domain of vMIA, between the putative BH1-like and BH2-like 
domains. This potentially explains the specificity of vMIA for Bax alone (Pauleau et 
al., 2007; Galluzzi et al., 2008a). 
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1.20.5 Virus-mediated transcriptional regulation of apoptosis 
As well as interfering with the pathways already in place, viruses have also adapted 
methods of inhibiting the effect of apoptosis at the transcriptional level. Such 
transcription factors are able to directly up or down-regulate the genes that are 
involved in apoptosis, as necessary. Many virus replication strategies depend on the 
cell entering the S phase of the cell cycle which is often followed by an increase in 
levels of the cellular transcription factor p53. As activated p53 leads to apoptosis 
induction, the viruses have evolved unique ways of counteracting this problem. For 
example, Adenovirus protein E1B-55K, Simian Virus 40s LT protein and Human 
papillomavirus E6 all eliminate p53 function by binding to its DNA-binding domain or 
targeting it for ubiquitination (Chen and Hahn, 2003; Stewart et al., 2005; Muller and 
Dobner, 2008). 
1.21 Mechanisms by which viruses induce l activate apoptosis 
it has long been assumed that apoptosis could play a role in the end stage of a viral 
replication cycle, killing the cell and releasing the viral progeny. Viruses have 
developed many mechanisms to trigger apoptosis, as discussed below. 
1.21.1 Caspase Activators 
Many of the proteins produced by Human Immunodeficiency Virus-1 'HIV-1' lead to 
the activation of caspases during infection. The Tat protein is responsible for the up- 
regulation of caspase-8 in CD4+ T cells, whereas the Viral Protein R (Vpr) is able to 
induce apoptosis through a caspase-9 mediated mechanism (Stewart et al., 1999). 
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The picornavirus Avian Encephalomyelitis Virus 'AEV' non-structural protein 2C 
protease and the structural protein VP3 are able to induce apoptosis by creating a 
flux of cytochrome c through the mitochondrial pathway. This leads to the 
activation of upstream caspase-9 and then downstream caspase-3 (Liu et al., 2002; 
Liu et al., 2004). Another picornavirus, poliovirus, is also thought to induce apoptosis 
through a similar mechanism to that of AEV (Belov et al., 2003; Blondel et al., 2005; 
Buenz and Howe, 2006). 
1.21.2 Inhibition of Bcl-2 family members 
HIV-1 Trans-acting transcription factor (TAT) and protease both have been shown to 
affect the Bcl-2 family members. TAT has been demonstrated to down regulate Bcl-2 
followed by mitochondrial membrane potential loss (Aim) and Reactive Oxygen 
Species 'ROS' over-production, leading to caspase activation through the 
mitochondrial pathway (Macho et al., 1999). However, the HIV Protease is thought 
to deplete Bcl-2 in vivo, demonstrated through in vitro cleavage of purified Bcl-2 
between phenylalanine-112 and alanine-113 (Strack et al., 1996; Nie et al., 2002). 
1.21.3 Receptor signalling mimics 
The nef and tat proteins produced by HIV-1 are good examples of this group. In the 
early stages of HIV-1 infection when levels of TNF are low, virally encoded proteins 
such as nef or tat mimic TNFR signalling to result in sustained viral growth within 
infected cells. This mimicking of the ligands of the TNFR pathway modulates HIV-1 
gene expression, in particular activating transcription from the HIV long terminal 
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repeat and stimulating T cell apoptosis. These two events give rise to both immune 
suppression (due to T cell apoptosis) and the formation of viral reservoirs, thereby 
increasing TNFR-signalling, allowing for increased viral replication (Herbein and Khan, 
2008). 
1.22 Calicivirus-induced Apoptosis 
Feline calicivirus is the best characterised calicivirus due to the availability of an 
effective tissue culture system. It has been demonstrated that cells infected with 
FCV undergo apoptosis (Sosnovtsev et al., 2003; Al-Molawi et al., 2003). It was 
demonstrated that during infection caspase-2, -3 and -6 were activated and that 
other biochemical and morphological changes associated with apoptosis such as 
chromatin condensation and PARP cleavage could be observed (Al-Molawi et al., 
2003) Work has also focused on establishing the actual pathway of apoptosis that is 
initiated during infection (Natoni et al., 2006). Here it was confirmed that the 
mitochondrial pathway of apoptosis is activated, via the demonstration of Bax 
translocation to the mitochondria, depolarisation of the mitochondrial membrane 
potential, release of cytochrome c from the mitochondria to the cytosol and the 
activation of caspase-3 and -9 (Natoni et al., 2006). All investigations led to the 
hypothesis that the activation of the apoptotic machinery occurs and is crucial in 
FCV-F9 replication in infected cells (Sosnovtsev et al., 2003). 
However, recent reports have found that certain strains of FCV, namely those that 
have been isolated from cats with a newly reported virulent system disease 
(Pedersen et al., 2000; Hurley et al., 2004), had a different in vitro phenotype and 
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behaviour compared to other FCV isolates, particularly FCV-F9. These VS strains are 
able to produce more effective infections by replicating more efficiently and to 
higher titres over multiple growth cycle conditions. At lower multiplicities of 
infection VS strains displayed cytopathic effects earlier than in cells infected with 
non-VS or the vaccine strain of FCV. However, it was shown that this cytopathic 
effect did not correspond to a drop in cellular ATP levels, and the VS-FCV infected 
cells maintained their ATP levels longer than the non-VS infected cells. This led the 
authors to predict that the VS strains may delay the onset of apoptosis, allowing the 
production / release of more virus progeny (Ossiboff et al., 2007). It is this 
prediction that will be examined in later chapters of this thesis. 
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1.23 Project Aims 
Apoptosis induction during calicivirus infection has now been reported and 
documented for over 10 years. More recently the mechanisms of apoptosis 
induction in feline calicivirus infection have also been elucidated as described in 
Section 1.22 (Sosnovtsev et al., 2003; Natoni et al., 2006). 
The aims of this present study were to further define the mechanisms of apoptosis 
that lead to the activation of the mitochondrial pathway in FCV infection. Therefore 
the calpains and the cellular proteasome were examined and their role in FCV 
replication investigated. Secondly, the reported delay of apoptosis in VS strains was 
investigated. Finally, due to the recent discovery of a tissue culture based system for 
murine norovirus-1, we studied the mechanism of apoptosis induced during murine 
norovirus-1 infection through examination of the role of caspases, cytochrome c and 
the mitochondria. This will allow for a comparative analysis of the role of apoptosis 
during a variety of calicivirus infections. Murine norovirus-1 studies will also further 
help understand the pathology of human norovirus infection, by acting as a model of 
infection. 
We believe that these approaches will help us to answer the following questions: 
" What is the trigger of the mitochondrial pathway during FCV-F9 induced 
apoptosis? 
" Do virulent systemic isolates of FCV delay the onset of apoptosis? 
" How do the virulent systemic isolates of FCV delay apoptosis? 
" What is the major pathway of apoptosis activated by MNV-1 infection? 
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2 MATERIALS AND METHODS 
2.1 Growth and maintenance of cell lines 
2.1.1 Growth of Crandell-Rees Feline Kidney cells (CRFK) or Feline Embryonic Cell 
Line A (FEA) 
CRFK cells (European Culture Collections' Organization) or FEA cells (gift from the 
Radford Lab, Liverpool) were grown in modified Eagles medium (MEM)(Gibco) 
containing 10% heat-inactivated foetal bovine serum (FBS) (Gibco), 100 U/ml 
penicillin (Gibco), 100 jig/ml streptomycin (Gibco) and 1% (Fiore et al., 1998j) non 
essential amino acids (Gibco). The cell lines were grown in a humidified incubator at 
37°C with 5% CO2 (Incubator Galaxy S; Wolf Laboratories). 
When the cells were 90% confluent, the FBS-MEM medium was removed and the 
cells were washed twice with 5ml of 1: 10 trypsin/versene for 3-5 min in a 37°C 
incubator with 5% CO2. The cells were then collected in a 30ml universal tube 
containing 5m1 of fresh FBS-MEM to neutralize the trypsin, and centrifuged at 2,500 
rpm for 2.5 min. The supernatant was discarded and the cell pellet was resuspended 
in 10 ml of growth media. From this 10 ml, 1ml was seeded into a new 75 cm2 flask 
containing 15ml of fresh medium. The cells were maintained at 37 °C and 5% CO2 
until the next passage. 
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2.1.2 Growth of RAW 246.7 murine macrophages 
RAW cells (European Culture Collections' Organization) were grown in D-modified 
Eagles medium (D-MEM)(Gibco) containing 10% heat-inactivated foetal bovine 
serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin and 1% (Fiore et al., 1998i) 
non essential amino acids. The cell lines were grown in a humidified incubator at 
37°C with a 5% CO2 atmosphere. 
Cell maintenance differs from that described in sub-section 2.1.1 as the RAW cells 
were removed from the cell culture flask using a cell scraper. The suspension was 
collected in a 30m1 universal tube and centrifuged at 2,500 rpm for 2.5 min; the 
procedure followed sub-section 2.1.1 from this point onwards. 
2.2 Growth of FCV-F9, UKOS-A, AB087, AB088 or MNV-1 for viral stock 
Confluent 75 cm2 flasks of either CRFK / FEA or RAW cells were infected with 400 µl 
of FCV-F9, UKOS-A, AB087, AB088 or MNV-1 viral stock in 4 ml of 2% FBS MEM / D- 
MEM (for MNV-1) and rocked for 1h at RT. After incubation, the virus was removed 
and 8mI of the appropriate growth media was added to the flask. The cells were 
then incubated at 37°C until cytopathic effects were observed (6 h post infection 
(p. i. ) in CRFK cells, 18 h p. i in RAW cells) at which time the cells were frozen at -20°C 
o/n. The cells were thawed, the supernatant collected in a universal tube and 
centrifuged at 2,500 rpm for 2.5 min. The supernatant was filtered through a 0.2 µm 
ministart filter (Millipore), aliquoted (400 µl) and stored at -80°C. 
Tissue Culture Infectious Dose50 Assay (TCID50) was then performed for all viruses to 
determine the titre of the virus. 
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2.3 Tissue Culture Infectious Doseso Assay (TCID50) 
From a confluent (approximately 80%) T75 tissue culture flask, cells was harvested as 
in subsection 2.1.1 and used in preparation for seeding into a 96 well plate (40,000 
cells/well). Serial dilutions of the stock virus were prepared in MEM and 50 µl of 
each dilution was added to 6 wells. The last row was mock-infected (negative 
control). One hundred µl of cells were added to each well from the T75 cell stock. 
The cells were incubated at 37°C o/n. The next day each well was scored as infected 
or uninfected and the titre of the virus was calculated using the following formula. 
Viral titre = I(% of wells infected at dilution above 50%) - 50%1 
[(% of wells infected above 50%) - (% of wells infected below 50%)I 
2.4 Time course of infection 
Cell lines (approximately 80% confluent) were inoculated with the appropriate virus 
(CRFK/FEA - FCV-F9/UKOS-A/AB087/AB088; RAW - MNV-1) or 2% FBS growth media 
(mock-infected control) at the appropriate multiplicity of infection (MOI) in 2% FBS 
growth media and then rocked at room temperature for 1h to allow for viral 
adherence to the cells (Table 2.1). Following the 1h incubation the inoculum was 
removed and replaced with fresh 10% FBS growth media, the cells were then 
incubated as stated in sub-section 2.1.1. Samples were taken at specific time points 
following infection and analysed with the different assays described subsequently. 
In certain experiments it was necessary to infect cells that were pre-treated and co- 
treated with various different chemicals e. g. caspase, calpain and proteasome 
inhibitors (Table 2.2). 
80 
Materials and Methods 
Dish Size 2% Growth Media 10% Growth Media 
6 well plate 500 µl per well 2 ml per well 
35 mm dish 50041 2 ml 
60 mm dish 1ml 4ml 
T-75 Flask 4 ml 8 ml 
Table 2.1: Cell Culture Vessels. The volume of media used in the types of dishes used in the 
following experiments. 
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. Chemical 
Chemicals Use 
z-VAD-fmk 
(Bachem) 
Pan-caspase inhibitor 
ALLN Calpain / Proteasome Inhibitor 
(Calbiochem) 
MG-132 
(Calbiochem) 
Proteasome Inhibitor 
Epoxomycin Proteasome Inhibitor 
(Calbiochem) 
Calpeptin 
(Calbiochem) 
Calpain Inhibitor 
Final Concentration 
100 µM 
50 µM 
10 µM 
200 nM 
100 µM 
Table 2.2: Chemicals used in combination with virus infection. The final concentrations of 
various inhibitors in viral infections. 
Abbreviations: (Martinet, 2006 229 /id) z-VaI-AIa-DL-Asp-fluoromethylketone; (Kwak, 17005 562 /id) 
N-acetyl-leucinyl-norieucinal; (MG-132) carbobenzoxy-Ieucyl-leucyl-Ieucinal; (Meng et al., 1999) 
Epoxomicin. 
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2.4.1 Calculation of Multiplicity of Infection 
To calculate the appropriate multiplicity of infection for the viral infections it was 
necessary to first calculate the TCID50 of viral stock and estimate the number of cells 
within the culture vessel. The formula used to obtain the amount of this stock in 
microlitres needed is: 
Amount of Stock (pi) = No. cells in culture vessel x MOI required 
TCIDSO value of viral stock 
2.5 Transfection of plasmid DNA into CRFK cell line 
CRFK / RAW cells were grown in 35 mm2 dishes until 80% confluent. For each dish 
prepared, 50 µl Optimem (Gibco) +6 µI Fugene 6 Transfection Reagent (Pauleau et 
al., 2007) and 50 µl Optimem +2 µg of the plasmid DNA to be transfected were 
added to individual bijoux tubes and incubated at RT for 15 min. The DNA/Optimem 
mix was then added into the Fugene 6/Optimem mix and incubated for a further 45 
min at RT. 
The growth media from each dish was removed and cells washed with 1 ml pre- 
warmed Optimem; this was removed and replaced with 900 gl Optimem. The 100 µI 
transfection complex was then added drop wise onto the cell monolayers. The cells 
were incubated at 37 °C for 5 h, rocking the dishes every half hour to ensure efficient 
coverage of the media over the cell monolayer. Following incubation, 500 µl 15% 
FBS MEM (see appendix) was added to each dish and the cells incubated at 37 °C for 
the appropriate length of time (24/48 h) depending on the experiment. The 
transfected cells were infected or mock infected as described in section 2.4 and 
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extracts analysed by flow cytometry (Section 2.6) or by Western blotting (Section 
2.9). 
2.6 Flow CytometricAnalysis 
2.6.1 Cell Culture 
CRFK / RAW cells were grown in 35mm2 dishes until they were approximately 80% 
confluent. The cells were infected or mock infected as described in section 2.4. At 
each time point post infection, the cell medium was collected in a universal tube and 
the remaining cell monolayer was trypsinized with 500 µl 1: 10 trypsin/versene. 
Following trypsinization, the cells were added into the previously collected medium 
and centrifuged at 2,500 rpm for 2 min. The cells were analysed as described below. 
2.6.2 Annexin V Binding Assay 
The supernatant from subsection 2.6.1 was discarded and the pellet was 
resuspended in 1 ml of Annexin V binding buffer (Annexin V-FITC Apoptosis 
detection kit; Calbiochem) to obtain a cell density of 1x106 cells/mi. Five hundred µI 
of the cell suspension was transferred to a clean eppendorf and incubated with 1.25 
µI Annexin V-FITC (Calbiochem) for 15 min at RT in the dark and 10 VI propidium 
iodide (Calbiochem) was added to each sample. Samples were then wrapped in foil, 
placed on ice and analysed immediately by flow cytometry (10,000 events) using 
Beckman-Coulter Epics XL using FL1 (Annexin V-FITC detection) and FL3 (Propidium 
iodide detection) channels. 
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2.6.3 Active Caspase-3 detection 
Pelleted cells from subsection 2.6.1 were resuspended in 500 µl of ice cold 
Cytofix/Cytosperm solution (BD Pharmingen, see Appendix). The samples were 
transferred to eppendorfs and incubated on ice for 20 min. The samples were 
centrifuged at 2,500 rpm for 2.5 min at RT, the supernatant was discarded and the 
cells were washed twice with 500 µl of cold Perm/Wash buffer (BD Pharmingen, see 
Appendix). After washing, the cells were resuspended in 100 µI of cold Perm/Wash 
buffer and incubated with 20 µl of phycoerythrin conjugated monoclonal rabbit anti- 
active caspase-3 antibody (BD Pharmingen) in the dark for 30 min at RT. The cells 
were washed with 1 ml Perm/Wash buffer, centrifuged at 2,500 rpm for 2 min and 
resuspended in 500 µl of Perm/Wash buffer (All carried out in a dimly lit laboratory). 
The samples were wrapped in foil and analysed by flow cytometry (10,000 events) 
using Beckman-Coulter Epics XL using the FL3 channel. 
2.6.4 Mitochondrial Membrane Potential Analysis 
Cells from subsection 2.6.1 were resuspended in 1 ml PBS containing 5 mM glucose 
and transferred to an eppendorf tube. Three dishes/eppendorfs were used for the 
mock infected sample and as positive controls for depolarisation of the 
mitochondrial membrane. To one of the mock infected dishes, 20µM Carbonyl 
cyanide 3-chlorophenylhydrazone (CCCP), a Protonophore (Alonso et al., 1998b) and 
uncoupler of oxidative phosphorylation in mitochondria, was added to completely 
depolarise the mitochondria, and the cells incubated at RT for 3 min. Following 
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incubation, 100 nM Tetramethylrhodamine ethyl ester (TMRE) was added to the 
tube containing the CCCP and another separate mock infected control tube. TMRE 
(100 nM) was also added to tubes harvested from each time point to act as a 
measure of membrane depolarisation. All sample tubes were then wrapped in foil 
and incubated in the dark at 37 °C for 40 min. Samples were analysed by flow 
cytometry (20,000 events) using Beckman-Coulter Epics XL using the FL3 channel. 
2.7 Calpastatin / GFP Plasmid Construction 
Due to the lack of cell permeable and specific calpain inhibitors, it was necessary to 
attempt to create an expression plasmid that could deliver the inhibitory portion of 
the highly specific endogenous calpain inhibitor, calpastatin. The inhibitory portion 
of domain I was cloned into a GFP expressing vector under the control of the EMCV 
IRES to enable identification of transfected cells. 
2.7.1 Plasmid Vector Preparation - digestion and dephosphorylation 
The plasmid vector pEGFP-N1 containing PTB1 was digested with the restriction 
enzymes BamH1 and KpnI to linearise the vector and remove the PTB 1. The 
restriction digest contained the following: 10 µl pEGFP-N1 (Invitrogen), 5 .d 
Multicore Buffer (Promega), 1.5 VI BamHl enzyme (Promega), 1.5 .d Kpnl enzyme 
(Promega), 33.5 µl MQ water in a sterile eppendorf. The samples were then 
incubated at 37°C for 3h and de-phosphorylation of the plasmid DNA was achieved 
by the addition of 1 unit of the enzyme alkaline phosphatase (Promega). The digest 
was then incubated again for 30 min at 37 °C, after which time the preparations 
86 
Materials and Methods 
were run on a 1% agarose gel and visualised using UV illumination as described 
below. 
2.7.2 Gel electrophoresis and visualisation of plasmid DNA 
A 1% (w/v) agarose (Melford) gel was made up in 1x TAE buffer (See Appendix) 
containing 0.5 µg/ml ethidium bromide (Sigma). The sample was mixed with 6x gel 
loading buffer (Promega) and was loaded into wells of the agarose gel along with a1 
kb DNA ladder (Promega). The gel was electrophoresed at 100 V for 1h in 1x TAE 
buffer and visualised using a UV transilluminator (UVI tec). 
2.7.3 Purification of DNA sample using gel extraction (QlAquick Gel Extraction Kit) 
DNA backbone was extracted from 1% agarose gels and purified using the QlAquick 
gel extraction kit (Qiagen). The procedure was carried out according to 
manufacturer's protocols. 
2.7.4 Human calpastatin cDNA preparation - Primer design 
Full length human calpastatin cDNA was obtained in the form of plasmid pTicCS (gift 
from Prof M Maki, Japan). Primers were designed to the first 251 amino acids of the 
calpastatin cDNA as the inhibitory calpain recognition site is contained within this 
region and synthesised by Sigma (Table 2.4). 
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Primer Name Sequence (5' - 3') 
Calp. Forward ATGGTACCATCCACCATGGACCCCACAG 
Calp. Reverse ATGGATCCTGCTTGATCACTCATTGTATC 
Table 2.4: Primer sequences designed to the plasmid pTicCS to isolate the first 251 amino 
acids of the human calpastatin cDNA. (Red) KpnI restriction site; (Blue) BamHI restriction site. 
2.7.5 Human calpastatin cDNA preparation -PCR 
To a 0.5 ml PCR tube, fifty microlitre reaction mixes were added containing 10 ld Taq 
polymerase 5x buffer (Promega), 2 µl 5mM dNTP mix (Promega), 1 µl forward 
primer (Calp. Forward: Table 2.4), 1 µl reverse primer (Calp. Reverse : Table 2.4), 1 µl 
Taq DNA polymerase (Promega), 1 µl plasmid DNA containing human calpastatin 
cDNA (diluted 1: 10) and 34 µl MQ water; this was overlaid with 30 µl of paraffin oil. 
The samples were placed in a thermocycler programmed to run the following cycle: 
95 °C for 10 min; then 30 amplification cycles of 95 °C for 1 min (denaturation step), 
60 °C for 1 min (annealing step), 72 °C for 1 min (extension step) followed by a final 
extension step of 72 °C for 10 min. 
Agarose electrophoresis was performed as stated in Sub-section 2.7.2 and the gels 
visualised using ultra-violet illumination to confirm the presence of correctly sized 
fragments. The PCR product was excised from the agarose gel as in section 2.7.3 and 
stored at -20°C until needed. 
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2.7.6 Ligation of calpastatin PCR fragment into pGEM T-Easy Vector 
Purified samples of the calpastatin cDNA (from section 2.7.5) were used to set up the 
ligation reactions into the pGEM T Easy vector (Promega). The ligation mixes were 
set up in sterile 1.5 ml eppendorfs as follows; 5 lal Calpastatin PCR Product, 1 gl T4 
DNA ligase (Promega); 2 µl 2x rapid ligation buffer; 1 pl pGEM T Easy vector and 11 
gl MQ water. A control reaction was also set up in which the 5 µl calpastatin PCR 
DNA was replaced with MQ water. All reactions were incubated at 16 °C o/n. 
2.7.7 Transformation of competent E. coli DHSa cells with ligation mix 
Ligation mix created in section 2.7.6 (7 µl) was added to pre-cooled eppendorfs on 
ice, each containing 50 µl of competent E. coli DH5a cells (prepared by Marion 
Chadd, FHMS). The mixture was allowed to incubate on ice for 30 min, followed by 
heat-shock at 42 °C for 45 sec, and subsequent cooling on ice for a further 5 min. 
Luria- Bertani (LB) broth (see Appendix) (200 VI) was added to each mixture and 
incubated at 37 °C for 60 min. The samples were centrifuged for 1 min at 1,000 rpm, 
150 µl supernatant removed, and the pellet resuspended in the remaining 50 µl. 
Fifty µl of E. coil DH5a cells were spread on previously prepared LB agar plates 
containing ampicillin (25 mg/ml) (Sigma), IPTG (0.25 mM) (NBL Gene Sciences) and X- 
gal (1004g/ml) (Melford). The plates were allowed to dry and incubated overnight at 
37 °C. 
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2.7.8 Overnight Broth Cultures 
Ten individual white colonies were selected from the LB plate prepared in 2.7.7. 
These colonies were used to inoculate 5 ml LB broth with 25 mg/ml ampicillin. The 
universals were placed into an orbital shaker and incubated at 250 rpm and 37 °C 
o/n. 
2.7.9 Minipreparations of plasmid DNA by 'Phenol method' 
Samples of the overnight broth cultures from section 2.7.8 (1.5 ml) were pipetted 
into sterile eppendorfs and centrifuged at 8,000 rpm for 1 min. The supernatant was 
discarded by pipetting; the remaining pellet was resuspended in 100 pd of re- 
suspension solution (see Appendix). Lysis solution (200 µl) (see Appendix) was 
added to each eppendorf, followed by 150 µl neutralisation solution (see Appendix). 
The tubes were chilled on ice for 5 min and centrifuged at 13,000 rpm for 5 min. 
The plasmid DNA-containing supernatant was pipetted into a new 1.5 ml eppendorf 
tube. 
Four hundred µI Phenol Chloroform was added to each sample, vortexed for 1 min 
and centrifuged at 13,000 rpm for 1 min. The top phase was removed through 
pipetting, taking care to avoid contamination from the interface, and placed into a 
new sterile eppendorf tube. 1000 µl of 100% Ethanol was added to each of the 
eppendorfs and the samples left to stand at room temperature for 10 min. The 
samples were centrifuged at 13,000 rpm for 15 min and the resulting supernatant 
discarded. The remaining pellet was washed in 100 µl of 70% ethanol and 
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centrifuged at 13,000 rpm for 1 min. The supernatant was removed using a syringe 
and the pellet air dried for 5 min before it was resuspended in 20 µl of MQ H2O. 
2.7.10 Restriction enzyme digest screening for calpastatin fragment insertion 
This was performed to screen the minipreps for the presence of the calpastatin 
fragment insert. Restriction enzyme digests were prepared by the addition of 4 µl 
plasmid DNA (section 2.7.9), 2 Rl Multicore Buffer, 0.5 gl BamHI and 0.5 pl Kpnl 
restriction endonuclease (see Appendix) and 11 pl of MQ water to a 1.5 ml 
eppendorf. The samples were incubated for 2 hrs at 37 °C. 
Agarose gel electrophoresis was performed as stated in Sub-section 2.7.2 and the 
gels visualised using ultra-violet illumination to confirm the presence of correctly 
sized fragments. The samples that released correctly sized fragments were chosen 
and full scale restriction digest of the calpastatin-containing pGEM T-Easy Vector, gel 
electrophoresis and gel extraction of released fragment were performed as stated in 
sections 2.7.1 - 2.7.3. The extracted calpastatin fragment was stored at -20°C ready 
for further use. 
2.7.11 Ligation of calpastatin PCR fragment into pEGFP-N1 vector 
Samples of the calpastatin fragment (from section 2.7.10) were used to set up 
ligation reactions into the pEGFP-N1 vector that had been prepared as described in 
Subsection 2.7.1. The ligation mixes were set up in sterile 1.5 ml eppendorfs as 
follows; 5 lal Calpastatin PCR Product, 1 gl T4 DNA ligase (Promega); 2 µl 2x rapid 
ligation buffer; 1 µl linearised pEGFP-N1 vector & 11 µl MQ water. A control 
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reaction was also set up in which the 5 µI calpastatin PCR DNA was replaced with MQ 
water. All reactions were incubated in a water bath at 16 °C o/n. 
The preparations were transformed into DH5a, subcultured into overnight broths 
and mini preparations of plasmid DNA made as in sections 2.7.7-2.7.9. 
2.7.12 Restriction enzyme digest screening for calpastatin fragment insertion 
This was performed to screen the minipreps for the presence of the calpastatin PCR 
insert. Restriction enzyme digests were prepared by the addition of 4 µl plasmid 
DNA (section 2.7.11), 2 pl Multicore Buffer, 0.5 µl BamH! and 0.5 µI Kpnl restriction 
endonuclease (see Appendix) and 11 µl of MQ water to a 1.5 ml eppendorf. The 
samples were incubated for 2h at 37 °C. 
Agarose gel electrophoresis was performed as stated in Sub-section 2.7.2 and the 
gels visualised using ultra-violet illumination to confirm the presence of correctly 
sized fragments. 
2.7.13 Extraction of EMCV IRES 
A T-Easy Vector containing the EMCV IRES element was donated by Dr E Royall 
(University of Surrey). A 50 µl digest was performed of the plasmid DNA containing 
10 µl plasmid DNA, 1.5 µl BamH I restriction enzyme (Promega), 5 µl BamH I Buffer E 
(Promega) and 33.5 VI MQ water. The digest was incubated for 2 hrs at 37 °C. The 
DNA was run on a 1% agarose gel and visualised as described in Sub-section 2.7.2. 
The IRES-containing fragment produced from this reaction was then gel extracted 
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using the QlAquick Gel Extraction Kit (QlAgen) according to the manufacturers' 
protocol and stored at -20 °C until needed. 
2.7.14 Restriction digestion of pEGFP-N1/Calpastatin construct 
A plasmid with the correct sized Calpastatin insert generated as described in sub 
section 2.7.11 - 2.7.12 was digested with restriction enzyme BamHI as stated in 
subsection 2.7.13. An agarose gel electrophoresis was performed as in subsection 
2.7.2 to visualise the linearisation. The linearised pEGFP-N1/Calpastatin vector 
produced from this reaction was then gel extracted using the QlAquick Gel Extraction 
Kit (QlAgen) according to the manufacturers' protocol and stored at -20 °C until 
needed. 
2.7.15 Ligation of EMCV IRES into pEGFP-N1/Calpastatin linearised vector 
Samples of the EMCV IRES fragment (from section 2.7.13) were used to set up 
ligation reactions into the pEGFP-N1/calpastatin vector that had been prepared as in 
Subsection 2.7.14. The ligation mixes were set up in sterile 1.5 ml eppendorfs as 
follows; 5 pl EMCV IRES, 1 µl T4 DNA ligase (Promega); 2 µl 2x rapid ligation buffer; 1 
gl linearised pEGFP-N1/Calpastatin vector & 11 pl MQ water. A control reaction was 
also set up in which the 5 pl calpastatin PCR DNA was replaced with MQ water. All 
reactions were incubated in a water bath at 16 °C o/n. 
The preparations were transformed into DH5a, subcultured into overnight broths 
and minipreparations of plasmid DNA made as in sections 2.7.7-2.7.9, using 
kanamycin for antibiotic selection. 
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2.7.16 Restriction enzyme screening for EMCV IRES insertion 
This was performed to screen the minipreps for the presence of the EMCV IRES 
insert. Restriction enzyme digests were prepared by the addition of 4 µl plasmid 
DNA (section 2.7.15), 2 lal Buffer E, 1 µl BamH! (Promega) and 13 lal of MQ water to a 
1.5 ml eppendorf. The samples were incubated for 2 hrs at 37 °C. 
Agarose gel electrophoresis was performed as stated in Sub-section 2.7.2 and the 
gels visualised using ultra-violet illumination to confirm the presence of correctly 
sized fragments. The samples that released correctly sized fragments were chosen 
and used to transform E. coli DHSa cells as in sub section 2.7.17. 
2.7.17 PCR to check the orientation of EMCV IRES in pEGFP-N1/Calpastatin vector 
In a 0.5 ml PCR tube, fifty microlitre reaction mixes were prepared containing 10 µl 
Taq polymerase 5x buffer (Promega), 2 lal 5mM dNTP mix (Promega), 1 µl forward 
primer (Calp. Forward: Table 2.4), 1 gl EMCV reverse primer (Obtained from E 
Royall), 1 ld Taq DNA polymerase (Promega), 1 µl plasmid DNA containing pEGFP- 
N1/IRES/Calpastatin (minipreps from subsection 2.7.15 that had the correctly sized 
EMCV IRES fragment) (diluted 1: 10) and 34 µl MQ water; this was overlaid with 30 µl 
of paraffin oil. 
The samples were placed in a thermocycler programmed to run the following cycle: 
95 °C for 10 min; then 30 amplification cycles of 95 °C for 1 min (denaturation step), 
60 °C for 1 min (annealing step), 72 °C for 1 min (extension step) followed by a final 
extension step of 72 °C for 10 min. 
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Agarose electrophoresis was performed as stated in Sub-section 2.7.2 and the gels 
visualised using ultra-violet illumination to confirm the orientation of the EMCV IRES. 
Minipreps that contained the correctly sized EMCV IRES fragment (Subsection 
2.7.16) and produced a positive PCR result were used in subsequent reactions. 
2.7.18 Transformation of competent E. coli DHSa cells for midipreparations 
Minipreps displaying a correctly sized gel amplicon (1µI) (section 2.7.17) were added 
to pre-cooled eppendorfs on ice, each containing 50 µl of competent E. coli DHSa 
cells. The mixture was allowed to incubate on ice for 30 min, followed by a heat- 
shock at 42 °C for 45 sec, and subsequent cooling on ice for a further 5 min. Two 
hundred µl of Luria-Bertani (LB) broth was added to each eppendorf and incubated 
at 37 °C for 60 min. The culture was added to 50 ml of LB broth with 100 mg/ml 
kanamycin, in a 250 ml Duran flask. 
2.7.19 Midipreparations of plasmid DNA 
A QlAgen plasmid midi purification kit was utilised to purify the plasmid, performed 
as stated in the manufacturers' handbook. 
2.7.20 DNA Concentration and Purification 
Aliquots of the midiprep DNA (300 µl) were taken and placed in a fresh eppendorf 
with approximately 30 µl 3M sodium acetate and 600 µI 100% Ethanol. The sample 
was vortexed and stored at -20°C o/n. The following day, the samples were allowed 
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to equilibrate to RT for 10 min and then centrifuged at 14,000 rpm for 15 min. 
Following centrifugation, the supernatant was removed and 1 ml of 70% Ethanol was 
added to the eppendorf. The sample was vortexed and centrifuged once more at 
14,000 rpm for 1 min. After this, the supernatant was removed with a syringe and 
the pellet allowed to dry at RT for approx. 5 min. Following drying, the pellet was 
resuspended in 30 µl MQ H2O and the concentration of DNA determined by 
Nanodrop (Aglient Technologies; ND-1000). 
2.7.21 Sequencing of vector to confirm EMCV IRES Inserted 
Purified constructs obtained as in subsection 2.7.20 were sent for sequencing to 
confirm the presence of the EMCV IRES, its orientation and the correct reading frame 
with respect to the GFP protein (Figure 2.1). 
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A 
Protein 
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Kan'gene 
B 
EJ 
BamHl 
EMCV IRES 
BamHl 
Calpastatin Fragment 
(1-251amino acids) Green Fluorescent 
Kpnl ----- 
1 
4- 753 bp ý 
L12345678 
NOV 
12345t, 78 
500 bp 1153 bp 
Figure 2.1: Creation of Calpastatin domain I expressing construct. (A) Schematic 
representation of the finished construct within the pEGFP-N1 vector backbone. Italics represent 
specific restriction endonuclease sites used to insert designated components of the construct. (B) 1% 
agarose gel electrophoresis. Product of PCR using primers designed to pTicCs containing the cDNA for 
human calpastatin gene, for use in the new construct. L: 1 kb DNA Ladder; 1: Calpastatin PCR product 
(C) 1% agarose gel electrophoresis. Restriction endonuclease digests with BamH1 to determine if 
insertion of EMCV IRES into p-Calp-EGFP-N1 was successful. (D) 1% agarose gel electrophoresis. 
Orientation of EMCV IRES in vector was determined by PCR (Calp FWD & EMCV REV Primers). Correct 
size PCR product is 1253 bp (753 bp Calp (B) + 500 bp EMCV IRES (C)). (C & D) L: 1 kb DNA Ladder; 1- 
8: minipreps of final construct. 
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2.8 Preparation of cell extracts for Western Blot Analysis 
2.8.1 Preparation of total cell extracts 
CRFK / RAW cells were grown in 35mm2 dishes until they were approximately 80 % 
confluent. The cells were infected as stated in section 2.4. At each time point p. i., 
the cell medium was collected in a universal tube and the remaining cell monolayer 
was trypsinized with 500 µl of 1: 10 trypsin/versene. Following trypsinization, the 
cells were added to the medium and centrifuged at 2,500 rpm for 2.5 min. The 
supernatant was discarded and the pelleted cells resuspended in 100 µl of ice cold 
lysis buffer (see Appendix) and incubated on ice for 20 min. After this time the cells 
were vortexed and centrifuged at 14,000 rpm for 5 min at 4°C. The supernatant was 
collected in an eppendorf and stored at -80°C. These total cell extracts were used to 
examine the cleavage of caspases -3, -8 & -9; fodrin cleavage; and for Calpain activity 
experiments. 
2.8.2 Preparation of cell extracts for cytochrome c analysis. 
CRFK / RAW were grown in 60 mmz dishes until they were approximately 80% 
confluent. The cells were infected as stated in section 2.4. At each time point p. i., 
the cell medium was collected in a universal tube and the remaining cell monolayer 
was trypsinized with 1000 µl of 1: 10 trypsin/versene. Following trypsinization, the 
cells were added to medium and centrifuged at 2,500 rpm for 2.5 min. The 
supernatant was removed and the pellet resuspended in 1 ml of cold buffer A (see 
Appendix) and transferred to an eppendorf. The samples were centrifuged at 2,500 
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rpm for 2.5 min at 4°C , the supernatant discarded and the pellet washed a further 
time with 1 ml of cold buffer A. To obtain the cytosolic fraction, the samples were 
centrifuged as before, the supernatant discarded and the pellet was resuspended in 
60 µl of cold buffer B (see Appendix) supplemented with 600 Vg/ml of digitonin 
(Calbiochem) to permeablise the plasma membrane. The cell suspension was left for 
2.5 min until approx 90% of the cells were permeabilised. To confirm this, 2.5 µl of 
the sample was added to 100µI of 1: 1 (v/v) 0.4% Trypan Blue / PBS and 10 µI of this 
was placed on a haemocytometer chamber. Upon examination using an inverted 
light microscope, blue cells indicated membrane permeabilisation. After this, the 
samples were centrifuged at 2,500 rpm for 5 min at 4°C and the supernatant was 
collected in an eppendorf tube and stored at -80°C. To obtain the mitochondrial 
fraction, the remaining pellet was resuspended in 100 µI of Total cell lysis buffer (see 
Appendix; Subsection 2.9.1) and incubated on ice for 20 min. After incubation, the 
samples were vortexed, centrifuged at 14,000 rpm for 5 min at 4°C, and the 
supernatant collected in a clean eppendorf and stored at -80°C. 
2.8.3 Quantification of protein concentration in cell extracts 
This was performed according to the manufacturers instructions; the BCA Protein 
Assay Kit (Pierce) was used to determine the concentration of the proteins in the cell 
extracts. 
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2.8.4 SDS-PAGE and Western Blot Analysis 
Equal amounts of protein from each sample were added to the appropriate volume 
of H2O and 3X SDS Buffer (NEB) to a final volume of 30 µl. The samples were heated 
at 95°C for 5 min and then loaded into the stacking gel (see Appendix) along with a 
pre-stained protein marker (broad range 6- 175 kDa, NEB). Resolving gels (see 
Appendix) with different percentages of acrylamide were used according to the size 
of the protein analysed. 
The proteins were electrophoresed at 120 V, 0.2 A for 90 min in running buffer (see 
Appendix). Proteins were transferred on to a nitrocellulose membrane 
(ImmobilionTM, Millipore) by electroblotting at 110 V, 0.4A for 90 min in transfer 
buffer (see Appendix). The membrane was blocked with 5% blocking buffer (see 
Appendix) for a minimum of 3h at 4°C and then incubated with the appropriate 
primary antibody. Incubation conditions and length were antibody dependent and 
are summarised in Table 2.3. 
Following incubation with the primary antibody, the membrane was washed 4 times 
in 1X TBS-0.1% (Fiore et al., 1998f) Tween 20 (see Appendix) for 2x washes of 30 sec 
and 2x washes of 10 min. The membrane was incubated with an appropriate anti- 
IgG peroxidase conjugate secondary antibody for 1h at RT °C. The membrane was 
washed as before and the detection was facilitated through the use of enhanced 
chemiluminescence using SuperSignal ®West-Pico chemiluminescent substrate 
(Pierce). In some cases it was necessary to re-probe the membrane to detect gel 
loading controls. In the case of cytochrome c detection the controls were the 
cytochrome c oxidase subunit IV (COX), heat shock cognate protein 70 (Hsc70) or 
actin. 
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Re-probing was carried out by washing the membrane three times in 1X TBS-0.1% 
(Fiore et al., 1998e) Tween 20 for 10 min at RT °C and then one wash in PBS 
containing 1mM sodium azide for 3h at 4°C. Following incubation, the membrane 
was washed three times as before and incubated with 5% blocking buffer for 3h at 
4°C. The blots were incubated with mouse anti-COX IV monoclonal antibody 
(Molecular Probes; 1: 1000) or rat anti-Hsc70 polyclonal antibody (Stressgen; 1: 1000). 
Membranes were washed as before and incubated with the appropriate anti-IgG 
peroxidase conjugated secondary antibody. Washes and detection were performed 
as previously described. 
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Antigen MW % Antibody Isotype Dilution Length of 
kDa Acrylamide incubation 
Cytochrome 15 15 Anti-cyt c Mouse IgG 1: 1000 Overnight 
c monoclonal 
antibody clone 
7H8.2C12 
BD Pharmingen 
Caspase-3 17 10 Anti-Caspase 3 Mouse IgG 1: 1000 Overnight 
monoclonal 
antibody 
Cell Signalling 
Caspase-8 Pro-form: 53 10 Anti- Casp 8 Rabbit IgG 1: 500 Overnight 
Active: polyclonal 
43/18 antibody 
Calbiochem 
Caspase-9 Pro-form: 47 10 Anti-Casp 9 Mouse IgG 1: 500 Overnight 
Active: monoclonal 
32/17 antibody 
Gift from Y. 
Lazebnik 
Fodrin 240 6.5 Anti-aFodrin Mouse IgG 1: 1000 1h 
monoclonal 
antibody 
Biomol Ltd. 
c-myc Fusion 15 Mouse IgG 2 Vg/ml Overnight 
protein 
dependent 
Green 28 10 Anti-GFP Rabbit 1: 1000 Overnight 
Fluorescent monoclonal 
Protein antibody 
(GFP) Molecular 
Probes 
COX IV 19.6 Loading Anti-COX IV Mouse IgG 1: 1000 Overnight 
Control monoclonal; 
clone 20E8 
Molecular 
Probes 
Actin 42 Loading Anti-actin 
Control polyclonal 
antibody 
Sigma 
Table 2.3: The table shows the final concentration, incubation times and targets of the primary antibodies used in this 
thesis. 
102 
Materials and Methods 
2.9 Caspase -3/-7 Activity Assay 
2.9.1 Cell Preparation 
CRFK cells were grown in 35 mm2 dishes until they were approximately 80% confluent. The 
cells were infected or mock infected as described in section 2.4 at a multiplicity of infection 
of 1 or 100. At each time point p. i., the medium containing floating cells was collected in a 
universal tube and the remaining cells were trypsinized with 1 ml of 1: 10 trypsin/versene. 
After trypsinization, the cells were mixed with the medium and centrifuged at 2,500 rpm for 
2.5 min. The supernatant was removed and the pellet was washed 3 times with 1 ml pre- 
warmed PBS. The pellet was resuspended in 30 µl of caspase-3 lysis buffer (see Appendix). 
The cells were lysed by snap freezing the pellet in ethanol/dry ice and thawing in a water 
bath at 42°C, the process being repeated three times. Following the freeze / thaw cycles the 
samples were centrifuged at 14,000 rpm for 30 min at 4°C, the supernatant collected in a 
clean eppendorf and the protein concentration determined as stated in 2.9.3. 
2.9.2 Caspase -31-7 Activity Assay 
Fifty Vg of protein was mixed with caspase -3/-7 assay buffer (Promega; see Appendix) 
containing 40 µM of benzyloxycarbonil-Asp-Glu-Val-Asp-7-amino-trifluoromethylcoumarin 
(z-DEVD-AFC), a fluorogenic substrate, total volume of sample = 100 µl. After cleavage of 
the DEVD sequence by caspase -3/-7, the fluorophore AFC disassociates from the tetra- 
peptide and emits fluorescence at 505 nm when it is excited at 400 nm. Control samples 
were also set up containing just the ac-DEVD-AFC alone to allow for the calculation of the 
inherent fluorescence of the substrates. The samples were loaded into a 96-well plate and 
103 
Materials and Methods 
the fluorescence liberated was measured with a microfluorometer (SpectraMax 340PC384 
system; Gemini XS) using 355 nm excitation and 538 nm emission filters. The 
measurements were recorded at intervals of 2.5 min for 1h at 37 °C. The caspase activity 
was calculated as follows: The inherent fluorescence of ac-DEVD-AFC was subtracted from 
the fluorescence recorded at each time point for all of the samples. The resulting 
fluorescence was then plotted against the time of the analysis (2.5 min intervals for 1 h) and 
the slope (indicative of the actual caspase -3/-7 activity) was obtained by using linear 
regression analysis of the linear range of the plot (10 min - 40 min). The caspase -3/-7 
activity of the infected samples was normalised against activity of the mock infected control, 
and presented as mean ± standard error of three independent experiments. 
2.10 Determination of Intracellular and Extracellular Viral Titres 
CRFK cells were infected with FCV-F9 as stated in section 2.4. At different time points p. i. 
the cell medium was removed from the cell monolayer and aliquoted into an eppendorf 
tube. The medium was centrifuged at 2,500 rpm for 3 min, and the supernatant removed 
into a fresh eppendorf tube. After centrifugation the supernatant was filtered through a 0.2 
gm ministart syringe filter and stored at - 80°C for further use (Extracellular Fraction). The 
remaining cell monolayer was overlaid with 2 ml of fresh growth media and stored at -20 °C 
overnight. The following day, the cells were allowed to thaw to RT. The lysed cells were 
collected in an eppendorf and centrifuged at 2,500 rpm for 3 min at 4°C. Following 
centrifugation, the supernatant was collected in a fresh eppendorf and stored at -80°C 
(Intracellular Fraction). The viral titres of both fractions were determined by TCID50 assay as 
described in section 2.3. 
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2.11 Lactate Dehydrogenase Assay (LDH) Cytotoxicity Assay 
CRFK cells were infected with various strains of FCV as stated in section 2.4. At each time 
point post infection, 110 VI of the cell growth media was sampled and added to an 
eppendorf, avoiding sampling the cell monolayer. The media were centrifuged at 2,500 rpm 
for 2.5 min. Following centrifugation the supernatant (approx. 100 VI) was aliquoted into a 
96-well plate and stored at 4 °C until the end of the time course. After the last sample had 
been taken, it was necessary to prepare a high cell toxicity control for LDH release. This was 
done through the addition of 100 µl of 0.1% Triton X100 to the cell culture dish and 
incubation at RT for 10 min. After incubation, the cell growth medium was sampled as 
previously stated. A low LDH control well was also added to the plate consisting of 100 gI 
fresh growth media. The assay was carried out using the BioVision LDH Cytotoxicity Assay 
Kit, 100 µl LDH Assay Kit +2 VI WST substrate mix (see Appendix) was added to each well 
containing samples in the 96-well plate, the plate covered in foil and incubated at RT for 
approximately 30 min. Absorbances of all samples were read using an ELISA Plate reader 
equipped with a 450 nm filter, and a reference absorbance read at 630 nm. The percentage 
cytotoxicity of each sample was calculated using the following equation: 
Cytotoxicity (%) = (Timeooint sample - Low LDH Control) x 100 
(High LDH Control - Low Control) 
2.12 Isolation of Viral RNA from Tissue Culture 
2.12.1 RNA Isolation Procedure 
A T-75 Tissue culture flask was seeded with CRFK cells and allowed to grow until 80% 
confluent. The cells were infected with 400 V1 UKOS A Strain of FCV as per section 2.2. 
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After 5h the growth media was discarded and the cell monolayer was resuspended in 1 ml 
of RNAzoIT" B Reagent (IsoTex Diagnostics) and harvested into an eppendorf tube. To allow 
for separation of the sample of the organic / inorganic phase, 200 µl of chloroform was 
added to the eppendorf and the tube shaken vigorously for 30 sec to facilitate mixing. The 
sample was incubated on ice for 5 min and subsequently centrifuged at 10,000 rpm for 15 
min at 4 °C. The top aqueous phase was carefully removed and transferred to an eppendorf 
tube. The RNA was precipitated by the addition of 500 µI isopropanol and incubated at RT 
for 15 min, after which time it was centrifuged at 10,000 rpm for 5 min at 4 °C. The 
supernatant was removed and the RNA pellet was washed once with 70% ethanol, vortexing 
to ensure that the pellet was dislodged from the tube. The sample was centrifuged at 5,000 
rpm for 5 min and the supernatant removed using a syringe and the pellet air dried for 10 
min. The RNA pellet was then resuspended in 30 µl diethyl pyrocarbonate (DEPC) treated 
H2O. A small aliquot of RNA (5 µl) was analysed by agarose gel electrophoresis as in section 
2.7.2 (with the exception of the use of Tris Borate EDTA buffer (TBE) instead of TAE Buffer) 
to check that the RNA extraction procedure had been successful. 
2.12.2 Reverse Transcription Polymerise Chain Reaction 
In order to amplify FCV sequences from the extracted viral RNA (subsection 2.13.1) it was 
necessary to perform a reverse transcription polymerase chain reaction. To a sixty 
microlitre PCR tube, 5 lal of the RNA sample prepared in section 2.13.1 was added along 
with 1.5 µI random primers (50 ng/ml) (Promega) and 5.5 µl H2O and incubated at 70 °C for 
5 min followed by an incubation at RT for 10 min. After incubation, 4 µl x5 First strand 
buffer, 0.5 µl BSA (5 mg/ml) 1 µl dNTPs (10 mM), 2 µl DTT (x30) and 1 µl MoMLV reverse 
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transcriptase (200 u/µl) (Promega) were added and incubated at RT °C for 5 min. The 
reaction was incubated at 37 °C for 45 min. Once prepared, the samples were stored at -20 
°C ready for use in subsequent PCR reactions. 
2.13 Primer design for UKOS A Sequencing 
A consensus sequence was obtained from known virulent systemic and non virulent 
systemic strains of FCV and compiled using the AlignX Software. From this the consensus 
sequence was used to design primers targeted towards 500 - 600 bp overlapping fragments. 
PCR reactions using high fidelity polymerase enzymes can then be used to piece together 
the sequence of the UKOS A genome. The primers created towards the UKOS A genome are 
listed in Table 2.4. Primers were synthesised by Sigma. 
2.14 Amplification of fragments of UKOS A genome by PCR 
Fragments 1,3 and 15 from table 2.4 were selected to begin sequencing of the UKOS A 
genome. These fragments were selected as they represent the very 5' end of the UKOS 
genome, the start of ORF 1 and a region of the capsid protein respectively. PCR reactions 
were carried out using the KOD Hot Start DNA Polymerase Kit according to the 
manufacturer's instructions. Agarose gel electrophoresis was used to visualise PCR products 
and DNA excised and purified as stated in subsections 2.7.2 and 2.7.3. 
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2.14.1 Processing of UKOS A PCR Fragments 
Purified PCR products were cloned into the pCR®-Blunt II-TOPO® vector and transformed 
into E. coli using the Zero Blunt® TOPO® PCR Cloning Kit, according to the manufacturer's 
protocol. Cultures were spread on agar plates containing kanamycin (100 gg/ml) using the 
method stated in subsection 2.7.7. Five individual colonies were picked as in subsection 
2.7.8 and inoculated into 5 ml LB broth with 100 Vg/ml kanamycin. Mini preparations were 
performed as in subsection 2.7.9, followed by restriction enzyme screening using 1µI EcoRl 
as per subsection 2.7.10. 
Samples that released correctly sized fragments were chosen and minipreps using the 
Qiagen Miniprep Kit were obtained. These samples were then sent off to be sequenced 
(Lark Technologies). 
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Fragment 
Base 
Pair 
Sense 5' 3' 
11 Fwd GTAAAAGAAATTTGAGACAA 
537 Rev TCAAGDGGTTTRGARAAGAAT 
2 515 Fwd AAATTCTTYTCYAAACCHCTT 
1089 Rev CCRTTGTTTGGAATTAACCC 
3 1030 Fwd TGGTAVATGGCWGCWGCWAT 
1582 Rev CCAGTGTABGTGTCRTGGTG 
4 1511 Fwd GCAAAGAARYTKTCKGAYCARGA 
2034 Rev TTCATAGTTTGAGCTARRGA 
5 2006 Fwd AACATTGAYTCYYTAGCTCAAACTATGAA 
2541 Rev AGCACATCATATGCGGCTCTGAT 
6 2462 Fwd TTTGATTTGGCCTGGGCT 
3020 Rev CMACTGAYARRTCYAAYTTTC 
7 2960 Fwd GATGAYGARTAYGAYGARTGG 
3516 Rev TTCCAYTCWGTKGCMACRGGVGANCCCCA 
8 3404 Fwd AATGGTGAATTYTGTTGCTT 
4056 Rev GTTTCWGARGARATRTTCAADGGGACAAA 
9 3926 Fwd ATTGTWGTTGAYTCWCTRAARCCDTATTGTGA 
4539 Rev AAGTAYCGHARGATGTCAAT 
10 4457 Fwd GTGTTTGCRGTTGAYTAYTCMAA 
5022 Rev TCACCYTTKATGTAGTAGAATTG 
11 4094 Fwd CCAATYGACCCTGAATCAGT 
5341 Rev TAAGCACGTTAGCGCAGGTT 
12 5234 Fwd AATGGTGTGGAGGCGCGGTC 
5765 Rev GCCATGTCAGCAGCDGTTGACA 
13 5647 Fwd AAGGCTTGGGATCCAAACCTGCC 
6128 Rev AAATCAGGGATAGTAAAGATGAC 
14 6034 Fwd GTTGACCCTGTTCAAAGCAC 
6570 Rev ATCAGGTATTCCAGGNACAAT 
15 6433 Fwd CACTTTGATTTTAATCAAGAAAC 
7035 Rev TTCTTGTAGAAGATTGGGTGGTT 
16 6965 Fwd AGGGTGGTGCGCATCAGTGT 
7336 Rev TCATAATTTTGTCATTGTACTCCT 
Table 2.4: Table displaying the sequences of the primers used to sequence the UKOS A 
genome used in Chapter 4. 
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3 ASSESSING THE ROLE OF CALPAINS IN FCV-INDUCED APOPTOSIS 
3.1 Introduction 
Cells infected with FCV have been shown to undergo apoptosis (Al-Molawi et al., 
2003; Natoni et al., 2006). It was established that FCV infection induces the 
activation of caspase-2, -3 and -6 and other biochemical and morphological changes 
associated with apoptosis, such as chromatin condensation and PARP cleavage (Al- 
Molawi et al., 2003). Further to this, it was subsequently demonstrated that the 
mitochondrial pathway of apoptosis is activated, through the demonstration of Bax 
translocation to the mitochondria, depolarisation of the mitochondrial membrane 
potential, release of cytochrome c from the mitochondria to the cytosol and the 
activation of caspase-3 and -9 (Natoni et al., 2006). 
It had been proposed that the mitochondrial pathway of apoptosis could be 
activated through an amplification loop of the death receptor pathway. During this 
process, caspase-8 cleaves and activates the Bcl-2 family member Bid, this is 
truncated and translocated to the mitochondria, where it promotes the release of 
cytochrome c and Smac. The cleaved N-terminus of Smac facilitates its binding to 
BIR (baculovirus IAP repeat) domains on the Inhibitor of Apoptosis Proteins 'IAPs' 
and competes for these domains with the executioner caspases, which eliminates 
the inhibitory effects of the IAPs on the executioner caspases.. Once activated, 
caspase-3 has been shown to act in a positive feed back manor, cleaving caspase-6, 
which in turn activates the initiator caspase-8. Caspase-3 is also thought to act back 
on the apoptosome and promote the cleavage of procaspase-9 (Chang et at., 2003; 
Pop et al., 2006; Pop et al., 2007). However, this was shown not to be the case for 
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cells infected with FCV as caspase-8 was not cleaved until 8hp. i., two hours after 
the release of cytochrome c was observed (Natoni et al., 2006). Therefore, caspase-8 
could not be responsible for the release of cytochrome c from the mitochondria 
(Natoni eta/, Unpublished Data). 
It has been reported in the literature that a family of cytoplasmic cysteine proteases, 
activated by increased calcium levels, called the calpains, can affect apoptosis at the 
mitochondrial level. They have been implicated in the truncation of Bax and its 
translocation to the mitochondria from the cytosol, as well as cleavage of Bid, 
leading to formation of truncated Bid (tBid). tBid can then promote the direct 
release of cytochrome c and /or permeablise the MOM allowing for the translocation 
of calpain to the inter-membrane space, which causes AIF truncation and release 
from the mitochondria. Calpains have also been shown mediate BcI-XL inactivation 
of Bax, by binding to the Bcl-XL protein (see Figure 1.12) (Altznauer et al., 2004; 
Raynaud and Marcilhac, 2006). Calpain activation has also been shown to be crucial 
in the replication cycle of Echovirus and Coxsackie B virus infections, through the use 
of calpain inhibition techniques. Calpains have also been shown to play a key role in 
the apoptosis induced by Reovirus infection (Debiasi et al., 1999; Upla et al., 2008; 
Yoon et al., 2008). Together, this data prompted us to investigate the role of 
calpains as a potential trigger for the activation of the mitochondrial pathway of 
apoptosis in FCV-infected cells. 
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3.2 Calpains are activated in FCV-infected cells 
The calpains are a diverse group of calcium-activated non-lysosomal proteases that 
are involved in a variety of calcium-regulated cellular processes such as signal 
transduction, cell proliferation and differentiation, membrane fusion, platelet 
activation and apoptosis (Saez et al., 2006). The calpains have been shown to be 
involved in Bax and Bid translocation from the cytosol to the mitochondrial outer 
membrane, important events in the apoptotic process (Raynaud and Marcilhac, 
2006). 
The activity of the calpains in FCV infected cells was detected by analysis of the 
cleavage of the cytoskeletal protein fodrin. Fodrin is cleaved during apoptosis by 
either the calpains or the caspases, or both (Wang, 2000). The cleavage of the 240 
kDa fodrin by the calpains produces two fragments of 150 and 145 kDa in size, 
whereas the caspase-mediated cleavage produces two fragments of 150 and 120 
kDa in size. Therefore, it can be assumed that the presence of a 145 kDa band 
represents calpain-mediated cleavage of fodrin and a 120 kDa band represents 
caspase-mediated cleavage (in particular, caspase-3 mediated cleavage) (Wang et al., 
1998). 
Figure 3.1 shows Western blot analysis of FCV-infected CRFK cell extracts specifically 
looking at fodrin cleavage. The calpain-mediated 145 kDa band was detected from 2 
h p. i. and increased in intensity up until 8hp. i. At 8h p. i., a 120 kDa caspase- 
mediated cleavage product of fodrin appeared. The timing of these events suggests 
that the calpains were activated during FCV infection and that this occurred before 
the activation of the effector caspases such as caspase-3. 
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To further confirm the observation that calpains are activated, we also analysed 
calpain activation using calpain-cleavage reporter plasmids (gift from M. Courtney; 
University of Kuopio). These constructs contained a calpain cleavage substrate 
(Spectrin based; amino acid sequence: SSSEL*QQEVYG*GTSGSEF) or a Cathepsin B 
cleavage substrate (amino acid sequence: SSSELSGS*RR*GGTSGSEF) as sequences in 
a linker region between the cyan and yellow fluorescent protein sequences. Calpain 
activity results in the liberation of the yellow fluorescent protein, which can be 
detected by Western blot. The plasmids were transfected in to CRFK cells as 
described in section 2.5, cells were infected or mock infected with FCV as in section 
2.4 and cell extracts analysed by Western blotting (Section 2.8). 
As presented in Figure 3.2, calpain activity was detectable at 4hp. i. and 6h p. i. in 
cells transfected with the plasmid that contained the calpain-cleavage site as 
evidenced by the appearance of a 28 kDa cleavage product. As expected, it was 
demonstrated that cathepsin B, which can also be activated during apoptosis to 
cause Bid truncation and translocation to the mitochondria (Lamparska-Przybysz et 
al., 2005), was not active during FCV-infection as evidenced by the lack of the 28 kDa 
cleavage product. These results correlated with those obtained from the Western 
blot analysis of fodrin cleavage, and indicated that calpains are fully activated by 4h 
p. i. in FCV-infected cells, prior to the activation of the caspases. 
113 
Assessing the role of calpains in fcv-induced apoptosis 
Cont 8h 2h 4h 6h 8h (h) p. i. 
qua om 
240 kDa 
(Uncleaved Fodrin) 
4 145 kDa 
4 120 kDa 
Cleavage 
Products 
Figure 3.1: Detection of fodrin cleavage during FCV-F9 Infection. CRFK cells were infected or 
mock infected with FCV-F9 (MOI=100). At the times indicated p. i., the cells were lysed and equal 
amounts of cell extract were analysed by Western blotting. The 145 kDa and 120 kDa cleavage 
fragments are produced by calpains and caspases respectively. 
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Figure 3.2: Detection of calpain activity during FCV-F9 infection. CRFK cells were transfected 
with 1 Vg of plasmids containing either a calpain cleavage site (Wang et al., 1998) or a cathepsin B 
cleavage site (negative control) for 24 h. Transfected cells were then infected or mock-infected with 
FCV-F9 (MOI=100). At the times indicated p. i., cells were lysed and equal amounts of cell extract were 
analysed by Western blotting. The 28 kDa cleavage product is released if active calpain or cathepsin B 
is present that can cleave the substrate between the two fluorescent proteins. The results shown are 
representative of two independent experiments. 
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3.3 Inhibition of calpain activity prevents apoptosis in FCV-infected cells 
It has been shown that both reovirus and echovirus induce the activation of calpains 
in infected cells and that calpain inhibitors, such as ALLN, prevent reovirus-induced 
apoptosis of infected cells or the replication of echovirus RNA (Debiasi et al., 1999; 
Upla et al., 2008). 
The course of apoptosis was analysed during FCV infection by examining 
phosphatidylserine (PS) translocation and exposure on the cell surface in the 
presence of three different inhibitors. The inhibitors used were N-acetyl-leucinyl- 
norleucinal; (ALLN; inhibits calpains but has been reported to also inhibit the cellular 
proteasome), carbobenzoxy-leucyl-leucyl-leucinal; (MG-132; inhibits cellular 
proteasome but has been reported to also inhibit calpain activity) and Epoxomicin 
(highly specific inhibitor of the cellular proteasome). The use of these three different 
inhibitors is needed as these chemicals exhibit reported cross-reactivity with other 
cellular pathways, other than the ones they were designed to inhibit (Lee and 
Goldberg, 1998; Meng et al., 1999; Kwak et al., 2008; Giguere and Schnellmann, 
2008). 
The exposure of PS on the surface of a cell is reported to be an early feature 
displayed by a cell undergoing apoptosis (Fadok et al., 1992). In a normal system, 
the PS exposure would trigger removal of the cells by phagocytes to prevent an 
inflammatory response, but in vitro PS exposure is very useful. PS exposure can be 
detected using an anticoagulant called Annexin V (AV) which interacts with PS in the 
presence of calcium. Since membrane permeabilisation is seen during necrosis, the 
AV can interact with PS on the inner layer of the plasma membrane of necrotic cells. 
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In the absence of phagocytosis the effect described occurs at the late stage of 
apoptosis due to the necrotic-like disintegration of the cell. Propidium iodide (PI) 
was used in conjunction with the AV, PI being a nucleic acid stain that is unable to 
penetrate the membrane of viable cells, thus giving us the ability to distinguish 
between healthy viable cells, early stage apoptotic and late stage apoptotic / 
necrotic populations of cells (Table 3.1) 
Figure 3.3 shows that the AV-FITC / PI analysis of FCV-infected CRFK cells indicated 
that apoptosis was occurring in FCV-infected cells approximately 8hp. i., as seen 
previously by (Al-Molawi et al., 2003) and (Natoni et al., 2006). 
Stage Annexin V Propidium Quadrant on 
iodide histogram 
Viable cells - 
Early Stage Apoptosis + 
Late Stage Apoptosis/Necrosis + 
Table 3.1: Flow cytometry indicators of apoptotic cell death 
+ 
A 
B 
C 
When treated with the proteasome inhibitor MG-132 there was a decrease in the 
number of cells undergoing apoptosis (13 %) compared to the untreated FCV-F9 
infection (34.4 %). Cells treated with the proteasome inhibitor epoxomicin showed 
only a slightly reduced number of cells undergoing apoptosis (30.8%) compared to 
that of the untreated control infection. Finally, there was a reduction in the number 
of cells undergoing apoptosis (20.6 %) when cells were treated with ALLN. 
This data suggests that the calpains are involved in apoptosis during FCV-infection, as 
the use of a calpain inhibitor inhibited apoptosis. 
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Figure 3.3: Calpain inhibitors prevent apoptosis in FCV-infected cells. CRFK cells were infected 
with FCV-F9 (M0I=100) in the presence/absence of MG-132 (10µM), expoxomicin (200 nM) and ALLN 
(50µM) for the times indicated and analysed for PS exposure using the AV/PI assay. A minimum of 
10,000 events were analysed by flow cytometry. The results are presented as plots using WinMDI 
software and are representative of five independent experiments. 
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3.3.1 Calpain inhibitors prevent caspase-3 activation during FCV-induced apoptosis. 
To further analyse the role of calpains in apoptosis seen during FCV-infection, we 
analysed the level of caspase-3 activation in infected cells in the presence of MG-132 
(10 µM), expoxomicin (200 nM) and ALLN (50 µM) or in untreated cells. The 
activation of caspase-3 was measured by flow cytometry using a phycoerythrin (PE) 
conjugated anti-active caspase-3 antibody targeted towards the p17/p12 cleavage 
product of pro-caspase-3. 
Figure 3.4 shows the resulting histograms from the active caspase-3 flow cytometry. 
In the untreated FCV-F9 infected cells, caspase-3 activation was detected, evidenced 
by the secondary peak in the right hand section of the histogram at 8hp. i. 
Treatment of the cells with MG-132 or ALLN inhibited caspase-3 activation. At 8h 
p. i. however, epoxomicin had no effect. In line with the AV/PI assay, this suggests 
that the calpains are involved in apoptosis during FCV infection, as the use of the 
calpain inhibitor ALLN inhibited caspase-3 activation. 
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Figure 3.4: Calpain inhibitors block caspase-3 activation in FCV-infected cells. CRFK cells were 
infected with FCV-F9 (100 pfu/cell) in the presence/absence of MG-132 (101W), expoxomicin (200 
nM) and ALLN (50µM) for the times indicated and analysed for caspase-3 activation using a PE- 
conjugated monoclonal antibody to the p17 / p12 active form of caspase-3. A minimum of 10,000 
events were analysed by flow cytometry. The results are presented as histogram plots using WinMDI 
software. 
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3.4 The Calpain inhibitor calpeptin prevents PS translocation in FCV-infected cells 
To further analyse the role of calpains in FCV-induced apoptosis, another calpain 
inhibitor was used to treat cells during infection. This was because ALLN is known to 
inhibit the cellular proteasome as well as calpain activity. This inhibitor, Z-Leu-Nle- 
CHO (Calpeptin), is a potent inhibitor of calpain I, calpain II and papain. Analysis of 
the role of calpains in FCV-induced apoptosis was carried out by examining PS 
translocation in cells infected in the presence of Calpeptin (Du, 2000 100 /id). 
As shown in Figure 3.5 A, at 8hp. i., calpeptin inhibited PS translocation in FCV-F9 
infected cells, compared to the untreated mock infected control. Figure 3.5 B shows 
a graph representing the proportion of cells in the late stage of apoptosis (AV and PI 
+ve; Table 3.1) for both untreated and calpeptin treated FCV-F9 infected cells, 
harvested 8hp. i. In each individual experiment, the number of apoptotic cells in the 
untreated samples was normalised to 100% and the number of AV/PI positive 
calpeptin treated cells expressed as a percentage of this. 
121 
Assessing the role of calpains in fcv-induced apoptosis 
A 
FCV-F9 Infection 
FCV-F9 Infection 
+100uM 
Calpeptin 
B 
8h Mock Inf. 
F9 infection 8h pi+/- 100uM Calpeptin 
F9 8h pi AV/PI -ve 
8h Post Infection 
F9 8h pi + 100uM Calpeptin 
Figure 3.5: Calpeptin prevents apoptosis in FCV-infected cells. CRFK cells were infected with 
FCV-F9 (100 pfu/cell) in the presence/absence of Calpeptin (negative control) for the times indicated 
and analysed for PS exposure using the AV/PI assay. A minimum of 10,000 events were analysed by 
flow cytometry. (A) The results are presented as representative plots using WinMDI software. (B) 
Results are presented as mean ± standard error of percentage of cells AV/PI +ve for untreated and 
calpain treated cells 8hp. i (three independent experiments). * indicates p<0.05, T-Test used for 
statistical analysis. 
122 
Assessing the role of calpains in fcv-induced apoptosis 
3.5 The specific calpain inhibitor calpastatin inhibits apoptosis in FCV-infected 
cells 
Calpastatin is a ubiquitously expressed specific endogenous inhibitor for the 
regulation of the proteolytic activity of calpains in mammalian cells. Therefore, the 
creation of a calpastatin domain I (one of four repeated calpain inhibitory domains of 
the calpastatin protein) expressing plasmid was necessary to further examine the 
role of the calpains in FCV-induced apoptosis. Calpastatin is the endogenous 
inhibitor of the calpains and has no reported cross reactivity with any other cellular 
pathways; therefore it provides a highly specific reduction in their activity when 
expressed. As shown in Figure 3.6 (A), at 8h p. i. the cells that had been transfected 
with the plasmid containing the inhibitory portion of calpastatin/EMCV IRES/GRP 
(pCalpl) showed a reduction in the number of cells that had undergone apoptosis 
(17.9%), in comparison to those cells transfected with the empty GFP expressing 
vector backbone (pEGFP-N1) (31.7%). Figure 3.6 (B) shows the proportion of cells 
expressing GFP for each of the corresponding samples in Figure 3.6 (A). Although the 
level of expression is low, as seen in the empty GFP expressing vector backbone 
transfected sample (8.3 % expression of GFP), it is in line with levels of GFP 
expression seen during transfection experiments into BHK21, HEK293T, or Vero cells 
performed in other studies (Chang et al., 2008). 
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Figure 3.6: Specific calpain inhibitor calpastatin inhibits apoptosis in FCV-infected cells. CRFK 
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3.6 Effect of the calpain inhibitors Calpeptin and ALLN on FCV replication and 
virus release 
Having demonstrated that calpains are required for apoptosis induction during FCV 
infection, we wanted to assess if the calpains are necessary for efficient viral 
replication or release from cells. Roles for the calpains in apoptosis to mediate viral 
release or RNA replication have been reported for other viral infections such as 
Reovirus and Echovirus; in both cases the use of calpain inhibitors ablated either 
virus induced apoptosis or caused significant reduction in the viral titre (Debiasi et 
al., 1999; Upla et al., 2008). We therefore infected cells in the presence or absence 
of calpeptin and measured resulting viral titres. As shown in Figure 3.7, at 8hp. i., 
calpeptin treatment did not alter the intracellular viral titre, reflecting viral 
replication. However, there was a significant inhibition in extracellular virus titres in 
calpeptin-treated cells, suggesting that there was an inhibition of release from the 
cell into the surrounding growth media. Figure 3.8 shows that at 10 h p. i., no effect 
on viral replication was observed in cells treated with ALLN, as there was no 
significant difference in the viral titres of the cell associated virus fractions. 
However, ALLN did reduce the amount of virus released into the extracellular 
fraction. This was demonstrated by a significant reduction in viral titre at 10 h p. i. 
between the untreated and ALLN-treated FCV infected cells. This data suggests that 
the calpains are not implicated in the replication of FCV as no significant changes 
were seen in the viral titres between treated and untreated cells. However, the data 
suggests that apoptosis is needed for release of the virus into the surrounding 
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environment, as inhibition of apoptosis through calpain inhibition significantly 
reduced the virus titre detected in the growth media. 
126 
Assessing the role of calpains in fcv-induced apoptosis 
1.00E+10 
1.00E+08 
1.00E+06 
1.00E+04 
1.00E+02 
1.00E+00 
Intracellular Virus Extracellular Virus 
Virus Fraction 
 8h  8h+100uM 
Calpeptin 
Figure 3.7: The effect of calpeptin on FCV replication and virus release in CRFK cells. CRFK 
cells were infected with FCV-F9 virus (MOI=100) in the presence/absence of calpeptin (100 µM). At 8 
h p. i. the titres of the intracellular (cell associated) virus and the extracellular virus fractions were 
tested by TCID50 assay. Results are presented as mean ± standard error of three independent 
experiments. *** indicate p <0.01 compared to the untreated extracellular virus control. T-Test was 
used for statistical analysis. 
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Figure 3.8: The effects of ALLN on FCV replication and virus release in CRFK cells. CRFK cells 
were infected with FCV-F9 virus (MO1=100) in the presence/absence of ALLN (Jackson et al., 2005). At 
10 h p. i. the titres of the intracellular (cell associated) virus and the extracellular virus fractions were 
tested by TCID50 assay. Results are presented as mean ± standard error of three independent 
experiments. *** indicate p<0.05 compared to the untreated extracellular virus control. One way 
ANOVA was used for statistical analysis. 
128 
Assessing the role of calpains in fcv-induced apoptosis 
3.7 Discussion 
Cells infected with FCV have been shown to undergo apoptosis. More specifically it 
has been demonstrated that the apoptosis that occurs during FCV-infection is 
mediated through the mitochondrial pathway (Al-Molawi et al., 2003; Natoni et al., 
2006). Work is still ongoing into trying to establish the sequence of molecular events 
that occur upstream of the activation of this pathway. The aims of this current study 
were to understand if calpains are the potential triggers of the mitochondrial 
pathway of apoptosis, leading to cytochrome c release, the activation of caspase-9 
through the formation of the apoptosome and finally, the activation of the 
executioner caspase, caspase-3 (Natoni et al., 2006). Previous work has shown that 
neither the death-receptor pathway nor oxidative stress played a role in activating 
the mitochondrial pathway during FCV-induced apoptosis (Natoni et al, unpublished 
data). 
Many studies have now demonstrated that the calpains can activate the 
mitochondrial pathway of apoptosis, leading to cytochrome c or truncated AIF 
release (Raynaud and Marcilhac, 2006). The calpains have also been implicated as 
crucial factors in the apoptosis seen during reovirus-infection of Murine L929 
fibroblasts (L cells) (Debiasi et al., 1999) and the replication of echovirus RNA (Upla 
et al., 2008). Through the use of calpain inhibitor or siRNA studies, both groups 
demonstrated that the abrogation of calpain activity lead to an inhibition of 
apoptosis or viral replication. In this study, activation of calpains was demonstrated 
in FCV-infected cells by two different approaches; the detection of the 145 kDa 
calpain-mediated cleavage product of the cytoskeletal protein fodrin (Figure 3.1) and 
129 
Assessing the role of calpains in fcv-induced apoptosis 
the detection of a 28 kDa YFP protein from a 58 kDa protein containing CFP and YFP 
with an interlinking region that possessed a calpain cleavage site (Figure 3.2). In 
both assays, the substrates are only cleaved through the specific proteolytic activity 
of the calpains (Wang, 2000). Both assays showed the activation of calpains early in 
FCV infection (2 -4hp. i. ) before the activation of caspase-3. As evidenced by Figure 
3.1 there is a 120 kDa cleavage product of fodrin 8hp. i., which is reported to be 
generated by caspase-3 (Wang et al., 1998). 
Flow cytometric analysis of PS translocation and caspase-3 activation was performed 
in the presence and absence of several pharmacological inhibitors of cellular 
pathways in order to assess the role they played in FCV-induced apoptosis. The four 
pharmacological inhibitors used in this study were ALLN, a calpain inhibitor that also 
exhibits some inhibition of the cellular proteasome (Kwak et al., 2008); MG-132 a 
peptide aldehyde that inhibits the chymotrypsin like activity of the proteasome, but 
is also reported to inhibit calpain activity (Lee and Goldberg, 1998); Calpeptin a 
potent inhibitor of calpain I and II, that also inhibits cathepsin L and K (Giguere and 
Schnellmann, 2008); finally, Epoxomicin, a specific inhibitor of the proteasome that 
does not inhibit non-proteasomal proteases such as the calpains (Meng et at., 1999). 
In untreated FCV-F9 infected cells, PS translocation and caspase-3 activation was 
seen at 8hp. i., as seen in previous studies (Natoni et al., 2006). In infected cells 
treated with either MG-132 or ALLN there was a reduction in the number of cells 
that were undergoing apoptosis at 8hp. i and 10 h p. i., compared to untreated 
infected cells (Figure 3.3). A similar observation was seen when looking at the 
activation of caspase-3, both ALLN and MG-132 reduced the proportion of cells 
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containing active caspase-3 (Figure 3.4). It was also shown that calpeptin could 
inhibit PS translocation, and hence delay apoptosis (Figure 3.5). All of the 
pharmacological inhibitors mentioned above have been reported to inhibit calpains 
either primarily (ALLN & Calpeptin) or through unwanted secondary cross-talk (MG- 
132). However, cells treated with Epoxomicin, a specific proteasome inhibitor, did 
not display this inhibition of PS translocation or caspase-3 activation. In this 
particular case the number of cells AV/PI +ve and containing active caspase-3 was 
greater than that of the untreated FCV-F9 infected cells, casting doubts on the 
involvement of the proteasome in FCV-induced apoptosis. Therefore, to assess 
whether specific inhibition of the calpains would prevent apoptosis seen during FCV 
infection, we designed a plasmid that expresses one of the inhibitory domains of the 
endogenous and highly specific calpain inhibitor, calapastatin (Figure 2.1). Cells that 
were transfected with the plasmid containing domain I of calpastatin/EMCV 
IRES/GFP resulted in an inhibition of apoptosis (Figure 3.6). However, we were not 
successful in totally inhibiting apoptosis with this system and there are several 
reasons that could explain this finding. Firstly, the transfection efficiencies achieved 
in these experiments were low (approx 20 %). This means that the remaining 80% of 
infected cells analysed would still display detectable calpain activity, potentially 
diluting out the inhibitory effect seen. Perhaps, the isolation of these cells through 
the use of a FACS cell sorter, and sorting of the GFP-expressing cells and hence 
calpastatin-expressing cells would show a greater effect. Another possibility is that 
the level of expression of domain I cannot easily be controlled in this system. In the 
transfected cells, the level of calpastatin domain I produced from our construct may 
not be sufficient to have had a total inhibitory effect on the calpain activity; wild type 
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calpastatin contains four identical calpain binding domains. Our construct only 
contains one, thereby giving it a four-fold reduction in its capacity to bind to and 
inhibit calpain activity compared to the full length protein. This does however seem 
unlikely, as the production of calpastatin domain I under the control of the CMV 
promoter on the pEGFP-N1 vector should be more than sufficient to achieve over- 
expression of domain I of calpastatin (Ray et al., 2003; Wendt et al., 2004; Suzuki et 
al., 2004). Of note also is the low level of GFP expression seen during transfection in 
our experiments. It is known that IRES activity is dependent upon the cell type they 
are used in, and influenced by cellular and viral proteins present in a particular 
system. For example, in poliovirus or FMDV infection, the viral proteins PV 2A and 
FMDV Lb proteases induce cleavage of eIF4G as well as other cellular proteins that 
can influence IRES function (Borman et al., 1997; Roberts et al., 1998). Perhaps 
therefore, the IRES is not functioning as well as anticipated in this feline cell line, as 
an inhibitory effect on apoptosis was observed even with minimal GFP expression 
(Figure 3.6B). Another approach, as used in Upla et al (2008), was to use siRNA to 
reduce the levels of calpain to undetectable levels to further clarify the role of the 
calpains in this system. Also very recently, calpastatin domain I peptides have 
become commercially available; in conjunction with siRNA techniques these could 
also provide an excellent way of assessing the contribution of calpains to apoptosis 
seen during FCV-infection. The addition of this data will complement and further 
strengthen the solid base of evidence we have already obtained demonstrating the 
crucial role of calpains in apoptosis seen during FCV infection. 
The effects of apoptotic inhibitors on viral replication and release has now been 
investigated for a number of different viruses such as Astrovirus, where it was shown 
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that the pan-caspase inhibitor z-VAD-fmk prevented apoptosis induced in infected 
CaCo-2 cells, subsequent processing of the capsid protein and ultimately the release 
of the virus from the cell (Mendez et al., 2004). Or Coxsackievirus B3, where it was 
shown that the addition of z-VAD-fmk decreased the virus replication, evidenced by 
a decrease in viral RNA synthesis and viral protein production, mediated by the 
interaction of z-VAD-fmk with the viral proteins 2A and 3C (Martin et al., 2007). 
However, the results have been highly variable depending on the virus, cell line or 
nature of the study. Here, we demonstrate that neither ALLN nor Calpeptin had an 
effect on viral replication, as the viral titre of cell-associated virus did not change 
when compared to untreated cell-associated virus titres at 8h or 10 h p. i (Figures 3.7 
& 3.8). These two chemicals did, however, have an effect on the amount of virus 
found in the extracellular fractions. These chemicals have been demonstrated to 
delay the onset of FCV-induced apoptosis through the mitochondrial pathway by the 
inhibition of calpains. It is therefore hypothesised that this delay in apoptosis delays 
the destruction of the host cell needed for the release of the viral progeny. 
Taken together, the fodrin cleavage and spectrin cleavage data demonstrates that 
the calpains are activated during the apoptosis seen in FCV-infected cells. Through 
the use of several pharmacological agents and expression of the endogenous calpain 
inhibitor calpastatin during infection, we have demonstrated the inhibition of PS 
translocation and caspase-3 activation. We have also demonstrated that neither the 
apoptotic inhibitors ALLN nor Calpeptin, affect viral replication. They did however 
reduce the number of virus particles released from the cells compared to untreated 
cells. Due to their ability to delay the onset of apoptosis through calpain inhibition, 
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we suggest that apoptosis is required for the efficient release of mature virus 
particles. 
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4 FELINE CALICIVIRUS ISOLATED FROM CATS WITH VIRULENT SYSTEMIC 
DISEASE APPEARS TO DELAY APOPTOSIS IN VITRO. 
4.1 Introduction 
Feline calicivirus is one of the most common viral pathogens of cats and is the 
second largest cause of feline respiratory tract infection behind feline herpesvirus 
(Edwards et al., 2008). The clinical symptoms of FCV-infection are wide ranging and 
can occur in acute or chronic manifestations. Infection with FCV can manifest in 
symptoms ranging from a sub-clinical presentation to signs of oral ulceration and a 
mild respiratory disease that is rarely fatal (Studdert et al., 1970; Pedersen et al., 
2000). 
Within the last 10 years, there have been increasing reports of more severe forms of 
FCV disease, with mortality rates approaching 50% in some cases. These cases were 
first reported in the United States in 1997 and the United Kingdom in 2006 and are 
generally associated with situations where crowded feline populations occur, such as 
catteries (Turnquist and Ostlund, 1997; Coyne et al., 2006). These outbreaks have 
been associated with a new range of clinical symptoms, which have been termed 
FCV-associated virulent systemic disease (Ohe et al., 2008) or haemorrhagic-like 
fevers. In addition to the previously described symptoms, cats suffer from pyrexia, 
cutaneous oedema, ulcerative dermatitis, anorexia and jaundice, leading to death. 
Adult cats seem to be more affected by this form of FCV-infection as opposed to 
kittens and the standard vaccination regime does not appear to be protective (Coyne 
et al., 2006). 
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Work has begun to try to understand the differences in the pathologies of the VSD 
strain infections. Due to the unspecific manner of FCV related symptoms of disease 
and the reported FCV asymptomatic carrier state, generally occurring after clinical 
infection, when clinically recovered animals remain persistently infected and shed 
virus continuously, a variety of symptoms have been incorrectly attributed to FCV 
infection. However, in the case of the VSD strains, clinical symptoms and 
manifestations have been reproduced experimentally following inoculation of 
healthy cats with an American VSD-FCV strain (Pedersen et al., 2000). 
Now it is clear that these particular strains are responsible for the more severe 
disease phenotype, investigation has turned to understanding the mechanisms by 
which the viruses can achieve this. Work by Ossiboff et al (2007) was the first to 
examine the in vitro phenotypes of the VSD-FCV isolates compared to those causing 
the less severe disease. The in vitro properties, as well as sequence analysis of the 
capsid and pro-pol regions of the genome of seven VSD-isolates and selected non- 
VSD-isolates, were examined. This group reported that all of the strains had similar 
growth kinetics under single cycle conditions, but that the VSD-isolates replicated in 
tissue culture monolayers more efficiently over multiple growth cycle conditions. 
Sequence analysis revealed that there were no conserved changes that correlated to 
a virulent phenotype between the VSD and non-VSD isolates. It also revealed that 
the VSD-isolates were no more similar to each other than to the non-VSD isolates, 
implying that the virulent phenotypes had arisen independently of each other 
(Ossiboff et al., 2007). More interestingly, however, was the finding that under 
single cycle growth conditions, the cells infected with VSD isolates maintained 
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cellular ATP levels for longer than the non-VSD isolates (Ossiboff et al., 2007). This 
lead the authors to hypothesise that VSD-isolates may delay the onset of apoptosis, 
rather than induce it as reported during FCV-F9 infection (Sosnovtsev et al., 2003; AI- 
Molawi et al., 2003; Natoni et al., 2006). 
In order to determine if apoptosis is occurring in VSD isolate-infected cells and the 
timing of these events we studied the molecular mechanisms of apoptosis in VSD- 
FCV infection, by analysing cellular cytotoxicity, various apoptotic events, and 
sequence analysis of one VSD-isolate (UKOS A) isolated from the first reported case 
of VSD-FCV infection in the UK (Coyne et al., 2006), two putative VSD-isolates 
(AB087/AB088; gift from Alan Radford) and the vaccine strain of FCV (FCV-F9). 
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4.2 Apoptosis is the mechanism of cell death occurring during UKOS A infection 
Firstly, we wanted to establish whether UKOS A (a VSD causing clinical isolate of FCV) 
infection induced apoptosis in CRFK cells, and if so, would we see any delay in 
apoptosis as hypothesised by Ossiboff et al (2007). Therefore, in order to determine 
if apoptosis was occurring during UKOS A infection a time course of infection was 
performed and PS exposure on the cell surface was measured using an AV/PI 
Apoptosis detection kit, as described in Section 2.6.2. 
Both F9 and UKOS A-infected cells undergo apoptosis, with approx 15% of cells AV/PI 
+ve in the case of UKOS A infection at 10 h p. i. (Figure 4.1). However, less of the 
cells infected with UKOS A have undergone apoptosis at 6,10 and 12 h p. i. (-1%, 
15%, 19% respectively for UKOS A and 2%, 18% and 27% for F9) compared to cells 
infected with F9. The percentage of dead cells seen during UKOS A infection does 
however eventually reach the same level as those infected with FCV-F9, with a larger 
proportion of cells having undergone apoptosis at 14h p. i. 
it should be noted that an MOI of 100 was used during this experiment, in line with 
work carried out in the previous chapter. However, as Ossiboff et al (2007) 
conducted their work using a low MOI (approx. 5), to further examine this potential 
delay in apoptosis and due to reports in the literature of differing in vitro phenotypes 
of the VSD isolates at lower MOTs (Ossiboff et al., 2007), an MOI of 1 was used for 
further experimentation in this chapter. 
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4.3 UKOS A-infected cells show a delay in cell death when compared to FCV-F9 
infected cells 
As cells infected with UKOS A seemed to display a delay in apoptotic cell death, we 
next wanted to examine whether the delay in apoptosis induction correlated with 
cell survival. Cellular cytotoxicity (cell death) was monitored in FCV-F9 and UKOS A- 
infected CRFK cells with samples of the tissue culture growth media sampled at 
various time points post infection. To assay cell death we measured the levels of 
lactate dehydrogenase (LDH) present in the growth media. LDH is an abundant 
cytoplasmic enzyme that is rapidly released into the cell culture supernatant upon 
damage to the plasma membrane, in this case induced by viral infection. Figure 4.2 
shows that there is a significant difference in the level of cell death between F9 and 
UKOS A-infected cells at 14 h and 18 h p. i., with fewer UKOS A-infected cells 
displaying cytotoxicity. By 24 h p. i., the levels of cell death in both F9 and UKOS A- 
infected cells are comparable, with both showing approximately 95% of the cells as 
dead and dying. This indicates that the UKOS A strain is somehow delaying the onset 
of cell death. 
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Figure 4.2: UKOS A delays cell death detected during infection of CRFK cells. CRFK cells were 
infected with either FCV-F9 or UKOS A (M01=1) for the times indicated and the growth media assayed 
for cellular cytotoxicity using the LDH Cytotoxicity Assay Kit. Data is presented as percentage of 
complete cytotoxicity, generated by addition of 0.1% Triton-X to the cells. Data is presented as mean 
± standard error of 5 independent experiments. t-Test was used for statistical analysis, ** indicates p 
< 0.01 
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4.4 UKOS A-infected cells show a delay in PS translocation 
To determine if the cell death seen during UKOS A infection was apoptotic in nature, 
as opposed to necrotic or another cell death mechanism at lower MOTs, we analysed 
the course of cell death during F9 and UKOS A infection by measuring PS exposure 
on the cell surface and PI uptake by the cell. 
AV-FITC and PI analysis of CRFK cells infected with the F9 strain of FCV (Figure 4.3) 
showed that apoptosis occurred at 14h and 18h p. i., at an MOI=1. However, in the 
UKOS A-infected cells apoptosis was much less evident at the same time points (-8% 
AV/PI +ve for UKOS A infection vs -33% AV/PI +ve for F9 infection at 18h p. i. ). The 
data from flow cytometric analysis correlates well with the cell death data obtained 
in Section 4.3. A positive PI result during flow cytometric analysis is also an 
indication of cell death; at 18 h p. i. ^'50% of the cells are PI positive in the flow 
cytometry analysis of F9-infected cells.. The cytotoxicity data obtained for UKOS A 
also correlated well with the PI staining for this time point. 
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4.5 Caspase -31-7 activation is delayed in UKOS A-infected cells 
Now that we have established that apoptosis was occurring in UKOS A infected cells 
but at a delayed rate compared to that of FCV-F9 infection, it was necessary to 
examine where and when this delay was occuring. Therefore, we examined various 
events of the apoptotic process to assess where the UKOS-A mediated delay of 
apoptosis is taking place. Firstly, we measured caspase -3/-7 activity in FCV-infected 
cells using the cell permeable fluorogenic caspase substrate (benzyloxcarbinonil-Asp- 
Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin; z-DEVD-AFC). As shown in Figure 
4.4, in FCV-F9 infection, caspase -3/-7 activity increases steadily from 10 h p. i. to a 
peak level at 14 h p. i. In contrast, the caspase -3 /-7 activities measured in UKOS A- 
infected cells were just detectable at 10h p. i. and remained low until 18h p. i., at 
which time activity peaked. 
The activation of caspase-3 in infected cells was also monitored by Western blotting. 
As shown in Figure 4.5, the 17 kDa active form of caspase-3 was detected from 14 h 
p. i. in F9-infected cells. However, this band did not appear until 18h p. i. in the case 
of UKOS A-infected cells, suggesting that caspase-3/-7 activation was delayed. These 
results again show a delay in the onset of apoptosis in the UKOS A-infected cells 
compared to that of the F9-infected cells. 
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Caspase -3/-7 activity assay (F9 vs UKOS A) 
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Figure 4.4: Caspase -3/-7 activity in FCV infected cells. CRFK cells were infected with FCV-F9 or 
UKOS A (MOI=1). At the times indicated p. i., caspase -3/-7 activity was analysed by monitoring z- 
DEVD-AFC fluorescence emission. Data is normalised for the control level of fluorescence in each case 
and is presented as the mean ± standard error of three independent experiments. 
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Figure 4.5: Detection of active caspase-3 in FCV-infected cells. CRFK cells were infected with 
FCV-F9 or UKOS A (MOI=1). At the times indicated p. i., mock infected and infected cells were lysed 
and equal amounts of cell extract were analysed by Western blotting. The active form of caspase-3 is 
represented by the appearance of a 17 kDa band on the Western blot. 
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4.6 Caspase-9 activation is delayed in UKOS A-infected cells 
As reported in the previous chapter and in the literature, FCV-F9 infection leads to 
activation of the mitochondrial pathway of apoptosis (Natoni et al., 2006). 
Therefore, the next step to be examined upstream in the pathway was the formation 
of the apoptosome and activation of caspase-9. Caspase-9 activity was measured 
using a proluminogenic substrate for luciferase containing the LEHD sequence which 
is selectively cleaved by caspase-9. Cleavage by caspase-9 results in the release of 
aminoluciferin and a subsequent reaction occurs that generates a luminescent signal 
proportionate to the amount of caspase-9 activity in the sample (Caspase-Glo 9 
Assay kit; Promega). As shown in Figure 4.6, there was a slight increase in caspase-9 
activity at 10h and 14 h p. i. and a large increase in activity at 18h p. i. in the F9- 
infected cells when compared to the mock infected control. This increase was not 
detected in the UKOS A-infected cells and there were only small increases in 
caspase-9 activity detected compared to the mock infected control (represented as 
Oh p. i., Figure 4.6). 
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Figure 4.6: Caspase-9 activity during FCV infection. CRFK cells were infected with FCV-F9 and 
UKOS A (MOI=1) and at the indicated times p. i. were analysed for caspase-9 activity using 
aminoluciferin (Caspase-Glo 9 Kit; Promega). Results are presented as the mean ± standard error of 
three independent experiments. ** indicates ap<0.01 comparing activation in F9 or UKOS A- 
infected cells at each time point. T-test was used for statistical analysis. 
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4.7 Cytochrome c release from mitochondria is delayed in UKOS A-infected cells 
The next step upstream of the activation of caspase-9 in the mitochondrial pathway 
is the release of cytochrome c from the mitochondria. We therefore analysed the 
location of cytochrome c during FCV-F9 and UKOS A infections. As shown in Figure 
4.7, in the F9-infected cells at 12 h p. i. the appearance of cytochrome c is detectable 
in the cytosolic fraction. However, in the case of UKOS A-infected cells, even at 14 h 
p. i. there was no translocation of cytochrome c from the mitochondria to the 
cytosol. This result also correlates with the lack of caspase-9 activation, as 
cytochrome c is a key component of the apoptosome which is necessary for the 
activation of procaspase-9. Detection of cytochrome c oxidase subunit IV 'COX IV' is 
used as a control for the mitochondrial fraction as this mitochondrial inner 
membrane protein does not translocate during apoptosis. It can therefore be used 
as in indicator for the quality and specificity of the permeabilisation procedure used. 
As no bands were detected in the cytosolic fraction, this indicates that the process of 
permeabilisation did not affect the mitochondria. The detection of actin was used as 
a loading control. 
This data suggests that the delay in apoptosis seen in UKOS A-infected cells is 
mediated upstream of cytochrome c release from the mitochondria. It also suggests 
that an alternative mechanism for the activation of the executioner caspases is 
occurring, other than through the mitochondrial pathway of apoptosis, as caspase-3 
activation was still detected in UKOS A infected cells, at 18 h p. i. (Figure 4.4 & 4.5). 
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Figure 4.7: Cytochrome c release is delayed in UKOS A infection. CRFK cells were infected with 
FCV-F9 or UKOS A (MOI=1). At the times indicated post infection, cells were harvested and their 
plasma membranes permeabilised with digitonin. Following separation of the mitochondrial (M) and 
cytosolic (C) fractions, samples were analysed by Western blotting for cytochrome c translocation. 
Controls were obtained by re-probing the blots for COX IV (mitochondrial fraction) and actin (loading 
control). 
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4.8 The delay in apoptosis in UKOS A-infected cells is not due to a delay in viral 
replication 
Now that we have demonstrated that the delay in apoptosis was occurring upstream 
of cytochrome c release during UKOS A infection, we wanted to establish the 
mechanism behind this delay. We therefore looked at the virus growth kinetics 
using a single cycle growth curve, to determine if the delay in apoptosis was due in 
part to lower replication efficiency of the UKOS A strain. Therefore, infection time 
courses were performed for both FCV-F9 and UKOS A and the total viral titres were 
assessed at various time points by TCID50 assay. Figure 4.8 shows the viral titres 
obtained during F9 and UKOS A infection in CRFK cells over a 24 hour period. In both 
cases the viruses replicated quickly and efficiently and reached viral titres of 
approximately 2x 109 TCID50 units/ml at 24 h p. i. From the data obtained it is clear 
that between 10 - 24 h p. i. the UKOS A virus has replicated more efficiently and to a 
higher titre than that of FCV-F9. However, there was no significant difference in the 
final titre between the two strains at 24 h p. i. This finding suggests that the VSD- 
strains may not be using the delay in apoptosis to establish a higher viral titre per cell 
in vitro, as the final titres between the two strains were not significantly different. 
However, how different these titres are in vivo and in the context of disease 
pathology needs to be examined. 
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Figure 4.8: FCV-F9 and UKOS A growth curve in infected CRFK cells. CRFK cells were infected 
with FCV-F9 or UKOS A (MOI=1). At various time points the total virus (both intra- and extracellular 
virus) was measured using the TCID5Ö assay. Results are presented as mean ± standard error of three 
independent experiments. 
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4.9 Other putative VSD-isolates also delay apoptosis 
In order to examine whether the phenomenon of delaying apoptosis was specific to 
the UKOS A VSD-strain or whether it was a general feature of all VSD strains of FCV, 
we obtained two further putative virulent systemic disease causing strains (AB087 
and AB088; gift from Dr Alan Radford; University of Liverpool) and examined PS 
translocation during infection. CRFK cells were infected at the same multiplicity of 
infection and for the same length of time, and the amount of PS translocation was 
examined using the AV/PI assay as previously stated. Figure 4.9(a) shows histograms 
of the number of cells showing PS translocation and those that are PI positive, 
indicating that they are in the late stages of apoptosis. In the case of FCV-F9,39% of 
the cells were AV/PI +ve at 18h p. i. whereas in the case of UKOS A, AB087 and AB088 
this is reduced to 8.9 - 18.6% (Figure 4.9(b)). 
Overall, from the examination of other putative VSD-strains, it appears that the delay 
in the onset of apoptosis seen upon infection is not specific to the UKOS A strain. 
Rather, it is a general feature associated with infection with these viral strains in 
vitro. 
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Figure 4.9: PS translocation in CFRK cells infected with various VSD FCV strains. (A) CRFK cells 
were infected with FCV-F9, UKOS A, AB087 or AB088 (MOI=1) for the time indicated and analysed for 
PS exposure using the AV/PI assay. (B) Graph showing percentage of cells AV/PI +ve at 18h p. i. for 
various VSD-FCV strains, presented as percent AV/PI +ve compared to FCV-F9 infecion. Results show 
as mean ± standard error of three independent experiments. A minimum of 10,000 events were 
analysed by flow cytometry. The results are presented as histogram plots using WinMDI software. 
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4.10 UKOS A genome sequencing 
To further investigate the potential cause of this apparent delay in apoptosis, we 
decided to undertake the sequencing of the UKOS A genome to determine if 
mutations in a particular region are responsible. 
Thus far, other studies have shown the sequences of the protease-polymerase or the 
capsid protein region of the VSD-isolates to be genetically distinct from each other, 
and found no sequence or amino acid changes unique to all VSD-isolates. It has been 
reported that the sequences of the VSD strains of FCV are no more or less similar to 
FCV-F9 than they are to each other, making the search for any changes responsible 
for the hyper-virulent phenotype very problematic (Coyne et al., 2006; Ossiboff et 
al., 2007). Here, we started to analyse the sequence differences in the UKOS A 
genome, starting with the first region of ORF 1, encoding the FCV non-structural 
protein, NTPase. Primers were designed to this segment of the UKOS A genome and 
it was amplified by PCR. The PCR product was then sequenced and translated. 
Figure 4.10 shows the amino acid sequence alignment results for the first segment of 
the UKOS A genome representing the first 172 amino acids produced from the start 
codon of ORF 1. It is clear that there are some differences in the residues present 
between the UKOS A strain and other selected FCV isolates (highlighted in red). 
Isolates range from known VS strains of FCV (UTCVM-H1 / -H2), various isolated 
clinical strains and two vaccine strains (FCV-F4 / -F9). These represent residues in 
UKOS A that are different to all other conserved residues at that location. The 
functional significance of this, in terms of the VS phenotype, is still unclear and will 
only be resolved through mutagenic analysis of the residues individually. 
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Figure 4.10: Amino acid alignment of a range of FCV isolates compared to the UKOS A strain. A 
region representing the first 172 amino acids of the UKOS A genome was amplified from cDNA 
(obtained through reverse transcription of viral RNA isolated from infected cells) via PCR. The 
fragment was subsequently sequenced and aligned to a range of FCV isolates to search for any 
changes to the amino acid sequence that may account for the VS phenotype. Isolates range from 
known VS strains of FCV (UTCVM-H1 / -H2), various isolated clinical strains and two vaccine strains 
(FCV-F4 / -F9) (Neill et al., 1991; Tohya et al., 1991; Carter et al., 1992a; Oshikamo et al., 1994; 
Sosnovtsev and Green, 1995; Glenn et al., 1999; bd-Eldaim et al., 2005). Alignment was performed 
using the MEGA 4.0.2 (1993-2008) protein alignment software. 
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4.11 Discussion 
Since the first reports of highly virulent FCV strains with a wide new range of clinical 
signs, work has focused on identifying the mechanisms that allow these viruses to 
cause this new disease phenotype (Pesavento et al., 2004; Hurley et al., 2004; Coyne 
et al., 2006; Foley et al., 2006; Ossiboff et al., 2007). Ossiboff et al (2007) were the 
first group to report that the VSD strains of FCV had a different behaviour in vitro to 
that of the non virulent strains, in particular FCV-F9. They inferred a potential delay 
in apoptosis was occurring during infection with the VSD-strains evidenced by the 
maintenance of cellular ATP levels (Ossiboff et al., 2007). 
Consistent with this hypothesis, we have provided evidence of this delay in apoptosis 
through analysis of various different points along the apoptotic pathway in virulent 
strain (UKOS A) and vaccine strain (FCV-F9) infection in CRFK cells. Firstly, we have 
shown that at high multiplicities of infection there is a reduction in the level of PS 
exposure on the cell surface of UKOS A-infected cells vs. FCV-F9-infected cells, up to 
14h p. i., when UKOS A-infected cells undergo a sudden surge in apoptosis. This 
demonstrates that UKOS A does indeed induce apoptosis but it is at an initially 
delayed rate compared to that of FCV-F9 (Figure 4.1). We have also shown that this 
delay in apoptosis during UKOS A infection corresponds to less of a reduction in cell 
viability, as demonstrated by the LDH assay (Figure 4.2). 
To bring our research in line with work from other groups, the MOI was reduced 
from 100 to an MOl of 1. We demonstrated that the delay in apoptosis was much 
more pronounced, and in line with what is reported in the literature (Ossiboff et al., 
2007) (Figure 4.3). 
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In order to understand the molecular events that lead to the delay in apoptosis, 
several apoptotic events were examined. As the mitochondrial pathway of apoptosis 
has been implicated in the apoptosis seen in FCV-F9 infected cells, events occurring 
within this pathway were examined (Natoni et al., 2006). We demonstrated that 
caspase-3 activation was delayed in UKOS A-infected cells in comparison to F9 but 
that activation was observed at 18h p. i (Figure 4.4). We also demonstrated that 
caspase-9 activation was delayed in UKOS A infected cells when compared to FCV-F9 
infected cells (Figure 4.6). This is an interesting finding, as in work by Natoni et al 
(2006) caspase-9 and the apoptosome were implicated in the activation of caspase- 
3. In the case of UKOS A-infection, caspase-9 activity has not risen significantly 
above background levels by 18h p. i; as caspase-3 activation had occurred at this time 
point, it seems unlikely that caspase-9 is responsible for the activation of caspase-3 
in UKOS A infected cells, and that caspase-3 is being activated by a mechanism 
independent of the mitochondrial pathway of apoptosis. To further support these 
findings, the release of cytochrome c from the mitochondria was also seen to be 
delayed in UKOS A-infected cells compared to F9 infection (Figure 4.7). As 
cytochrome c is a key factor in the formation of the apoptosome, its absence in the 
cytosol leads us to question whether the mitochondrial pathway is utilised during 
VSD strain infection or just simply delayed until a later time p. i. 
The delay in apoptosis observed in UKOS A infection was not due to inefficient 
replication of the virus in CRFK cells, as we showed that the virus replicates as 
efficiently as FCV-F9 (Figure 4.8). This would suggest that UKOS A is not capable of 
replicating more efficiently than FCV-F9 in vitro over single cycle growth conditions. 
UKOS A did appear to replicate to a higher titre than FCV-F9 by 18h p. i., but not 
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statistically significantly. However, it has been reported that the VSD FCV strains 
have faster growth kinetics and yielded greater amounts of infectious virus quicker 
(2 loglo p. f. u. ml-1 greater titre at 4h p. i. in the VSD-isolate-infected cells vs. the non- 
VSD isolates) than non-VSD strains over multiple-cycle growth conditions (Ossiboff et 
al., 2007). It could be that under multiple-cycle growth conditions (more comparable 
to the natural infection process) a delay in apoptosis could be beneficial to the virus, 
and allow it more time to replicate to higher viral titres. 
The first round of sequencing of the UKOS A genome showed a few amino acid 
residue changes compared to other FCV isolates. Although some residues present in 
the UKOS A genome appeared to be different to all other isolates examined, we 
cannot rule out that this is just an artefact of the alignment software. To 
demonstrate this point, this artefact (residues at certain loci, conserved in all strains 
except the primary alignment) could be recreated when any other of the isolates 
were used as the primary alignment. Therefore, to test whether these changes are 
responsible for the VSD phenotype, the complete sequence of the UKOS A genome 
needs to be obtained. Then further mutagenic analysis using infectious clones and 
reverse genetics can be utilised. This will allow for examination and alterations of 
these amino acid residues to see if the VSD phenotype is lost. To truly ascertain 
where the mutations lie in the genome, and to examine if there are any conserved 
changes within the VSD strains, the full length sequencing of all known VSD strains 
needs to be performed. Current sequence data for these strains is mostly limited to 
the capsid and / or protease-polymerase regions of the FCV genome, which to date 
have shown no sequence or amino acid changes unique to all VSD isolates (Hurley et 
al., 2004; Foley et al., 2006; Ossiboff et al., 2007). 
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5 INDUCTION OF APOPTOSIS IN MNV-1 INFECTED CELLS IN CULTURE 
5.1 Introduction 
As stated in the previous sections, FCV has until recently been the principle model 
for the human caliciviruses. While FCV is a member of the Caliciviridae, it is not 
classified within the norovirus genus. 
In 2003, a tissue culture and small animal model system was established for a newly 
discovered member of the Norovirus genus, Murine Norovirus-1 (MNV-1). MNV-1 
was first isolated from RAG-2/STAT-1 knockout mice that sporadically succumbed to 
a systemic disease that could be serially passaged by intracerebral inoculation (Karst 
et al., 2003). It was demonstrated that MNV-1 grows efficiently in murine 
macrophages, e. g. RAW 264.7 cells and dendritic cells, providing the first efficient 
tissue culture model for a norovirus (Wobus et at., 2004; Wobus et al., 2006). MNV-1 
shares many of the important characteristics and molecular properties with other 
noroviruses and caliciviruses in general such as size, icosahedral shape, buoyant 
density, as well as the three open reading frames characteristic of two genera within 
the Caliciviridae (Karst et al., 2003). This has made MNV-1 an ideal candidate to 
become the model virus for human norovirus biology; it has led to a large amount of 
work in recent years to characterise this virus and create easily manipulated reverse 
genetics systems (Ward et al., 2007; Chaudhry et al., 2007). The reverse genetics 
system, coupled with the genetic manipulability of the murine host and the tissue 
culture system for MNV-1, provides an exciting possibility to examine how the 
noroviruses interact with their host cells, both in vitro and in vivo. In this chapter we 
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have examined for the first time the mechanisms of cell death in MNV-1-infected 
RAW cells, to a) provide a potential model for what could be occurring during human 
norovirus infections and b) compare and contrast the mechanism of cell death with 
other Caliciviridae members to see if there is a general trend in the method of cell 
death amongst this family of viruses. 
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5.2 PS translocation during MNV-1 infection 
Annexin V/ PI analysis was carried out on MNV-1 infected RAW cells over a 24 hour 
period to ascertain which mechanism of cell death was occurring during infection. 
Cells were infected in the presence / absence of 100 VM of the pan caspase inhibitor, 
z-VAD-fmk. This allowed us to determine if the mechanism of cell death occuring 
during MNV-1 infection was apoptotic in nature, as inhibition of the caspase cascade 
should prevent cell death seen during apoptosis. In MNV-1-infected cells, cell death 
occurred from 18 h p. i. evidenced by the positive PI response. However, the cells do 
not appear to become AV positive, implying that apoptosis may not be the 
underlying mechanism of cell death. In cells treated with z-VAD-fmk we saw an 
unexpected increase, rather than reduction, in the proportion of cells undergoing 
apoptosis at 24 h p. i. This population of cells also appeared to be AV positive at 24 h 
p. i., in the treated cells (2% of cells AV/Pl+ve 24h pi in untreated cells, and 35.7% in 
z-VAD-fmk treated cells. This result contrasts with previous reports of the use of z- 
VAD-fmk in the inhibition of the apoptotic pathways induced through viral infection 
(Natoni et al., 2006). 
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Figure 5.1: PS translocation during MNV-1 infection. RAW 264.7 cells were infected with 
MNV-1 (MOI=100) in the presence or absence of z-VAD-fmk (negative control) for the times indicated 
and analysed for PS exposure using 
the AV/PI assay. A minimum of 10,000 events were analysed by 
flow cytometry. The results are presented as plots using WinMDI software and are representative of 
3 independent experiments. 
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5.3 Detection of caspase-3 activation during MNV-1 infection 
Caspase-3 activation is one of the last and final steps of the caspase cascade, as this 
enzyme is one of the main executioner caspases. Activation of the caspase cascade 
is a key component of apoptosis and allows for the distinction of which type of cell 
death has been initiated during infection. RAW cells were infected with MNV-1 in 
the presence / absence of 100 VM z-VAD-fmk and harvested at various times post 
infection. The cell extracts were then subjected to Western blot analysis and assays 
to detect active caspase -3 and caspase -3/-7 activity using the cell permeable 
fluorogenic caspase substrate (benzyloxcarbinonil-Asp-Glu-Val-Asp-7-amino-4- 
trifluoromethylcoumarin; z-DEVD-AFC). 
Activation of caspase-3 was observed in MNV-1 infected cells at 18h p. i. (Figure 5.2) 
and was more intense at 24h p. i. Treatment of the RAW cells with z-VAD-fmk 
reduced the amount of active caspase-3 seen in a dose-dependent manner, as seen 
by a decrease in band intensity when compared to untreated infected cells. 
We also analysed the timing of activation of caspase-3/-7 through the use of a 
fluorogenic caspase substrate, as shown in Figure 5.3. There was an increase in 
caspase-3/-7 activity in infected cells at 18h p. i. and a plateu of activity at 24 h p. i. 
This data, together with the caspase-3 Western blot analysis, suggests that the 
mechanism of cell death occurring in MNV-1-infected cells is apoptotic in nature. 
164 
Induction of apoptosis in MNV-1 infected cells in culture 
Oh 12h 
50 100 -- 50 100 
ý 
18h 
50 100 
24 h 
50 100 
(H) p. i. 
z-VAD (µM) 
17 kDa 
Active 
Caspase-3 
Figure 5.2: Detection of active caspase-3 in MNV-1-infected cells. RAW cells were infected 
with MNV-1 (MOI=100). At the times indicated p. i., mock infected and infected cells were lysed and 
equal amounts of cell extract were analysed by Western blotting. The active form of caspase-3 is 
represented by the appearance of a 17 kDa band on the Western blot. Results are representative of 3 
independent experiments. 
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Figure 5.3: Caspase -3/-7 activity in MNV-1-infected cells. RAW cells were infected with MNV- 
1 (MO1=100). At the times indicated p. i., caspase -3/-7 activity was analysed by monitoring z-DEVD- 
AFC fluorescence emission. Data is normalised for the control level of fluorescence in each case and is 
presented as the mean ± standard error of three independent experiments. 
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5.4 Cytochrome c translocation occurs during MNV-1 infection 
As stated in previous sections (Section 4.7), cytochrome c is a key event in the 
mitochondrial pathway of apoptosis seen in FCV infection. We therefore wanted to 
establish if the same pathway of apoptosis was triggered during MNV-1 infection. 
Cytochrome c translocation from the mitochondria to the cytosol was analysed by 
Western blot in the presence or absence of z-VAD-fmk. Low levels of cytochrome c 
were detected in the cytosol at 12 h p. i. and to a greater extent at 18 and 24 h p. i 
(Figure 5.4). Surprisingly, cytochrome c translocation appeared to be enhanced 
during MNV-1 infection of RAW cells treated with z-VAD-fmk. This is in contrast to 
what is seen during FCV infection in which cytochrome c release was inhibited by z- 
VAD-fmk treatment (Natoni, unpublished data). In line with the AV/PI assay and the 
caspase-3 activation, this data further suggests that apoptosis may be occuring in 
MNV-1-infected cells. 
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Figure 5.4: Cytochrome c release during MNV-1 infection. RAW cells were infected with MNV- 
1 (MOI=100). At the times indicated post infection, uninfected and infected cells, in the presence or 
absence of z-VAD-fmk (control) were harvested and their plasma membranes permeabilised with 
digitonin. Following separation of the mitochondrial (M) and cytosolic (C) fractions, samples were 
analysed by Western blotting for cytochrome c translocation. 
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5.5 MNV-1 infection induces a loss of d(Ib)m in RAW cells 
In order to define the events that lead to the release of cytochrome c observed in 
MNV-1 infection, we analysed MNV-1 infected cells for changes in the mitochondrial 
membrane potential A(ljl)m. The loss of A(LIJ)m has been demonstrated to be an early 
event occurring in cells undergoing apoptosis in FCV infection (Natoni et al., 2006) as 
well as other viral infections such as with hepatitis B virus or Semliki Forest Virus 
(Kim et al., 2008; Urban et al., 2008). Although the exact mechanism of A(l)1)m 
reduction is not fully understood, it is recognised as a clear indicator of 
mitochondrial involvement in the apoptotic process. The A(tIJ)m was measured by 
flow cytometry using tetramethylrhodamine ethyl ester (TMRE), a mitochondrial 
probe in which the fluorescence emmited is dependent directly upon A(1IJ)m. In these 
experiments, the chemical mesoxalonitrile 3-chlorophenylhydrazone (CCCP), a 
protonophore and uncoupler of oxidative phosphorylation in mitochondria, was 
used as a positive control for A(4)m depolarisation. In cells with normal levels of 
A(tI))m, TMRE is located within the mitochondria, but upon loss of A(l)), a reduction 
of TMRE signal is detected. 
As shown in Figure 5.5(A), a clear reduction in TMRE staining can be seen at both 
12h and 24 h p. i. in MNV-1 infected cells. This is visualised by a shift of the peak in 
the 0h sample to the left of the histogram to align with the positive control CCCP- 
treated cells. To demonstrate that this was not a post mortem cellular event the PI 
staining was examined at both time points (Figure 5.5(B)). This clearly demonstrated 
that, at 12 h p. i., the infected cells were not dead and that this depolarisation of the 
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mitochondrial membrane was occurring pre-mortem. The timing of A(i)m also 
coincides with the release of cytochrome c seen in Section 5.4. 
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Figure 5.5: Analysis of A(' )m in MNV-1 infected cells. (A) RAW cells were infected with MNV-1 
(MO1=100). At the indicated time p. i., the cells were stained with TMRE (1 µM, dependent on A(l11)m), 
and CCCP (1 µM, in the case of the positive control for A(i)m). (B) PI stained RAW cells for each time 
point; secondary peak represents cell death, as seen 24 h p. i. A minimum of 20,000 events were 
analysed by flow cytometry. The results are presented as plots using WinMDI software and are 
representative of three 
independent experiments. 
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The effect of z-VAD-fmk upon 1(ß)m was also examined, to see if membrane 
depolarisation could be the mechanism behind the increase in cytochrome c 
translocation from the mitochondria to the cytosol observed in treated cells. Figure 
5.6 shows that the addition of z-VAD-fmk alone to RAW cells is sufficient to induce 
depolarisation of the mitochondrial membrane, as observed in the uninfected 
control cells. The data also shows that at 24h p. i., cells treated with z-VAD-fmk 
contained mitochondria that were almost entirely depolarised, whereas the 
untreated cells still contained a significant population of cells in which mitochondrial 
membrane potential loss had not yet occurred. This suggests that z-VAD-fmk is 
enhancing the depolarisation of the mitochondria) membrane seen in MNV-1- 
infected cells. This z-VAD-fmk mediated depolarisation of the mitochondria) 
membrane will ultimately lead to cell death, as seen in Figure 5.1 and reported in the 
literature (Kim and Han, 2001; Vandenabeele et al., 2006). Therefore, a limited use 
of this chemical in the RAW 264.7 cell line should be observed, and any experimental 
data obtained using z-VAD-fmk will have to be carefully scrutinised. 
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Figure 5.6: Analysis of A(qi)m in MNV-1 infected cells. (A) RAW cells were infected with MNV-1 
(M01=100) in the presence or absence of z-VAD-fmk (negative control). At the indicated time p. i., the 
cells were stained with TMRE (1 µM, dependent on A(l(1)m), and CCCP (1 µM, in the case of the 
positive control for A(i)m). A minimum of 20,000 events were analysed by flow cytometry. The 
results are presented as plots using WinMDI software. 
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5.6 Discussion 
Since its discovery in 2003 (Karst et al., 2003), MNV-1 biology has been extensively 
studied and the knowledge gained used to answer some of the unsolved questions 
regarding human norovirus replication. In this chapter, we began to address one of 
the many uncharacterised events during the virus life-cycle, the mechanism of cell 
death in MNV-1 infection. 
The first experiment conducted was the AV/PI assay to provide an indication as to 
whether viral infection induced cell death. It can be seen from Figure 5.1 that the 
infected cells were dying and there was a large increase in the number of AV -/Pl+ 
cells from 14 - 18h p. i. and another from 18- 24 h p. i. This peculiar profile of cells 
could be due to a variety of reasons; firstly it could be that this cell AV -/PI + 
population as reported with FCV-infection is associated with cell populations that 
have defects in their plasma membrane through viral replication events. This could 
allow the cell to become permeable to PI and hence give the positive staining 
(Natoni, unpublished data; (Sosnovtsev et al., 2003)). Another explanation could be 
that the virus induces depletion of PS exposure on the cell surface as a potential 
mechanism for immune evasion, although this would need much further 
investigation. Upon addition of the pan caspase inhibitor z-VAD-fmk, the infected 
cells seemed to undergo apoptosis / necrosis at a greater rate than that of the 
untreated infected cells. The flow cytometry data suggests that this is a necrotic 
mechanism, as the cells do not seem to become AV+/PI -, which is an indication of 
the early stages of apoptosis. This phenomenon has been reported previously in the 
literature and seems to be an artefact of the macrophage cell line used; the authors 
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noted that the use of z-VAD-fmk in macrophage-based cell lines actually enhanced 
cell death rather than inhibiting it. This reported enhancement of cell death is 
consistent with the experimental data we have obtained here, (Kim and Han, 2001; 
Scheller et al., 2006; Vandenabeele et al., 2006). Unfortunately, these results 
suggest that the use of z-VAD-fmk in this cell system should be avoided and any 
further data obtained involving its usage should be interpreted very carefully. 
In order to confirm which mechanism of cell death was induced in MNV-1 infected 
cells, we analysed the activation of one of the main executioner caspases, caspase-3. 
Activation of caspase-3 was detected during MNV-1 infection and was sensitive to z- 
VAD-fmk treatment in a dose dependent manner (Figure 5.2). The activation of this 
crucial caspase strongly indicates that apoptotic cell death is occurring during MNV-1 
infection. 
The translocation of cytochrome c from the mitochondria to the cytosol was also 
observed during MNV-1 infection (Figure 5.4). This transiocation occurred, 
represented by detection of cytochrome c in the cytosol, at 12 h p. i. This also 
coincided with the detection of a loss in Aim in the mitochodria at 12 h p. i. (Figure 
5.5). Although the translocation of cytochrome c is implicated as a key step in the 
mitochondrial pathway of apoptosis, its translocation can also be seen in necrosis 
(Green and Kroemer, 2004). Interestingly, as observed with the AV/PI assay, the 
addition of z-VAD-fmk appeared to enhance cytochrome c translocation during 
MNV-1 infection as well as enhance the depolarisation of the mitochondrial 
membrane, causing aDIm similar to that seen in the CCCP treated (positive control 
for mitochondrial membrane depolarisation) sample 24 h p. i. (Figure 5.6). 
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In conclusion, we have highlighted the complex nature of the cell death mechanism 
occurring during MNV-1 infection. Through the detection of activated caspase-3, it 
can be suggested that apoptosis is playing a role during MNV-1 infection, but this 
may not be the only / major method of cell death activated. Defining the mechanism 
of cell death is further impeded by the results seen in this macrophage cell line when 
the pan-caspase inhibitor z-VAD-fmk is used. Further work needs to be conducted to 
establish whether apoptosis is the underlying mechanism of cell death occurring in 
this system. This can be achieved through the examination of the activation of other 
caspases, such as caspase-2, -8 and -9, examination of DNA fragmentation and 
cleavage of cellular proteins such as PARP. 
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6 GENERAL DISCUSSION 
Apoptosis is one of the most important cellular defence mechanisms that 
multicellular organisms have against viral infections. This mechanism of cellular 
proliferation regulation has been exploited by many viruses to their own advantage, 
through events mediated by the pathogen, which result in the inhibition or induction 
of apoptosis. This deregulation of the apoptotic response is key to the pathogenesis 
of many viral infections, such as HIV-1, HCV, HPV, FCV & MNV-1 (Lan et al., 2008; 
Fidan et al., 2008; Cossarizza, 2008). Several different mechanisms can be employed 
by the invading viruses to inhibit apoptosis, such as interfering with the interferon 
response, production of antagonists to the apoptotic pathways, production of viral 
caspase inhibitors, production of viral Bcl-2 like proteins and transcriptional 
regulation of factors such as NF-KB and p53. Conversely, some viruses have 
developed ways of inducing the apoptotic response, through the production of 
caspase activators, inhibitors of Bcl-2 proteins or death receptor signalling mimics. 
These mechanisms have been established to either facilitate the spread of progeny 
virus to neighbouring cells through the induction of apoptosis or to evade the host's 
immune response by delaying or inhibiting the onset of apoptosis. 
The association between calicivirus infection and the induction of apoptosis has now 
been established for over a decade. The first link was made by Alonso et al (1998a), 
when they demonstrated that RHDV infected cells undergo apoptosis in vitro and in 
vivo, in infected rabbits. More importantly, they inferred a link between the 
pathogenesis of the virus and apoptosis, by suggesting that the lethal hepatitis seen 
during the course of the disease was the consequence of apoptosis (Alonso et al., 
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1998a). More recently, work within our laboratory has focused on examination of 
the effects of FCV replication on CRFK cells and has highlighted that the 
mitochondrial pathway of apoptosis is induced during FCV infection (Roberts et al., 
2003; Al-Molawi et al., 2003; Natoni et al., 2006). In these reports it was 
demonstrated that FCV infection induces the activation of caspase-2, -3, -6 and -7, 
the cleavage of PARP and the condensation of chromatin. Further to this, it was 
shown that phosphatidyl serine translocation and cytochrome c release from the 
mitochondria occurred during infection, preceded by a translocation of Bax to the 
mitochondria from the cytosol. Natoni et 01(2006) also demonstrated the release of 
cytochrome c from the mitochondria during FCV infection, which led to the 
formation of the apoptosome responsible for the activation of caspase-9 and, 
ultimately, caspase-3. Although it had been shown which of the apoptotic pathways 
was activated during FCV-infection, the molecular events that occur upstream to 
trigger the mitochondrial pathway remained uncharacterised. 
In this present study, we have examined the early molecular events that lead to the 
activation of the mitochondrial pathway during FCV infection. Previous work from 
our laboratory had begun to characterise this mechanism and ruled out several 
possible triggers such as the activation of caspase-8. This caspase is normally 
associated with the death receptor pathway of apoptosis, but through cleavage of 
the protein Bid, which in turn activates Bax, can stimulate the mitochondrial 
pathway (Chang et al., 2003; Peter and Krammer, 2003; Pop et al., 2007). It was 
shown that caspase-8 was cleaved at 8h p. i., after the translocation of cytochrome c 
(at 6h p. i. ), from the mitochondria has occurred; therefore it was not an important 
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upstream event in the mitochondrial pathway (Natoni et al, unpublished data). 
Other potential mechanisms of activation were also examined, such as the 
production of ROS; this was also excluded as treatment of the CRFK cells with several 
different antioxidants prior to FCV infection did not prevent either PS translocation 
or caspase-3 activation (Natoni et al, unpublished data). A report by Debiasi et al 
(1999) had observed that apoptosis during reovirus infection of L929 cells was 
preceded by an increase in calpain activity and that inhibition of calpain activity led 
to the ablation of apoptosis. We therefore tested if this group of calcium-activated 
cysteine proteases was activated in FCV infection. The activation of calpains 
occurred before the activation of caspase-3 as reported here, and before the release 
of cytochrome c from the mitochondria, as reported by Natoni et al (2006). This 
result suggests that the calpains could be the upstream mediator of the events just 
described. 
There are many reports that suggest calpains have both pro- and anti-apoptotic 
functions. For example, calpain cleavage of Bax to a truncated p18 form promoted 
apoptotic induction; however, the cleavage of other substrates such as p53 or 
caspase-3, -7, -8 and -9 by calpains attenuates their activity, thus inhibiting 
apoptosis, reviewed by (Tan et al., 2006)). Other work has demonstrated that 
calpains are mediators of upstream events in apoptosis, that lead to the release of 
cytochrome c from the mitochondria through the cleavage of several Bcl-2 proteins 
such as Bax, Bid or Bcl-XL (Raynaud and Marcilhac, 2006). The activation of calpains 
has also been shown during echovirus and coxsackie B virus infections. Calpain 
activity was demonstrated to be crucial for efficient replication, evidenced by the 
demonstration that calpain inhibitors efficiently blocked virus particle formation, 
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even when echovirus RNA was microinjected into cells (Debiasi et al., 1999; Upla et 
al., 2008; Yoon et al., 2008). 
As well as being implicated in apoptosis seen during virus infections, as previously 
discussed, calpains are also implicated in the pathologies of many wide ranging non- 
viral diseases. Firstly, calpains have been linked to the modulation of memory within 
the brain and play a key role in the pathogenesis of Alzheimer's Disease (AD) 
(Raynaud and Marcilhac, 2006, Trinchese et al., 2008). This group have 
demonstrated a role for calpains in the degradation of proteins essential for 
neuronal survival. Through the use of the calpain inhibitor BDA-410, Trinchese et al 
(2008) showed that inhibition of calpains restored normal synaptic function in the 
APP/PS1 mouse, the animal model currently in use for AD. They also show that an 
improved spatial-working memory and associative fear memory could be obtained 
through calpain inhibition. The group hypothesised that as calcium levels are 
elevated in AD brains, the loss of calcium homeostasis disrupts the physiological 
regulation of calpains, leading to a dysregulation of calpain activity. This 
dysregulation is evidenced by autolysis of calpain-1 to its 76- and 78 kDa forms, 
increased levels of calpain-2 and a decrease in expression levels of calpastatin in AD 
brains. The authors also suggested that the study of calpains in 
physiological/pathological situations may lead to possible therapeutic strategies for 
the treatment of AD (Trinchese et al., 2008). 
Calpains have also been implicated in the L-glutamate-induced model for oxidative 
stress in the murine hippocampal HT22 cell line, an established model for oxidative 
neuronal cell death (Elphick et al., 2008). Here, the authors suggested that calpain 
inhibition, through the use of ALLN, prevented, cell death. The cytotoxic role of 
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calpain activity during oxidative glutamate toxicity in HT22 cells was evidenced by 
the cytotoxic response being dependent on an increase in intracellular calcium 
levels, detection of the 145 kDa cleavage product of the cytoskeletal protein fodrin 
and an increase in cleavage of the calpain substrate Suc-Leu-Leu-Nleu-CHO. This 
work contributes to the understanding of the complex role of calpains in oxidative 
neurotoxicity, which is be seen following stroke or ischemic injuries (Elphick et al., 
2008). Therefore, our work to understand the role and mechanism of calpain 
activation in virus infections may lead to an increased understanding of the 
physiological and pathological roles of these proteases in other important diseases. 
In our study, we have now confirmed that calpains are activated during FCV infection 
of CRFK cells. However, we wanted to clarify whether the activated calpains 
detected in cells infected with FCV-F9 were acting in a pro- or anti-apoptotic manner. 
In this report, through the use of several pharmacological inhibitors of calpains, we 
demonstrate that calpain activity contributes to the induction of apoptosis in FCV- 
infected cells. A wide panel of inhibitors was used to address the inherent problems 
of using inhibitors that lack complete calpain specificity, which can lead to a 
somewhat confused or misleading interpretation of the role of calpains in cell death 
signalling. We examined the inhibitory effects of ALLN, MG-132, epoxomicin and 
calpeptin and demonstrated that all of the calpain inhibitors inhibited apoptosis in 
infected cells. This indicates that the induction of apoptosis seen during FCV 
infection is mediated through the activity of calpains, rather than through other 
cellular structures, such as the proteasome. We also used the two most potent 
calpain inhibitors, ALLN and calpeptin, to determine the effect they had on the 
replication of FCV in CRFK cells and the release of virus into the external growth 
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media. In the presence of either of the inhibitors, no effect on viral replication was 
seen, indicating that calpain activity is not crucial for the replication of FCV. This is in 
contrast to other viral infections such as Echovirus replication in SAOS-a201 cells or 
Coxsackie B Virus replication in cultured rat cortical neurons in which the addition of 
calpain inhibitors inhbitied viral replication (Upla et al., 2008; Yoon et at., 2008). In 
FCV-infected cells there was, however, a significant difference between the levels of 
extracellular virus released in cells treated with calpain inhibitors. This suggests that 
apoptosis may be required for the efficient release of mature FCV virions into the 
surrounding environment. 
Previous work in our laboratory has demonstrated that the FCV capsid protein is 
cleaved by both caspase-2 and caspase-6 during infection (Al-Molawi et al., 2003). 
Both caspase-2 and caspase-6 can be activated by caspase-3 mediated proteolysis 
(Slee et at., 1999b; O'Reilly et al., 2002). As we have now shown that caspase-3 
activity is ablated by calpain inhibition, it is logical that the capsid cleavage will also 
be reduced. Whether this cleavage of the viral capsid protein by the caspases 
represents a general host defence mechanism, to reduce viral titres by preventing 
the formation of mature virus particles, or, whether the caspase cleavage is needed 
for the maturation of the capsid protein, thereby contributing to the pathogenic 
properties of viral infectivity, still remains unclear. The phenomenon of apoptosis 
being required for virus release is not uncommon and occurs in other viral infections, 
such as astrovirus infection of Caco-2 cells, in which the treatment of cells with the 
pan-caspase inhibitor z-VAD-fmk prevented the release of mature virions into the 
surrounding growth media. This is because the viral capsid protein precursor VP90 
(the primary product of ORF 2) is cleaved by caspases at a putative caspase cleavage 
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site to yield VP70, which is further processed to yield a fully infectious virus 
composed of the viral proteins VP34, VP27 and VP25. Therefore, in the presence of 
caspase inhibitors this cleavage would not occur, leading to decreased numbers of 
fully formed virus particles being produced, as reported (Mendez et al., 2004). 
Although it may appear that the cleavage of the capsid protein is a host defence 
mechanism, it may also be of benefit to the virus in vivo. The cleaved forms of the 
capsid protein may also function to induce a non-neutralizing antibody response in 
vivo, acting as a decoy for the immune response, which would be beneficial to viral 
immune evasion. Recently it has been shown that the antibody response during 
infection of another Caliciviridae member, MNV-1, is critical for the clearance of 
infection in mice (Chachu et al., 2008). Therefore, if cleavage of the FCV capsid 
protein occurs in a proportion of the virions produced during infection, it would help 
virus propagation by decoying the immunological response in vivo. It therefore 
seems it would be in the viruses' best interest to induce apoptosis and ensure this 
happens. 
To further confirm that it is indeed the calpains that are key in mediating apoptosis 
during FCV-infection, we examined the effects of the endogenous calpain inhibitor 
calpastatin on the apoptosis seen during FCV infection. At the time of 
experimentation, the only commercially available calpastatin protein was insoluble 
and difficult to deliver into cells, due to its large size (100 - 170 kDa; dependent on 
the isoform) (Goll et al., 2003). Therefore, the decision was taken to create a vector 
containing one of the inhibitory portions of the calpastatin protein, domain I, in a 
dicistronic construct containing GFP under the control of the EMCV IRES (described 
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in Section 2.7). Through the use of this construct, we further demonstrated the 
crucial role of calpains in apoptosis induced by FCV infection (Figure 3.6). 
Future work should focus on determining what is activating the calpains in this 
particular case. It is known that the activation of calpains is reliant on the levels of 
intracellular calcium. For this reason, an examination of the state of calcium flux 
from extracellular pools into CRFK cells or perturbations of intracellular Ca2+ 
compartmentalization during FCV infection should be undertaken. It has also been 
demonstrated that under pathological situations, the influx of extracellular calcium 
across the cell membrane has a role in the activation of the calpains (Orrenius et al., 
2003). As FCV infection may induce the permeablisation of the plasma membrane, 
as mentioned by Sosnovstev et al (2003), this could allow for the influx of calcium 
from the extracellular pool, thus promoting calpain activation. The influx of calcium 
could be measured using sensitive aequorin-based systems (Mithofer and Mazars, 
2002). Aequorin is a photoprotein composed of two distinct units, apoaequorin and 
the prosthetic group coelenterazine, a molecule belonging to the luciferin family. 
When added together to cells in culture, the two components of aequorin 
reconstitute spontaneously, forming the functional protein. The structure of 
aequorin functions to allow binding of Ca 2+ ions; when this occurs the protein 
undergoes a conformational change and converts the coelenterazine into excited 
coelenteramide. As the excited coelenteramide relaxes to the ground state, blue 
light (wavelength = 469 nm) is emitted, which can easily be monitored by a 
luminometer (Mithofer and Mazars, 2002; Nunez et al., 2007). Therefore, the influx 
of calcium can be detected by an increase in the amount of blue light emitted, 
corresponding proportionally to the increase in calcium in the system. This assay will 
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provide a great insight into the potential role of calcium influx on calpain activation 
during apoptosis seen in FCV infections. 
Other than a calcium-mediated response, the possibility of a viral protein activating 
the calpains cannot be ruled out at this stage. A recent report into apoptosis 
induced by human papillomavirus has suggested that the E7 protein is able to bind to 
µ-calpain (Darnell et al., 2007). It was demonstrated that a protein-protein 
interaction occurred between HPV E7 (eE7) and µ-calpain , evidenced by µ-calpain 
being pulled down with the HPV E7 protein. This study also demonstrated that the 
E7 bound the 37-kDa autocatalytic fragment of µ-calpain, representing the amino- 
terminal region of µ-calpain. More importantly, the study found that the eE7 protein 
reduced the calcium requirement for activation of µ-calpain. GST-eE7 was incubated 
with recombinant µ-calpain in the presence of a range of calcium concentrations 
from 0-1 µM calcium. The calpain activity was then measured using a fluorogenic 
calpain peptide substrate; surprisingly, in the presence of eE7 significant calpain 
activity was seen at concentrations of calcium as low as 50 nM. This is well within 
the range of normal physiological calcium concentrations of 50-300 nM. This 
provided the first evidence of a viral protein acting as a calpain binding-protein that 
reduced the calcium requirement of V-calpain required to activate its protease 
activity (normally in the µM range). However, the exact mechanism by which this 
occurs is not yet known (Darnell et al., 2007). Interestingly, the HPV E7 protein 
appears to share some amino acid sequence homology with the p30 region of ORF 1 
of the FCV genome, displaying some conserved sequence motifs. This raises the 
possibility that p30 could be the key to lowering the activation requirement for the 
proteolytic activity of the calpains during apoptosis occurring during FCV infection. 
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To test this theory, a tandem affinity purification (TAP) protocol developed by 
Bürckstümmer et al (2006) could be employed. This technique would allow for the 
isolation of proteins in CRFK cells bound to the p30 protein. Tap-tagged proteins in 
the cell lysate are bound to IgG Sepharose through two IgG-binding units derived 
from protein-G of Streptococcus sp. The protein G of the tag is linked to streptavidin 
binding protein (SBP) through a Tobacco Etch Mosaic virus protease cleavage site 
that is cleaved to release the p30, and any associated proteins, attached to the SBP. 
This protein complex is in turn bound to streptavidin Sepharose and then eluted with 
biotin. Following SDS-PAGE and silver staining, the protein bands are excised, 
digested with trypsin and analysed by mass spectrometry, to analyse any binding 
partners found. We can thus test in the case of p30, whether calpain is one of these 
binding partners. 
In summary, our results indicate the involvement of two proteolytic systems 
occurring during FCV-infection, the calpains and the caspases. However, the exact 
mechanism of activation of the calpains is still not clear. 
More recently, reports have been emerging of hyper-virulent strains of FCV that 
cause a severe viral systemic disease (VSD). In contrast to the work just described, it 
was hypothesised that they delayed rather than induced the onset of apoptosis 
(Pedersen et al., 2000; Pesavento et al., 2004; Hurley et al., 2004). This delay in 
apoptosis had not been characterised, but was of great interest as these strains 
display an apparently different mechanism of pathogenesis. These findings cast 
doubt on the hypothesis that the early induction of apoptosis could be a general 
feature of all calicivirus infections. 
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We addressed the hypothesis that there is a delay in apoptosis during infection with 
virulent systemic disease-causing strains of FCV. This potential delay was first 
suggested by Ossiboff et al (2007). Here, they demonstrated that CRFK cells infected 
with the VSD strains of FCV maintained cellular ATP levels when cytopathic effects 
were seen, and under single cycle growth conditions maintained ATP levels longer 
than the non VSD strains. They hypothesised that by maintaining cellular ATP levels 
the VSD strains could delay the onset of the final stages of apoptosis, allowing for 
further viral progeny production (Ossiboff et al., 2007). To test this hypothesis, we 
examined the course of infection of one of these VSD strains, UKOS A. In our present 
study we demonstrated that cells infected with the UKOS A strain undergo apoptosis 
but at a delayed rate relative to that of the vaccine strain FCV-F9. 
This initial work was performed at a multiplicity of infection equal to that used in all 
of our previous work, but this was much higher than that used by Ossiboff et al 
(2007). Therefore, to bring the experiments in line with those by Ossiboff et al the 
MOI was reduced to an MOI of 1. Upon doing this we detected a noticeable delay in 
the apoptosis occurring in VSD-infected cells (Figure 4.2). Now that the 
hypothesised delay in apoptosis had been confirmed, we wanted to establish where 
in the pathway of molecular events this delay was occurring. It was assumed that 
the VSD strains would also activate the mitochondrial pathway of apoptosis during 
infection, like the F9 strain. We examined a variety of cellular events that occur 
during the mitochondrial pathway, and found that there was a delay in PS exposure 
on the cell surface, a delay in the activation of caspase-3, and no detectable release 
of cytochrome c from the mitochondria or activation of caspase-9, in cells infected 
with UKOS A. Of particular note was the lack of cytochrome c release and absence of 
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caspase-9 activation in UKOS A-infected cells. This translocation of cytochrome c 
was detectable in FCV-F9 infected cells 12h p. i. (Figure 4.7), as was a significant rise 
in caspase-9 activity. Interestingly, the maintenance of the cellular ATP pools in VSD 
strain-infected CRFK cells reported by Ossiboff et al (2007) could explain the lack of 
cytochrome c release we have demonstrated in our experiments. Experimental 
evidence suggests that at physiological levels, nucleotides such as ATP / dATP can 
inhibit cytochrome c-initiated apoptosome formation (Chandra et al., 2006). Here, 
the authors found these nucleotides inhibited cytochrome c-dependent caspase-3 
and -9 activation. It was also noted that nucleotides, such as dATP, prevented the 
interaction between cytochrome c and Apaf-1 by binding to cytochrome c at several 
key lysine residues. The authors demonstrated Apaf-1 oligomerisation, formation of 
the apoptosome and the activation of caspases-3 and -9 were inhibited solely by 
increasing levels of dATP in a dose-dependent manner. These experiments were 
carried out in cells lacking caspase inhibitory proteins such as XIAP. In this particular 
example, the protein Smac was added to the reactions to inhibit any IAPs that could 
prevent caspase activity, thus eliminating the IAPs as a potential factor for the lack of 
caspase-3 or -9 activation seen at high levels of dATP. This study also noted that in 
the presence of 5 mM dATP, Apaf-1 eluted as a monomeric protein of "' 158 kDa 
(inactive monomer of the apoptosome) and caspase-3 and -9 were still detected in 
their zymogen form, indicating that the apoptosome had not formed. However, in 
cells that did not receive excess dATP, Apaf-1 eluted as ^' 700 kDa complex (fully 
formed apoptosome) and both caspase-3 and -9 were processed to their active 
forms (Chandra et al., 2006). The group demonstrated that in cell free reconstitution 
experiments, in the absence of exogenous ATP, increasing amounts of cytochrome c 
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lead to an increase in caspase-3 and -9 activation, as expected. However, in the 
presence of 2-5 mM ATP, caspase processing initiated by 2- 10 µg/ml cytochrome c 
was inhibited. When higher concentrations of cytochrome c were added (20 - 200 
µg/ml) this inhibition was overcome and detection of cleaved caspase-9 occurred 
(Chandra et al., 2006). From this data we can hypothesise that in FCV-infected cells 
the presence of the virus acts as a persistent apoptotic stimulus that results in 
mitochondrial damage, causing increased cytochrome c release. This, in conjunction 
with a decrease in intracellular nucleotide pools that are lost through leakage of ATP 
from the cells due to compromised membrane integrity (Figure 4.2), could result in 
the removal of the nucleotide inhibition of Apaf-1/cytochrome c release. This would 
then allow for the formation of the apoptosome and activation of both caspase-3 
and -9. We hypothesise that the UKOS A virus has evolved a way of maintaining this 
inhibition of apoptosome formation and cytochorome c release by regulating cellular 
ATP levels. Therefore, in subsequent experimentation it may be useful to measure 
the ATP levels during F9 and UKOS A infection; this can be done through the use of 
commercially available luciferase-based ATP assay kits. It may also be useful to 
deplete CRFK cells of ATP and then infect with UKOS A; if the delay in apoptosis is no 
longer seen, it would provide good preliminary evidence that ATP depletion is the 
key mediating step. 
We also observed that, despite the lack of cytochrome c release and activation of 
caspase-9, caspase-3 activity was still present in UKOS A-infected cells at 18h p. i. It 
may be that the caspase activity detected in Figure 4.4 is actually caspase-7 activity 
rather than caspase-3. However, the cleaved form of caspase-3 was detected by 
Western blot from UKOS A infected cell extracts from 14h p. i. (Figure 4.5). However, 
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the presence of the cleaved form of caspase-3 does not necessarily equate to its 
activity. It was demonstrated that during coxsackie B virus infection although 
caspase-3 was cleaved, its activity was attenuated by the viral protein 213C (Salako et 
al., 2006). It could be that one of the VSD-isolate viral proteins is binding to and 
attenuating caspase-3. The question of how caspase-3 activation is mediated in the 
absence of caspase-9 activation and apoptosome formation therefore arises. It has 
been demonstrated in certain cell lines such as Chinese hamster ovary cells that 
inhibition of caspase-3 leads to an increase/switch of activity to another executioner 
caspase, such as caspase-7, as a compensatory mechanism (Sung et al., 2005). 
Perhaps this can go some way to explaining the results we have obtained during 
UKOS A infection. There are several ways of testing this hypothesis such as 
evaluating the activity of caspase-7 in UKOS A infected cells by Western blot. Or, 
using Tap-Tag technology previously described in this discussion to determine what, 
if anything, is binding to the cleaved form of caspase-3. Finally it is also possible to 
co-immunoprecipitate the proteins that are bound to caspase-3. 
We also compared the kinetics of F9 and VSD strain replication over time, and found 
that in our system there was no statistical difference in overall virus production. 
However, we observed generally higher virus titres from the UKOS A-infected cells. 
This data was only obtained for single cycle growth kinetics; reports from Ossiboff et 
al (2007) suggest that under multiple growth cycle kinetics at an MOI of 0.01 (100 
times less than that used in our experiments) the VSD strains are able to produce 
infectious virions earlier and that higher viral titres are obtained vs. less virulent 
strains (Ossiboff et al., 2007). Therefore, we should also grow the UKOS A virus over 
multiple growth cycle conditions to compare its growth kinetics to other viral 
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isolates. Our data also excluded the possibility that the delay in apoptosis seen in 
the VSD-infected cells was simply due to insufficient viral replication, as it is known 
that apoptosis induction in FCV infected cells requires de novo viral protein synthesis 
(Sosnovtsev et al., 2003). This result also indicates that the delay in apoptosis 
probably does not allow the VSD strains to obtain a significantly higher viral titre 
than the F9 strain in vitro. However, we do not yet know the situation in vivo. 
Whether or not any differences in virus titre have any impact on the pathology of 
disease in vivo remains to be seen, but this requires virus challenge experiments in 
cats. 
During our research, we obtained two more putative VSD strains of FCV, isolated 
from cats with suspected FCV-related virulent systemic disease. It was noted that 
this disease was not as severe or as apparent as that induced by UKOS A (personal 
communication; Dr Alan Radford). Upon analysis of infection of CRFK cells with 
either AB087 or AB088, it was revealed that these strains also showed a delay in 
apoptosis induction, although to a lesser extent than that mediated by UKOS A. This 
data suggests that the delay in apoptosis seen in VSD strain-infected cells could be a 
general characteristic of such strains and therefore could be used as a diagnostic tool 
in determining whether a strain is able to cause the hypervirulent phenotype of 
disease. To further clarify this, a panel of viral isolates would have to be tested for 
apoptosis induction over an 18 h period, as per our experiments. Viral isolates 
would need to include known vaccine strains of FCV, strains capable of causing 
classical FCV-associated symptoms (e. g. Urbana) and a range of known VSD strains. 
This further evidence that other VSD strains may also be delaying apoptosis does 
raise the question; "How are these VSD isolates achieving this delay and why / how 
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are they different from the non-VSD strains? " To address these questions, we began 
the process of sequencing the UKOS A genome, to determine if there are any 
significant changes in the amino acid sequence of the viral proteins that could be 
responsible for the virulent phenotype. We began our sequencing from the 5' end of 
the UKOS A genome, and did detect some amino acid changes in the UKOS A 
sequence that were different to the conserved amino acids in all other strains. 
Whether these are functionally significant remains to be elucidated. To assess 
whether these changed amino acids contribute to the virulent phenotype, it will first 
be necessary to complete the sequencing of the UKOS A genome. This should allow 
for the identification of potential regions conserved in the VSD-isolate genomes that 
could be responsible for the virulent disease phenotype. Using the infectious clone / 
reverse genetics system established for the FCV-Urbana strain (Sosnovtsev et al., 
2005), it would be possible to introduce each of the amino acid mutations, or a 
combination of them, into the cDNA and determine if this alteration leads to the 
virulent phenotype in vitro. Tying in with data obtained from the previous chapter, 
perhaps a good place to start would be the p30 region of the FCV genome; if this 
region does encode a protein capable of inducing activation of calpains, we may see 
changes in this protein that may lead to the delay in apoptosis. However, it should 
be noted that the pro-pol regions of the genomes of many of these VSD strains have 
already been sequenced, and no sequence or amino acid changes unique to all of the 
VSD isolates in this region have been found. It was also noted that the sequences of 
these VSD isolates are no more different from non-VSD strains than they are to other 
VSD strains (Hurley et al., 2004; Coyne et al., 2006; Radford et al., 2007; Ossiboff et 
al., 2007). However, it is worth noting that the VSD strains alone are responsible for 
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the VSD phenotype, as disease has been induced experimentally in a sample of 
healthy cats (reviewed in Radford et al, 2007). 
Another possible explanation for the apparent delay in apoptosis is that the VSD- 
isolates are less efficient at binding to the JAM-1 cellular receptor (or perhaps even a 
different receptor) and entering the cell. However, experimental work carried out in 
our laboratory revealed that the binding affinities for UKOS A, AB087 and AB088 are 
similar to FCV-F9 and all enter CRFK cells by binding to the receptor JAM-1, ruling out 
this hypothesis (Gerondopoulos et al; personal communication). 
In order to truly understand the benefit to the virus in delaying apoptosis, it may be 
necessary to study its behaviour in vivo. To do this it would be necessary to perform 
experimental infections in cats and study any pathological lesions. From this 
necropsy of the infected tissues can be performed for immunohistochemical testing, 
such as the detection of virus particles in tissues using antibodies directed to the 
virus capsid protein. The detection of the early signs of apoptosis could be 
determined by TUNEL assay in infected tissues. It would also prove useful to assess 
the virus titres reached during in vivo UKOS A infection compared to those reached 
during FCV-F9 infection, through techniques such as quantitative PCR assays. This 
could provide us with an answer to the question of why the VSD-isolate infected cells 
show a delay in the apoptotic response in vitro, especially if increased viral titres 
correlated with an increased severity of disease. 
It could be that the non-VSD causing strains, or those that are used for vaccines, 
have lost the ability to effectively delay the onset of apoptosis and therefore 
replicate to lower titres and less efficiently in tissues, hence contributing to the less 
severe pathology of disease. It would therefore make sense that if these non-VSD 
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strains did not kill the infected cats they would be spread amongst the feline 
population more readily, and become more common. 
Taken together, this data presents several lines of evidence suggesting that 
apoptosis is delayed during infection of CRFK cells with VSD-causing isolates of FCV. 
This is consistent with previous reports of their behaviour in vitro (Ossiboff et al., 
2007). This data does not detract from the suggestion that apoptosis is a common 
feature of calicivirus infection, as even though the induction of apoptosis is delayed, 
apoptosis still occurs eventually in VSD-isolate infected cells. 
Another exciting development in the calicivirus field came in 2003, with the 
discovery of a murine norovirus, MNV-1, that replicated efficiently in an easily 
manageable murine macrophage tissue culture system (Karst et al., 2003; Wobus et 
al., 2004). This development has expanded research into all aspects of murine 
norovirus-1 pathology, with particular focus on the immune response to murine 
norovirus infection, and how this could provide a good model for the immunological 
response to human noroviruses. The tissue culture system, coupled with the 
availability of a genetically manipulable host, will allow for examination of the 
pathogenesis of this calicivirus both in vitro and in vivo. In our work, we wanted to 
examine the mechanism of cell death induced during MNV-1 infection of RAW 264.7 
murine macrophages. We did this to try to understand if apoptosis induction is a 
general characteristic of cells infected with Caliciviruses. This work was of great 
interest as it would be the first time cell death mechanisms for a member of the 
norovirus genus could be examined in vitro. 
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Our analysis demonstrated that apoptosis may not be the primary mechanism of cell 
death occurring in this system, and that necrosis may also be involved. This is 
supported by the observation that infected RAW cells did not become AV positive 
during the time course of infection, when analysed by AV/PI staining on flow 
cytometry (Figure 5.1). This data contrasts with the detection of active caspase-3 in 
RAW cells during MNV-1 infection. This is puzzling and suggests that the cells have 
undergone apoptosis, but yet they have not become annexin V positive. This lack of 
annexin V detection was a reproducible phenomenon in MNV-1 infected cells. This 
finding could be explained by two possibilities; firstly, this could be an indication that 
the cells are dying through a necrotic mechanism, or it could be that MNV-1 is 
somehow down-regulating the expression of phosphatidylserine on the cell surface 
of the macrophage during infection. This could represent an in vivo survival 
mechanism of the virus to prevent the infected macrophage from being 
phagocytosed, hence promoting the survival of the virus (Shiratsuchi et al., 2000). 
Recent reports have shown that Herpes simplex virus (HSV)-1 infection of human 
corneal epithelial cells induces an apoptotic response; this apoptotic response is 
then suppressed by the virus, evidenced by a reduction in PS exposure on the surface 
of infected cells (Miles et al., 2007). This hypothesis of down-regulation of PS 
exposure on the cell surface during MNV-1 infection, was further supported by 
reports that RAW cells treated with the apoptosis inducing chemical staurosporine 
are found to be AV positive when analysed by flow cytometry (Yamaki et al., 2002). 
Interestingly, during MNV-1 infection of RAW cells, the addition of z-VAD-fmk 
inhibited the activation of caspase-3 in a dose dependent manner, as expected 
(Figure 5.2 & 5.3). However, z-VAD-fmk actually enhanced cell death seen during 
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infection. Again, the cells displayed a necrotic-like profile upon examination by flow 
cytometry, with no cells showing the early stages of apoptosis (Figure 5.1). However, 
at 24h p. i., in cells treated with z-VAD-fmk we saw a large population of cells that 
were AV positive. The detection of PS externalisation in z-VAD-fmk treated cells is 
probably due to the increased membrane permeabilisation observed during the late 
stages of necrosis (discussed below). In this late stage of cell death, the AV protein 
will be able to enter the cell and bind to PS still internalised on the inner leaflet of 
the plasma membrane, hence, giving a false positive detection of PS exposure. This 
ability of z-VAD-fmk to enhance cell death has been previously observed in several 
TNF- or ROS-mediated cell death models (Vercammen et al., 1998, Kim and Han, 
2001, Cauwels et al., 2003, Liu et al., 2003, Martinet et al., 2006, May and Madge, 
2007). It was noted in these studies that the addition of z-VAD-fmk to a given system 
inhibited caspases and led to a switch from apoptosis to necrosis. More specifically, 
Kim & Han (2001) reported that z-VAD-fmk enhanced cell death in RAW 264.7 
macrophages; however, at the time they did not elaborate on a possible mechanism 
for this action (Kim et al., 2001). 
The effect of z-VAD-fmk on cell death in MNV-1-infected cells was most apparent 
upon examination of cytochrome c translocation from the mitochondria. Here, it 
was apparent that the addition of z-VAD-fmk enhanced the release of cytochrome c 
from the mitochondria, compared to that detected during infection of untreated 
cells (Figure 5.4). Recent work by Temkin, et al (2006) sheds some light on this 
result. 
It is known that RAW cells are a macrophage cell line, and this cell line stimulates the 
production of TNFa and ROS in response to stress. This group reported that in 
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certain cell types, when caspase activation is inhibited, ligation of TNFa to TNFR1 
results in necrotic cell death by a mechanism involving Receptor Interacting Protein I 
(RIP). Their observations demonstrate that in macrophages, following stimulation of 
the death-receptor pathway, cells that have the apoptotic phenotype prevented by 
z-VAD-fmk die through a death receptor-induced necrotic mechanism through the 
interaction of z-VAD-fmk with a protein adenine nucleotide translocase (ANT), 
mediated by RIP. The synthesis of mitochondrial ATP requires the transport of ADP 
into the mitochondria and ANT mediates this. ANT is also responsible for the release 
of cytochrome c from the mitochondria. It was shown that z-VAD-fmk translocated 
to the mitochondria and interacted with ANT when cells were pre-treated with 
TNFa. However, this translocation did not occur in RIP-depleted cells, implicating a 
role for RIP in mediating the interaction between ANT and z-VAD-fmk. These 
authors also demonstrated that z-VAD-fmk-mediated inhibition of ADP translocation 
into the mitochondria was dependent on the presence of RIP. This interaction of z- 
VAD-fmk with ANT forces the ADP transporter open, resulting in a massive release of 
cytochrome c into the cytosol (Temkin et al., 2006). 
ANT is also a known component of the mitochondrial permeability transition pore 
complex (MTPT). The MTPT, once triggered, induces an increased permeability of 
the mitochondrial membranes to proteins of less than 1500 kDa in weight. This 
causes an increase in the osmotic load within the mitochondria, allowing the 
mitochondria to swell. This swelling is damaging to the mitochondrial membranes, 
causing them to become leaky and hence allowing for the further release of 
cytochrome c. The induction of MTPT formation increases membrane permeability 
and causes the mitochondria to become depolarised, shown by a complete loss of 
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DJ,, (Kowalczyk and Zablocka, 2008). This loss of AO,, was also seen during MNV-1 
infection at 12h p. i. and complete depolarisation was seen upon the addition of z- 
VAD-fmk (Figure 5.5 & 5.6). These reports, therefore, may help to explain the 
phenomenon of enhanced cell death following caspase inhibition observed during 
MNV-1 infection. 
Our results so far cannot fully determine the mechanism of cell death occurring in 
MNV-1 infected cells. The loss of mitochondrial membrane potential and production 
of ROS are events commonly seen during necrosis (Festjens et al., 2006, Golstein and 
Kroemer, 2007). However, Oq)m can also be detected in certain cells undergoing 
apoptosis following virus infection (Natoni et al., 2006). The majority of the data we 
have presented so far suggest that the underlying mechanism of cell death during 
MNV-1 infection is necrotic in nature, apart from one major observation. This 
observation is the detection of activated caspase-3 during infection. This result 
indicates that, at least initially, the induction of cell death in MNV-1 infection is 
apoptotic in nature, as activation of the caspases is one of the defining traits of 
apoptotic cell death. Caspase activation is never observed during necrosis (Festjens 
et al., 2006, Vandenabeele et al., 2006, Golstein and Kroemer, 2007). 
From our work so far a few questions have emerged. Why does z-VAD-fmk enhance 
cell death in the macrophage cell line and not in CRFK cells? Is the mechanism of cell 
death occurring during MNV-1 infection primarily apoptosis, and then this is shifted 
to necrosis through the addition of z-VAD-fmk, or do secondary necrotic mechanisms 
occur in this tissue culture system? Is TNFa produced by the macrophages, acting as 
a positive feedback loop to enhance cell death or promote the switch either 
between apoptotic pathways or to a necrotic mechanism? To address the first 
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question, Scheller et al (2006) demonstrated that caspase inhibition in apoptotic T- 
cells triggered a necrotic type of cell death that was dependent on the cell type and 
apoptotic stimulus. They demonstrated that inhibition of the CD95 proapoptotic 
pathway activates an alternative death pathway, leading to a necrotic cell death. 
This cell death response remains hidden in the absence of caspase inhibition. It was 
noted that CD95-induced necrosis was still observed in the presence of z-VAD-fmk. 
Indicating that the pro-necrotic signalling from the death receptor complex had to be 
occurring upstream of caspase-8 activation, as the pathway was inhibited at this 
point through the use of the caspase inhibitor z-VAD-fmk. Therefore, it is assumed 
that apoptotic stimuli that act downstream of the point at which the proapoptotic 
and pronecrotic pathways divide can bypass the necrotic signalling, and fail to induce 
necrosis when caspase activation is inhibited (Scheller et al., 2006). Such is the case 
in the apoptosis of FCV infected CRFK cells; here this signalling is bypassed as 
apoptosis is occurring through the mitochondrial pathway. However, this hypothesis 
does imply that the death receptor pathway may be activated during MNV-1 
infection, which as yet remains untested. Other than the detection of active 
caspase-3, data presented here such as the lack of AV exposure, the loss of AqJm and 
subsequent cytochrome c translocation from the mitochondria are all events that 
can be attributed to necrosis, as well as the mitochondrial pathway of apoptosis. 
Further ways of clarifying our results would be to examine the activation of a panel 
of other caspases during MNV-1 infection; this would give a clear indication whether 
or not the mechanism is apoptotic. It was reported by Temkin et al (2006) that the 
fmk group of z-VAD-fmk was essential for the inhibition of ANT. Therefore, other 
pan-caspase inhibitors lacking this group (e. g. qVD-OPh or DEVD-CHO) should be 
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trialled in the RAW cell system to determine if they too switch the mechanism of cell 
death seen from apoptosis to necrosis. Another way of determining the mechanism 
of cell death is via morphological examination of the infected RAW cells, either by 
microscopy or flow cytometry. The morphological changes to the cell could provide 
an insight into the mechanism of cell death, with cell shrinkage being characteristic 
of apoptosis, and cell swelling a characteristic of necrosis (Festjens et al., 2006). 
It is possible that a necrotic mechanism could follow the induction of apoptosis 
occurring in MNV-1-infected cells. Cells undergoing apoptosis undergo a partitioning 
of their cytoplasm and nuclei into membrane bound vesicles (apoptotic bodies). In 
vivo, these apoptotic bodies are rapidly recognised and phagocytosed by phagocytic 
cells such as macrophages. As this is an efficient process in vivo, no inflammatory 
response is seen. However, in vitro this phagocytosis does not occur and the 
apoptotic bodies formed may begin to swell and undergo a necrotic-type cell lysis, 
thereby giving a necrotic cell death phenotype with detectable activation of key 
steps of the apoptotic machinery, such as the caspases (Rydell-Tormanen et al., 
2006; Kowalczyk and Zablocka, 2008; Costers et al., 2008). Further experimentation 
is required to be done to address the latter few questions, such as examination of 
TNFa production during infection, the role of ROS species, which can be tested 
through flow cytometry using the chemical 2', 7'-dichlorofluorescin diacetate 
(DCFDA) that can detect any ROS formation occurring during infection, and 
determination of the activation of apoptosis through morphological microscopic 
observation. 
200 
General Discussion 
In conclusion, we have demonstrated a role for the calpains in the early stages of 
apoptosis seen during FCV-F9 infection of CRFK cells. In addition, we have shown 
that infection with a virulent systemic disease causing strain of FCV elicits a delay in 
apoptosis induction in vitro. Whether this mechanism is to allow the virus to 
replicate to higher titres or avoid detection by immune surveillance mechanisms in 
vivo remains to be clarified. Finally, we have demonstrated the complex nature of 
cell death occurring during MNV-1 infection of RAW 264.7 murine macrophages and 
believe it to be primarily apoptotic in nature. We thereby provide further evidence 
that the induction of apoptosis is a characteristic of cells infected with multiple 
members of the Caliciviridae. 
Understanding the mechanisms responsible for the induction or inhibition of 
apoptosis mediated by viruses may eventually elucidate the molecular mechanism of 
cell death occurring during human calicivirus infections. The identification of a 
common trigger of apoptosis may pave the way for the development of anti-viral 
therapies or even vaccines, making the further work highlighted in this report 
invaluable. 
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8 APPENDICES 
8.1 EMCV IRES Orientation Sequencing 
Chromas 1 61 Fik: PCALPI CALPSEQFVD_A07. ab1 Sampk: BBR66907_01 CPI Run Ended: Jul 5,200; JlYnai ll: li /U A: ILOV 1 t700'tiuia r 
., 
3C 
G,..; :. GG. G G G- ° G: .u.. 
,i 
ii 
t3hnn nL 
6p 'C ý 9ý : 00 110 
A 
AM 
1Cp : 3C ia. isc :; o : ^ý 
. ... G.. ''; ,. ,ý:. : ., GG fG . .+.. 
_ . .... G 
-. BC . 210 __0 
2Y 
GGGG. ý ,. ý G .. G u.., ., ;. G... 
V 6 
" i\ \AM- 25C 260 280 230 G .- :. 00 0: TG G G .. nGG .-. a 
300 ! 10 37.0 330 
C. G uG G GGG uG 
n ^, ^ 1 n 1 r 1; ý 1 
3eC 3'C 380 39^ c00 4. " 
., GG GG GTG 
GG 
^ V n 
Continued overleaf... 
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Chromas 1.61 1 ile: PC: ALPI CALPSEQIWDAO'y. abl Sample: BBR66907 OI_C? I Run Ended: Jul 5,20UI J40a l,: l4 i V. q: 1L6V I race L ol 4 
G .. -ý.., G 
A l 
, %[ V\ M 1 W , ,,, j a MW , 190 190 5P: 0 S7_ý 5: n 53G .'ý. G .. GGGi 
 G 
60 610 63D rao 6 
GGG u. 
LSiM HI 
G S6C 6ýv 5FD e; *G '.. - 77ý 
.. _ .... .. ," , ,... .. .... . ,-- ._. .. . ". .Gý GT 
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8.2 UKOS A Genome Sequencing 
Lhrum; i I hl rUc ýoborn 1 SP6 NUa an] BBR820 iu SPn Run 1ndcd Aug 2 1, nom hIJMd tY»U A: L! r I., 'j t, l Y : '6y'C 1 L). 4 
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I rý A 
(1 
,I ý ýI ;ý ý iou 730 i3+! i4ü 
(AA 
ý) 
^ 
IIII 
I `, I 
ýI 
1 
iII 
In' lJýt 
i, f, IIIý! 
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'sfU 3'. G 7BC ]9U r=J 410 
ý^n 
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VVV 
_ 
continued overleaf... 
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Chromas 1.61 Fik: Colory I SP6 N04. abl 11)6 11Jlv. ýJV: 1. L;; ý7loL: L70 Ce1WCUýý sampleööK810)5 UI Nl'0 KUD tAOCtl: Aug Ll, 1UVU 
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8.3 Vector Map: Human Calpastatin Plasmid - pTicCs 
&aotl IIýnI aa. aL 
oAA'lTLTM; ATA U1CCA 1cCC11U1GAAAL. LMWI'GITTCCALiCGALY. YTAA----- 
MDPTSTRAZPVSQ 
Awaan oalpaetatsn 
Amino acid substitution at roa No, 2 (CAT Ann -> GAT Asp) 
To isolate the cDNA fragment, cut the plaimid with EcoRI or Xbal. 
Kazak'a consensus sequence for eukaryotic translation initiation site 
CCACCAIGG Ref. Kozak (1986) Cell, 44,283-292 
Kumar et al. (1986) EMBO J. 5,2231-2236 
Restriction sites 
E, EcoRI; Xb, XbaI; N, NCOI; RV, ECORV; B, BamNI; Kh, Xhol; 
P, Pst; S, Sac!; K, Kpnl; H, HindIIl; Sp, Sphl 
Multiple restriction sites from pUC119: H, Sp, K, S, E 
Vector: pUC119 
Selection marker: Amp 
Insert: - 2.3 kb (EcoRI fragment) 
Human calpastatin cDNA GenBank/EMBL/DDBJ acc. No: D16217 
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8.4 Vector Map: pEGFP-NI 
GenBank Accession #U55762 AseI 
(ai 
Catalog #6085-1 
EcoO109 I 
(3856) 
BsºG I (1389) 
Not I (1402) 
Xbalýi1412) 
All II (1640) 
Dra 111 f 18741 
5 01 60 1 611 621 631 661 E61 661 671 
_EGii 
G CTAýG CfA CCG GAC TCA GAT CIC GAG_ý, [C ftAGC. 7 CGA ATT_GTG CAG TCG ACCý. GTA CCG CGG 
_GCG 
CGG ýiATýACCG GTC GCC ACC ATG GTG 
NkoI E6ro171I1 B/III WO-1 
8\ýIHiad 
III EcroNI Psfl 
Aäll Aslll 8ý1101 1niH1 
ApI 
EcfA611 skcll sar I 
8.5 Chemicals 
" 30X Reducing agent Dithiothreitol (DTT) NE Biolabs 
" 3X SDS Sample Buffer. NE Biolabs 
" Ac-DEVD-AFC, BaChem, Stock Solution 100 mM in DMSO (Store -20°C) 
" ALLN. Calbiochem. Stock 10 mM in DMSO (Store -20°C) 
" Ammonium persulphate. Sigma 
" Aprotinin. Roche. Stock: 1 mgml-1 in dH2O (Store -20°C) 
" Calpeptin, Calbiochem Stock Solution 10 mM in DMSO (Store -20°C) 
" CCCP. Sigma-Aldrich. Stock Solution 10 mM in DMSO (Store -20°C) 
" Cyclosporine A, Calbiochem. Stock Solution 1 mM in Ethanol (Store -20°C) 
" Digitonin. Calbiochem. Stock Solution 60 mg/ml in dH2O, boil at 95°C to 
dissolve. Prepare fresh before every experiment. 
" Dimethyl sulfoxide (DMSO) Sigma (Store RT°C) 
" Epoxomicin. Calbiochem, Stock: 1mM Solution (Store -20°C) 
" Leupeptin. Roche. Stock: 1 mgml-1 in dH2O (Store -20°C) 
" MG-132. Stock 10 mM in DMSO (Store -20°C) 
" N, N, N', N' tetramethylethylenediamine (TEMED) Sigma 
" Pepstatin Roche. Stock: 1 mgml-1 in dH2O (Store -20°C) 
" PMFS. Roche. Stock: 100 mM in DMSO (Store RT°C) 
" TMRE, Molecular Probes. Stock Solution 100 µM in DMSO (Store -20°C) 
" z-VAD-fmk. BaChem. Stock: 100 mM in DMSO (Store -20°C) 
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8.6 General Solutions 
" 0.4% (w/v) Trypan Blue 
0.4g of Trypan Blue (BDH) in 100 ml dH2O. 
" 20% (w/v) SDS 
20 g SDS in 100 ml H20- 
Store at 37°C 
" Buffer A 
293 mg NaCl 
1.86g KCI 
102mg MgCl2 (6H20) 
90 mg EDTA 
1.49g HEPES 
1 µM Cyclosporine A 
Prepare in dH2O. pH 7.1, final volume 250 ml 
Prepare fresh before every experiment 
" Cell Lysis Buffer 
150 mM NaCl 
50 mM Tris"HCI pH 7.5 
0.2% of 20% (w/v) SIDS 
1% of 100% NP 40 
2 jig/ml of each of Leupeptin, Pepstatin and Aprotonin 
1 mM PMFS 
1 mM EGTA 
Prepare in dH2O. Final volume 10 ml. Filter sterilise with 0.2 µm ministart 
filter. 
Prepare fresh before each experiment. 
" PBS 
1 tablet of PBS (Oxoid) in 100 ml of H2O. 
Store at 4°C 
" PBSa 
9.6 g PBS (Gibco) 
100 mg/I of CaCI2 
Prepare in dH2O. Final volume 1 L. Filter sterilise with 0.2 gm ministart filter. 
Store at 4°C 
" Caspase-3 Lysis Buffer 
50 mM NaCl 
20 mM sucrose 
2 mM MgCI2" (6H20) 
5 mM EGTA 
10 mM HEPES 
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pH 7.0 
Prepare fresh before every experiment in dH2O. 
" Caspase-3 Assay Buffer 
100 mM HEPES 
10 mM DTT 
CHAPS 0.1% v/v 
10% sucrose w/v 
pH 7.25 
Prepare fresh before each experiment in dH2O. 
" Resuspension Solution 
50 mM Glucose 
25 mM Tris, pH 8.0 
10 mM EDTA 
Made upto 200 ml with dH2O. 
" Lysis Solution 
1% SDS 
0.2 mM NaOH 
dHzO 
" Neutralisation Solution 
60 ml 5M Potassium Acetate 
11.5 ml Glacial Acetic Acid 
28.5 ml dH2O 
" TE Buffer 
5 ml 1M Tris pH 7.5 
1 ml 0.5 M EDTA pH 8.0 
Made up to 500 ml with dH2O 
Sterilised by autoclave 
" TE/RNAse Solution 
450 µl TE Buffer 
50 µl RNase (50 mg/ml; Promega) 
" Ethidium Bromide 
100 mg (1 Tablet; Sigma) in 10 ml dH2O (10 mg/ml) 
" Ampicillin 
25 mg/ml Sigma, use as 50 µg/ml final concentration 
" Kanamycin 
15 mg/ml Sigma, use as 30 µg/ml final concentration 
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8.7 Cell Culture Media 
" 1: 10 (Fiore et at., 1998d) Trypsin / Versene 
10 ml Trypsin (Gibco) in 100 ml Versene (Gibco) 
" MEM / D-MEM 2% FBS (100 ml) 
96 ml Modified Eagle's Medium / D- Modified Eagle's Medium (Gibco) 
2 ml Fetal Bovine Serum (Gibco) 
1 ml Non-essential Amino-acids (Gibco) 
1 ml Penicillin (100 U/ml) / Streptomycin (100 µg/ml) (Gibco). 
Store at 4°C 
" MEM / D-MEM 10% FBS (100 ml) 
88 ml Modified Eagle's Medium / D- Modified Eagle's Medium (Gibco) 
10 ml Fetal Bovine Serum (Gibco) 
1 ml Non-essential Amino-acids (Gibco) 
1 ml Penicillin (100 U/ml) / Streptomycin (100 µg/ml) (Gibco). 
Store at 4°C 
8.8 Gel Electrophoresis Solutions 
" 50 x TAE Buffer 
242g Tris (Trizma base) 
57 ml acetic acid 
100 ml 0.5M EDTA, pH 8.0 
Made up to 1 litre with water and autoclaved 
1x TAE Buffer 
4 ml 50 x TAE Buffer (Appendix 4) 
Made up to 250 ml with MQ water 
" 1KB DNA Ladder (Promega) 
Band 
Size (bp) 
10,000 
8,000 
6,000 
5,000 
4,000 
3,000 
2,500 
2,000 
1,500 
1,000 
750 
500 
250/253 
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" 20% (w/v) Ammonium Persulphate 
0.1 g Ammonium Persulphate (Sigma) in 1 ml H20- 
Store at 4°C 
" 15 % resolving Gel (See table 6.4.10 for more) 
3.2 ml dH2O 
10 ml AX2 Buffer 
6.3 ml of 40% Acrylamide / Bis-acrylamide 
100 µl of 20% SDS 
200 µl of 10% ammonium persulphate 
50 µl TEMED 
" 10X TBS / Tween 20 
24.2 g Tris 
80 g NaCl 
Add 800 ml dH2O 
1X TBS / Tween 20 
100 ml of 10X TBS/Tween 20 
900 ml of dH2O 
Store at 4°C 
0 Acrylamide: Bis-Acrylamide (Ratio 37: 1,40% stock) 
40 g Acrylamide 
1.08 g Bis-Acrylamide 
Dissolve in 100 ml dH2O. 
Store at 4°C 
" AX2 Buffer (0.75 M Tris) 
45.3 g Tris 
Dissolve in dH2O, pH to 8.8 with conc. HCI, final volume 500 ml. 
Store at 4°C 
" BX2 Buffer (0.25 M Tris) 
15.12 g Tris 
Dissolve in dH2O, pH to 6.8 with conc. HCI, final volume 500 ml. 
Store at 4°C 
" PAGE Running Buffer 
3g Tris 
14.4 g Glycine 
5 ml 20% SDS 
Dissolve in 1000 ml of dH2O. 
" Transfer Buffer 
3g Tris 
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14.4 g Glycine 
200 ml Methanol 
800 ml dHzO 
" Stacking Gel 
3.7 ml dH2O 
5 ml BX2 Buffer 
1 ml 40% Acrylamide/Bis-acrylamide 
50 µI of 20% SDS 
100 µl of 10% ammonium persulphate 
30 µI TEMED 
" Resolving Gel Percentages 
7% (Urban et al., 10% (Urban et al., 15% (Urban et al., 
2008) 2008) 2008) 
H20 5.8 4.5 2 
AX2 10 10 10 
Acryl / Bis-Acryl 3.5 5 7.6 
10 % SDS 200 µI 200 µI 200 µI 
10 % Amm. Per. 200 µI 200 µI 200 µI 
TEMED 50111 50111 50111 
8.9 Western Blot Solutions 
" 5% (w/v) Blocking Buffer 
5g Dried semi-skimmed milk (Marvel) in 100 ml of 1X TBS/Tween 20. 
8.10 Commercial Kits Used 
" Annexin V-FITC Apoptosis detection kit, Oncogene Research Products 
" BCA Protein Assay Kit, Pierce 
" PE-conjugated monoclonal active caspase-3 antibody apoptosis kit. BD 
Pharmingen. 
" Super Signal West Pico Chemililuminscent Substrate, Pierce 
" LDH Cytotoxicity Assay, Biovision 
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